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1Introduction 
1 Introduction 
1.1 Pharmacokinetic/Pharmacodynamic Modeling and 
Simulation 
1.1.1 History and Overview 
With the introduction of the concepts of pharmacokinetics by Dost in his 1953’s book 
“Der Blutspiegel - Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit” [1] 
and the first review of the four kinetic elements, absorption, distribution, metabolism, 
and excretion in an international scientific journal by Nelson in 1961 [2], the 
importance of pharmacokinetics was recognized in the area of (clinical) pharmacology. 
Nelson made extensive reference to the pioneering work of Toerell who in 1937 first 
described the behavior of xenobiotics in the human body with mathematical 
equations [3,4]. These concepts are the basis of modern model-based pharmacokinetic 
(PK) data analysis.  
The by far most widely used mathematical models to describe the time course of drug 
concentration in body fluids (e.g., blood or plasma) are the mamillary compartmental 
models, where the human body is simplified to a system of connected tanks (i.e., 
compartments) with drug input and output to and from a central compartment. These 
models can be described as systems of differential equations or, after integration, as 
polyexponential terms. Many modifications to this basic model structure, such as 
delayed absorption or saturable elimination, have been described, demonstrating its 
flexibility [5]. Figure 1-1 shows a two-compartment model with absorption and 
elimination according to first-order processes together with the model equations.   
Pharmacodynamic (PD) models are often grounded on the law of mass action or 
Langmuir’s law of adsorption-desorption and were later reformulated by Ariens [6] and 
Stephenson [7] for the case of drug-receptor binding and agonist action. Fundamental 
models of pharmacological response in relation to drug concentrations were reviewed 
by Holford and Sheiner emphasizing the importance of quantitative prediction of drug 
effects in man [8]. One of those basic PD models is the Emax model, where a hyperbolic 
function relates a measure of drug exposure (e.g., blood concentration, area under the 
curve [AUC], dose) to some measure of pharmacological response (Figure 1-2).  
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Figure 1-1 
 
Mamillary two-compartment model. The amount of drug in the dosing 
compartment (Ad) enters the central compartment by a first-order process with a 
rate constant ka. Distribution of the drug to and from the peripheral compartment 
is described by k21 and k12. The drug’s elimination from the central compartment 
is quantified by the first-order rate constant k10. Rate constants can be easily 
transformed to the pharmacokinetic parameters clearance (CL), volumes of 
distribution of the central (V1) and peripheral (V2) compartment, and 
intercompartmental clearance (Q). The yellow box shows the system of 
differential equations describing the processes of absorption, distribution, and 
elimination. 
A1: amount in the central compartment; A2: amount in the peripheral 
compartment. 
 
The variety of useful pharmacodynamic models is tremendous, ranging from simple 
linear models to complex mechanistic models describing, for example, the 
receptor/gene-mediated effects of corticosteroids [9,10].  
 
 
Figure 1-2 
 
Maximal effect (Emax) model. 
E0: baseline effect; EC50: concentration 
eliciting half the maximal effect. 
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A key part of model-based data analysis is the estimation of model parameters by 
nonlinear regression. Many different algorithms and estimation procedures have been 
developed for the purpose to “fit” some mathematical function to a given set of 
observations [5]. The most widely used method is the maximum likelihood estimation, 
developed by Fisher between 1912 and 1922 [11]. Sophisticated optimization 
algorithms (e.g., Gauss-Newton, Levenberg-Marquardt) are then applied trying to find 
the maximum of the likelihood function by iteratively changing the value of the model 
parameters. Specialized software has to be used for this purpose and the introduction of 
the NONMEM software by Sheiner and Beal in the early 1980’s was one of the 
groundbreaking developments in the field of modeling and simulation [12-14]. For the 
first time the method of nonlinear mixed effects modeling (described in section 3.1.1) 
was incorporated into a piece of software, permitting the estimation of parameters from 
spares data and, importantly, providing estimates of the variability in model parameters 
between patients in a population [15]. Over the years NONMEM has become the by far 
most widely used software for the purpose of (population) 
pharmacokinetic/pharmacodynamic (PK/PD) modeling. 
While models used for the mere description of data can provide additional insight into 
the behavior of a drug in an individual or in a population, compared to non-model-based 
techniques, their strength lie in their ability to make predictions, that means to simulate 
unstudied situations and “what-if”-scenarios. Important questions like: “How would a 
patient’s response to a drug treatment change if his renal function declines?” or “Could 
additional benefit be gained giving a certain drug in a twice-daily schedule instead of 
only once a day?”, may be addressed with simulations.  
Over the past three decades the modeling and simulation approach has been increasingly 
recognized in preclinical and clinical research and drug therapy, and has eventually 
developed to an own discipline: Pharmacometrics - the science of quantitative 
pharmacology [16]. The following sections try to highlight some of the implications this 
approach had - and continues to have - on the development of new medicines and 
pharmacotherapy in clinical practice, and elucidate the key role that biomarkers play in 
this context.  
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1.1.2 Applications in Drug Development 
The ever increasing costs for the development of new drugs (over 1 billion US Dollars 
per approved drug in 2008) and stagnation of approval rates rises concern on the 
efficiency of the drug development process [17]. In 2004, the United States Food and 
Drug Administration (FDA) issued a key document entitled “Innovation or Stagnation? 
Challenge and opportunity on the critical path to new medical products” [18], where 
they recommended the use of new tools to improve the drug development process. One 
such tool they mentioned, is model-based drug development as a framework for the 
“mathematical and statistical characterizations of the time course of the disease and 
drug using available clinical data to design and validate the model” [18]. In fact, much 
of the inefficiency in the drug development process is attributable to a lack of 
understanding of the exposure-response relationship of a new substance, leading to the 
selection of inappropriate doses for phase III trials or even for labeling [19]. In a 
seminal publication, Sheiner argued for an increasing use of exploratory studies, with 
study designs appropriate to learn as much as possible about the behavior (i.e., the 
exposure-response relationship) of a drug across a wide range of doses and different 
patient populations [20]. What has been learned from these exploratory studies can then 
be used to design larger confirmatory trials (e.g., phase III trials) where the objective is 
to demonstrate efficacy and safety in a representative patient population. 
Modeling and simulation are essential tools in this learning and confirming concept and 
have a multitude of possible applications. PK/PD models developed on data from 
exploratory studies permit the examination of most beneficial dosing regimens. Data 
from larger studies can be used to identify patient characteristics (i.e., covariates) 
influencing the dose-concentration-response relationship. The models are then used to 
plan future clinical trials by simulating different trial designs in order to identify the one 
with the highest probability of success [21]. Defining optimal sampling times for 
concentration and response measurements within such trials complements this 
strategy [22]. In essence, the information gained with modeling and simulation supports 
the decision making on “whether” and “how” to continue the development of a new 
drug, with less room for subjective empiricism and wishful thinking.  
Modeling techniques are helpful at any stage of the development process [23]. Expected 
concentration-time profiles in humans can be predicted with, for example, 
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physiologically-based PK models, incorporating information obtained from in vitro and 
preclinical animal studies. A guideline on the strategy to identify risks of first-in-human 
studies, issued by the European Medicines Agency, explicitly recommends the use of 
PK/PD models for the estimation of the first dose in humans of high-risk drugs (e.g., 
monoclonal antibodies) [24]. Measurements of response (i.e., biomarkers, see section 
1.2) in phase I studies in healthy volunteers provide the first insight into the 
concentrations-response relationship of a drug in humans and are subsequently refined 
with data from studies in patients. In fact, the ability of models to be up-dated with 
newly arriving data, in other words, the propagation of knowledge from one step to the 
next, is an attractive characteristic of this approach. It is worth noting, that knowledge 
has not even to be created by oneself (i.e., the investigating company), but can be 
“borrowed” from the literature. An interesting example is given by Mandema et al., who 
evaluated the potential benefits of a new lipid lowering agent (gemcabene) over the 
competitor ezetimibe, using simulations from a PK/PD model developed with available 
information from the literature [25]. More examples how modeling and simulation have 
influenced drug development in recent years have been reviewed both from the 
pharmaceutical industry perspective [26-30] and from the regulatory point of view [31].  
Initial skepticism about the model-based approach has continuously diminished and 
recent publications like the FDA’s guidance on “End-of-Phase 2A Meetings” [32], 
strongly recommend the use of this method. A major management consulting company 
issued a business outlook on PK/PD modeling and simulation entitled “Pharma 2020: 
Virtual R&D” [33], underpinning the importance of the this approach for the efficient 
development of innovative medicines in the future.  
1.1.3 Applications in Treatment Individualization 
Many drugs are on the market with their package insert pretending that the same dose 
should be equally effective (safe) for every individual, from the young, maybe obese 
patient, to the 50-kg-weighing retiree. Alternatively, the use in such “non-normal” 
patient populations is simply not recommended due to lack of knowledge, preventing 
these patients to benefit from the drug or leaving the decision on the appropriate dose to 
the physician, without guidance. A retrospective evaluation of drugs approved by the 
FDA between 1980 and 1999 revealed that in 1 out of 5 drugs the initially claimed 
standard dose had to be changed after approval – in most cases (80%) it had to be 
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reduced [34]. This is because of insufficient knowledge of the dose-response 
relationship, as explained in the previous section, but more importantly because 
traditional drug development programs have been focused too much on finding a dosing 
regimen that is simple and easy to use for physicians and patients [19].  
Fortunately, the paradigm of one-size-fits-all does not apply to the majority of newly 
approved drugs. For about 50% of new drugs registered in Germany in 2008 and 2009 a 
priori dose individualization based on patient characteristics like body weight, age, or 
organ function (e.g., creatinine clearance) is recommended [35]. Population PK/PD 
modeling can be used to identify such characteristics. However, for drugs with a narrow 
therapeutic window a priori individualization of the dose may not be sufficient. Dose 
adjustments based on the occurrence of side effects, the absence of effect, a biomarker 
measurement (e.g., blood pressure, blood glucose), or drug concentrations is frequently 
done in clinical practice, although it may not be stated explicitly in the drug’s label. 
These a posteriori dose individualization strategies could greatly benefit from PK (or 
PK/PD) models, guiding dose adjustment instead of leaving it to trial-and-error. With a 
PK model at hand, individual PK parameters (e.g., clearance) of a patient can be derived 
using Bayesian estimation. The Bayesian method combines previous knowledge of the 
PK characteristics of a drug in a population (i.e., average parameter values and 
associated between-patient variability) and individual patient information (e.g., body 
weight, plasma concentrations etc.) in order to estimate individual PK parameters. 
Knowing the individual clearance (CLind) of a patient, for example, permits the 
calculation of the maintenance dose (MD) necessary to obtain a predefined target 
concentration: 
ind
ss
etargt CLC
MD   equation 1-1
where τ is the dosing interval and sstargetC  the desired steady-state target concentration.  
This method has the advantage that only a few concentration measurements per patient 
are necessary to obtain valid PK parameter estimates.  
With a PK/PD model the above example could be extended to calculate the dose that 
most likely achieves a desired biomarker response in a patient, thus not only accounting 
for PK variability between patients, but also for variation in the pharmacological 
response. Whereas many examples exist for PK-guided dose individualizations (e.g., 
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aminoglycosides, vancomycin, theophylline) [36-39], PK/PD models for this purpose 
are rare. One fit-for-purpose example has recently been proposed for the dose 
adaptation of etoposide based on the number of neutrophil granulocytes as a biomarker 
of myelosuppression [40].    
In the light of increasing public interest in terms like “personalized medicine” and 
“tailored therapy” PK/PD-guided dose individualization may also receive growing 
attention and more examples like these will be seen in the future [41].  
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1.2 Biomarkers 
1.2.1 Definitions and Overview 
In 2001 the Biomarker Definitions Working Group published the following 
comprehensive definition of a biological marker (biomarker) [42]: 
“…a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacological responses to a 
therapeutic intervention.” 
Biomarkers can be further divided into two groups [43]:  
 biochemical biomarkers (e.g., blood glucose, cytokines) 
 clinical biomarkers (e.g., blood pressure, tumor size) 
In oncology it is often distinguished between prognostic and predictive biomarkers. 
Prognostic biomarkers provide information about the patients overall cancer outcome, 
independent of therapy (e.g., prostate-specific antigen [PSA]), while predictive 
biomarkers can be used to estimate the response of a particular patient to a specific 
treatment (e.g., expression of human epidermal growth factor receptor 2 [HER2/neu] as 
a predictor of response to treatment with trastuzumab).  
Biomarkers should have a profound theoretical relation to the underlying disease 
mechanism and/or the mechanism of action of a pharmacological intervention. 
Moreover, biomarkers, particularly biochemical biomarkers, should be measured 
meeting acknowledged analytical standards in terms of stability, specificity, 
reproducibility, precision, and accuracy. However, it should be noted that assay 
development and validation for a biochemical biomarker is not as straightforward as it 
is for a drug assay and several issues may be challenging (e.g., lack of analyte-free 
matrices, availability of reference standards) [43].   
Biomarkers that proved to predict precisely and accurately clinical benefit may 
substitute for a clinical endpoint (i.e., a characteristic reflecting how a patient feels, 
functions, or survives [42]) and are therefore called surrogate endpoints. According to 
the International Conference on Harmonization’s guideline on “Statistical Principles for 
Clinical Trials” a surrogate endpoint must meet the following criteria [44]:  
 biological plausibility 
 prognostic value of the surrogate for the clinical outcome 
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 evidence from clinical trials that treatment effects on the surrogate correspond to 
effects on the clinical outcome 
Popular examples of reliable surrogate endpoints, accepted by regulatory agencies, are 
the human immunodeficiency virus (HIV) plasma viral load in conjunction with CD4 
cell counts for the evaluation of antiretroviral agents in patients with HIV infection, or 
blood pressure as a predictor for life-threatening cardiovascular events in hypertensive 
patients [45].  
1.2.2 Applications of Biomarkers 
Of course, clinical endpoints are generally the most reliable characteristics to assess the 
outcome of a therapeutic intervention and should be preferred over surrogate endpoints 
whenever possible. However, some clinical endpoints, such as survival, need long 
observation periods and a large number of patients in clinical trials to be robustly 
evaluated. This is impractical in many situations and renders clinical development of 
new drugs inefficient. The great demand for readily and timely measurable surrogate 
endpoints in order to accelerate approval of new drugs is obvious [18].  
Although it is desirable that a biomarker eventually becomes a surrogate endpoint, a 
biomarker that cannot substitute for a clinical endpoint may still be of great value in 
drug development and patient care.  
A measurable change of a biomarker in response to a pharmacological intervention may 
serve as proof-of-concept (POC) in early phases of development. This is valuable 
information when, for example, a selection has to be made between several candidate 
compounds. The POC is often possible even in preclinical animal testing if the 
biomarker exists (and behaves similarly) in species other than humans. Since the vast 
majority of drugs act on receptors or physiological structures that exist in humans 
irrespective of a disease, POC studies in healthy volunteers can provide important 
information. For example, a new antihypertensive drug that does not reduce blood 
pressure in healthy subjects will probably not be effective in hypertensive patients either. 
Integrating quantitative biomarker information into a PK/PD model (the biomarker 
represents the PD part then) facilitates rational decision making regarding dose selection 
and trial design (see section 1.1.2) or discontinuation of a project due to insufficient 
biomarker response. 
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In clinical practice physicians have been successfully using biomarkers to guide 
treatment individualization (e.g., international normalized ratio [INR] for the treatment 
with oral anticoagulants, blood glucose for insulin treatment) for years, although many 
of them do not have the status of a surrogate endpoint required for regulatory approval. 
The potential of biomarker-guided treatment individualization is tremendous both for 
drugs yet exiting and those that will be developed in the future.  
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1.3 Venlafaxine 
1.3.1 Therapeutic Use and Clinical Pharmacology 
Venlafaxine (Effexor®, Trevilor®, Wyeth Pharmaceuticals Inc.) is approved for the 
treatment of major depressive disorder, generalized anxiety disorder, panic disorder and 
social phobia [46]. It also showed to be effective for the relapse and recurrence 
prevention of major depressive episodes [47], and is currently the only antidepressant 
approved for this indication [46,48]. The recommended starting dose is 75 mg/day 
which can be increased up to 375 mg/day in severely depressed patients. The most 
common side effects during treatment with venlafaxine are gastrointestinal disorders, 
excessive sweating, and dry mouth [46]. 
Venlafaxine is rapidly absorbed after oral administration of an immediate release 
formulation reaching maximal plasma concentrations by approximately 3 hours [49]. It 
is metabolized to its major active metabolite O-desmethylvenlafaxine via the 
cytochrome P450 (CYP) 2D6 enzyme system in the liver and undergoes an extensive 
first-pass metabolism (Figure 1-3) [49]. In a mass balance study with radioactive 
labeled venlafaxine, over 90% of total radioactivity was recovered in urine: 5% as 
unchanged venlafaxine, 55% as conjugated and unconjugated O-desmethylvenlafaxine, 
and 15% as other, less active, N-desmethyl metabolites [50,51]. Binding to plasma 
proteins is relatively low with values of 27 and 30% for venlafaxine and 
O-desmethylvenlafaxine, respectively. The terminal half-lives of venlafaxine and 
O-desmethylvenlafaxine are 5 and 11 hours, respectively [46].   
OH
N
O
OH
N
HO
CYP 2D6
Venlafaxine (MW: 277 g/mol) O-desmethylvenlafaxine (MW: 263 g/mol)
* *
 
Figure 1-3 Chemical structure of venlafaxine and its major metabolite. The asymmetric 
center is marked with an asterix. Only the racemate is on the marked. 
CYP: Cytochrome P450; MW: Molecular weight. 
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Venlafaxine and O-desmethylvenlafaxine achieve their pharmacological effect by 
inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake from the synaptic gap. 
Preclinical findings showed that the affinity of venlafaxine and O-desmethylvenlafaxine 
for 5-HT transporters is about 3-fold higher as for NE transporters [52]. This property is 
of clinical relevance, as it has been demonstrated that with higher doses of venlafaxine, 
additional antidepressant effects can be achieved which could not be attributed to a 
single saturable dose-response relationship [53,54]. This means that at low doses, 
inhibition of 5-HT reuptake is the main mechanism of action, whereas at higher doses 
inhibition of NE reuptake exerts an additional effect [55]. 
1.3.2 Biomarkers of Interest 
The pharmacological treatment of depression and the development of new 
antidepressants could potentially benefit from a reliable and readily measurable 
biomarker. There is a considerable latency of about two weeks between the start of the 
treatment and noticeable improvement of the patients’ mood [56]. An early responding 
biomarker could be useful to adjust the dose without having to wait until the first signs 
(or lack of them) of clinical response are evident.  
During clinical development of a new antidepressant, a biomarker could be of use in 
POC studies in healthy subjects and, at later stages, it could help to establish the dose-
response relationship. A noninvasive test system to indirectly measure inhibition of NE 
reuptake (i.e., noradrenergic response) is pupillography. Constriction and subsequent 
dilatation of the pupil after a short light flash (i.e., the pupillary light reflex) is 
controlled by the parasympathetic and sympathetic nervous system and therefore is 
sensitive to inhibition of NE reuptake.  
In detail, an incoming light signal is transmitted by the optic nerve to the protectal area 
from which it is further passed to the Edinger-Westphal nucleus. Its axons run along the 
oculomotor nerve and synapse in parasympathetic cilliary ganglion neurons innervating 
the pupillary constrictor muscle of the iris. Projections from the midbrain contact 
thoracic segments of the spinal cord from which the sympathetic innervation of the 
pupillary dilatator muscle originates. The Edinger-Westphal nucleus is under tonic 
inhibitory noradrenergic control from the locus coeruleus and the corticolimbic system. 
Venlafaxine increases this inhibitory control by blocking the NE uptake form the 
synaptic gap, leading to a reduction of parasympathetic signals going to the eye. 
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Inhibition of NE uptake at the pupillary dilatator muscle by venlafaxine directly affects 
the pupil size. Figure 1-4 illustrates this pathway of the pupillary light reflex and the 
supposed sites of action of venlafaxine.  
 
 
Figure 1-4 Schematic representation of the neuronal pathway of the pupillary light reflex. 
(Modified from White & Depue [57]; further explanations see text) 
 
 
Changes of the pupil diameter after emission of a short light flash can be recorded with 
a pupillographic device shown in Figure 1-5. Four relevant parameters can be derived 
from such records: 
 Resting pupil diameter (i.e., the diameter shortly before the light flash) 
 Latency (i.e., the time difference between the end of the light flash and the 
onset of pupil constriction) 
 Amplitude (i.e., the difference between the initial and the minimal diameters) 
 Recovery time (i.e., the time it takes to redilatate to a predefined percentage of 
the initial diameter) 
The time course of a typical light reflex response is shown in Figure 1-6. 
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Figure 1-5 Subject during a pupillographic measurement (left photograph) and the 
operator’s view on the pupil (right photograph). (From AMTech GmbH, 
Dossenheim with permission) 
Placeholder 
Figure 1-6 Example of a light reflex response. Grey bar: light stimulus; A: onset of light 
stimulus; B: onset of response; C: time at maximal constriction. D: time at 
which 33% recovery is attained. (Modified after Bitsios et al. [58]) 
 
The resting pupil diameter reflects the balance between the opposing effects of 
sympathetic and parasympathetic innervations of the iris. A parasympatholytic drug like 
atropine for example, shifts the balance towards sympathetic activity resulting in an 
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increased pupil diameter. The recovery time is thought to reflect sympathetic activity in 
the iris, whereas the amplitude and latency are generally attributed to parasympathetic 
effects [58]. Bitsios et al. reported significant changes of the pupillary light reflex 
parameters 100 min after administration of a single dose of venlafaxine (75 mg or 
150 mg) to healthy subjects [58]. However, the time course of changes in pupillary light 
reflex parameters and its relation to plasma concentrations of venlafaxine and 
O-desmethylvenlafaxine have not been studied so far. 
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1.4 Sunitinib 
1.4.1 Therapeutic Use and Clinical Pharmacology 
Sunitinib malate (Sutent®, Pfizer Inc.) is a multitargeted tyrosine kinase inhibitor that 
inhibits tumor cell proliferation and angiogenesis. It is approved for the treatment of 
renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor 
(GIST) [59]. Its activity in other tumor types such as hepatocellular carcinoma or non-
small cell lung cancer is currently investigated in numerous clinical trials (see 
www.clinicaltrials.gov). Sunitinib is given orally, once daily as a 50 mg capsule over 4 
weeks, followed by a 2-weeks rest period in repeated 6-weeks treatment cycles. At this 
dose, the most frequently observed adverse effects are fatigue, hypertension, diarrhea, 
stomatitis and hand-foot syndrome [59]. 
Following oral administration sunitinib is slowly absorbed from the gastrointestinal 
tract reaching maximum plasma concentrations after about 6 to 12 hours. It is primarily 
metabolized by CYP 3A4 to its active N-desethyl metabolite (SU12662) and is subject 
to presystemic metabolism by this enzyme (Figure 1-7) [60]. In a mass balance study in 
humans with 14C-labeled sunitinib, 61% of the radioactive dose was recovered in feces 
and 16% in urine. In plasma samples sunitinib and SU12662 accounted for 71 and 
20.5% of the total radioactivity, respectively [61]. Approximately 95% (90%) of 
sunitinib (SU12662) is bound to plasma proteins. Because of the long terminal half-
lives of sunitinib and SU12662 (40 to 60 h and 80 to 110 h, respectively), steady-state 
concentrations are not achieved until 2 weeks of continuously daily dosing.  
N
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(MW: 398 g/mol) CYP 3A4
Figure 1-7 Chemical structure of sunitinib and its major metabolite SU12662. 
CYP: Cytochrome P450; MW: Molecular weight. 
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Sunitinib and SU12662 inhibit a variety of receptor tyrosine kinases (RTK) by 
reversibly binding to intracellular adenosine triphosphate (ATP)-binding sites [62]:  
 vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3 
 platelet-derived growth factor receptor (PDGFR) alpha and beta 
 stem-cell growth factor receptor (KIT)  
 fms-related tyrosine kinase-3 (FLT3) 
 colony stimulating factor-1 receptor (CSF1R) 
Inhibition of VEGFR-2 and PDGFR-β is predominantly responsible for the reduction of 
tumor-related blood vessel formation, which explains its activity against the highly 
vascular RCC [63]. By contrast, GIST is susceptible to sunitinib probably because of a 
high expression of KIT by this tumor [64].  
VEGF-A is released by tumor cells, as well as fibroblasts and other stromal cells 
(Figure 1-8 a). A trigger for the production of VEGF-A is tissue hypoxia. The 
decreasing oxygen supply in a growing tumor stimulates the production of hypoxia 
inducible factor-1 (HIF-1) which in turn increases the transcription of VEGF-A. It has 
further been shown that an inactivated von Hippel-Lindau tumor suppressor gene - 
occurring in about 50% of RCC tumors - leads to a higher expression of HIF-1 [65]. 
Tumor-derived PDGF plays an important role in tumor-vessel stability by recruiting 
pericytes to newly formed vessels. Via its receptor alpha it regulates VEGF-A derived 
from fibroblasts [66].  
After binding of VEGF-A to VEGFR-2 on the surface of endothelial cells, a signaling 
cascade is initiated leading to cell survival, proliferation, migration, and vascular 
permeability. Sunitinib inhibits the tyrosine kinase-mediated autophosphorylation of the 
receptor, thus blocking this signaling process (Figure 1-8 b). 
At present only two other antiangiogenic agents are on the market: the monoclonal 
antibody bevacizumab (Avastin®) and the tyrosine- and raf-kinase inhibitor sorafenib 
(Nexavar®). Development of new angiogenesis inhibitors is, however, a major area in 
oncology research and many promising drugs targeting the VEGF-pathway, such as 
telatinib and axitinib, are in the pipelines of pharmaceutical companies [68-70]. 
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Figure 1-8 
 
The role of VEGF-A in tumor angiogenesis. a release of growth factors in the 
tumor environment. b VEGF-A induced signaling process in the endothelial 
cell. (Adapted from Hicklin et al. [66], Takahashi et al. [67] and Faivre et 
al. [62]) 
VEGF: vascular endothelial growth factor; PDGF: platelet derived growth 
factor; Raf: rat fibrosarcoma (kinase); MEK: mouse embryonic kinase; ERK: 
extracellular signal-regulated kinase; PI3K: phosphatidylinositol 3-kinase; 
eNOS: endothelial nitric oxygen synthase; NO: nitric oxygen; mTOR: 
mammalian target of rapamycin; p38MAPK: protein 38 mitogen-activated 
protein kinase. 
 
1.4.2 Biomarkers of Interest 
For anti-VEGF drugs it is a major challenge to find the optimal biological dose 
associated with a low risk of toxicity and high efficacy [71,72]. The concept of using 
the maximum tolerated dose (MTD) as it is traditionally applied for cytotoxic agents 
may not always be appropriate for these substances. The mechanism of action of 
cytotoxic drugs often involves interaction with the tumor DNA, a virtually nonsaturable 
target structure, thus efficacy increases almost proportionally with the dose and the only 
limitation is toxicity.   
However, targeted drugs act on receptors (or other functional proteins) and from 
classical receptor theory it is known that the maximum effect is achieved when all 
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binding sites are occupied [7]. Increasing the dose further would then have no additional 
benefit. Applying the MTD concept in dose-finding studies of these new drugs could 
therefore result in unnecessarily high doses, when in fact lower, less toxic doses would 
be equally effective. To determine the optimal biological dose level, objectively 
measurable markers of early response to treatment have to be found. Biomarkers 
associated with target modulation have the potential to meet this challenge. In numerous 
reports it was shown that several circulating proteins (e.g., VEGF-A and VEGF-C, 
soluble (s) VEGFR-2 and -3) as well as blood pressure (BP) consistently changed in 
response to antiangiogenic therapy [73-81].  
Ebos et al. observed increasing VEGF-A and decreasing sVEGFR-2 concentrations 
after administration of sunitinib to nontumor bearing mice, to a similar extent as it was 
seen in xenograft models [73]. Tumor being the only (major) source of release of 
proangiogenic factors is therefore unlikely. In fact, these authors showed that the 
increase in VEGF-A is highest in heart and spleen tissue and the decrease in sVEGFR-2 
is highest in liver, heart, and spleen. In extensive studies in mice, it could be 
demonstrated that high levels of VEGF-A (induced by adenoviral-mediated delivery of 
the human VEGF-A gene) lead to a subsequent decrease in sVEGFR-2 plasma 
concentrations. Further in vitro experiments indicated that VEGF-A mediates the down-
regulation of VEGFR-2, which in turn leads to reduced levels of the soluble form of this 
receptor [82]. 
Despite these elaborate preclinical studies it is unclear whether VEGF directly mediates 
the decrease in sVEGFR-2 production. Since sunitinib blocks the activation of 
VEGFR-2 by VEGF-A, the signal for the downregulation of VEGFR-2 may not be 
trigged by this very same receptor in the presence of the drug. Given that a multitude of 
circulating proteins are involved in the regulation of angiogenesis, potentially 
interacting and influencing each other, it may be possible that the downregulation of 
VEGFR-2 is only indirectly mediated by VEGF [73].  
Based on clinical and preclinical observations it appears plausible that some sort of 
feedback mechanism controls plasma concentrations of VEGF-A, leading to higher 
levels when its receptor is blocked [73,76]. Figure 1-9 illustrates a proposed mechanism 
of biomarker response to VEGF receptor inhibition. 
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Figure 1-9 Proposed mechanism of biomarker response to VEGF receptor inhibition. 
The activation of VEGFR-2 by VEGF-A leads to a decreased cellular 
production of VEGF-A and thus controlling the plasma levels of VEGF-A. 
VEGF-A is involved in the downregulation of VEGFR-2 which in turn 
regulates plasma concentrations of sVEGFR-2. In the absence of tumor or 
VEGFR inhibitors the system is at equilibrium. 
Considerable increase in blood pressure has been reported in many studies with 
different antiangiogenic drugs as a frequent side effect, so that it is now considered as a 
class effect [83-87]. Mainly two mechanisms of action are discussed, (i) reduction in 
endothelial nitric oxide synthase (eNOS) expression which is controlled by VEGF 
signaling (Figure 1-8 b), and (ii) vascular rarefaction, that is, a decrease in perfused 
microvessels and a reduction in capillary density both controlling peripheral vascular 
resistance. Moreover, VEGF inhibition may induce renal thrombotic microangiopathy 
leading to blood pressure disequilibrium and proteinuria, another common side effect of 
VEGFR inhibition [87,88]. In a recent publication Keizer et al. presented an interesting 
PK/PD model for hypertension and proteinuria following treatment with a new VEGF-
inhibitor currently under clinical development [89].   
Generally, hypertension caused by antiangiogenic drugs can be well controlled by 
standard anti-hypertensive treatment (e.g., calcium antagonists) and may therefore not 
constitute a major safety concern [87]. Since blood pressure can be easily measured in 
clinical practice, this biomarker could be of great value as a tool for oncologists to 
assess and optimize antiangiogenic treatment. However, before any useful biomarker 
guided treatment optimization strategy can be developed a clear understanding of the 
dose-concentration-effect relationship is a prerequisite. 
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2 Objectives 
 
This thesis aims at illustrating the concept of PK/PD modeling and simulation using 
biomarkers on the example of two projects with drugs from different therapeutic areas. 
In both cases drug concentration and biomarker data were obtained from clinical studies 
in healthy volunteers.    
In the first project the noradrenergic response to venlafaxine (and 
O-desmethylvenlafaxine), measured by pupillography was subject to model 
development and, based on the modeling results, optimal pharmacodynamic sampling 
times for possible future studies were to be explored. Since venlafaxine is also available 
as an extended release formulation, the influence of a slower release on the PD response 
was to be assessed by deterministic simulations.  
In the second project PK/PD models had to be developed to quantify changes of blood 
pressure, plasma concentrations of VEGF-A and VEGF-C, and sVEGFR-2 in relation to 
sunitinib (and SU12662) concentrations. In order to address the question whether a dose 
adjustment based on blood pressure measurements could be beneficial with respect to 
clinical outcome, a hypothetical clinical trial was simulated comparing a dose 
individualized regimen to the standard dose regimen. 
 
Both projects discussed in this thesis have been previously published in part in 
international scientific journals: 
Lindauer, A., Siepmann, T., Oertel, R. et al. Pharmacokinetic/Pharmacodynamic 
modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. 
Clin Pharmacokinet 2008; 47: 721-731 
Lindauer, A., Di Gion, P., Kanefendt, F. et al. Pharmacokinetic/Pharmacodynamic 
modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 
2010; 87: 601-608  
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3 Material and Methods 
3.1 General Methods of PK/PD Data Analysis  
3.1.1 Nonlinear Mixed Effects Modeling 
The pharmacokinetic and pharmacodynamic data analyses described in this thesis were 
performed by means of nonlinear mixed effects modeling (NLME) implemented in 
NONMEM® (versions 6.0 and 6.2) [90]. This method is a special kind of nonlinear 
regression analysis where the observations (e.g., drug concentrations, biomarker 
measurements) are described by a mathematical function (i.e., a model) consisting of 
error-free independent variables (e.g., time, dose, covariates), the fixed effects, and 
variables that are subject to random error (e.g., between-subject variability, residual 
error), the random effects. Both effects are accounted for in the same model, therefore 
the term “mixed” effects modeling. 
In contrast to the standard regression analysis, this approach provides the possibility to 
analyze data from different individuals at once by simultaneous estimation of the typical 
(i.e., average) model parameters and their associated variability. The method is also 
termed population PK/PD modeling, as it is especially useful for the analysis of 
variability among individuals in large patient populations.  
NLME permits the distinction between different sources of variability associated with 
drug concentration or biomarker measurements. Model parameters may not only vary 
between different individuals (i.e., interindividual variability, IIV), but also within a 
particular subject from one occasion (e.g., day) to another (i.e., interoccasion variability, 
IOV). Finally, the discrepancy between observations and model predictions constitute 
the unexplained residual variability (i.e., residual error). A general mathematical 
expression of the NLME function is shown in equation 3-1: 
),,,z,x,(fY   equation 3-1
where Y represents the vector of all observations in all individuals, the function f is the 
NLME model that contains the vector of typical population parameters (θ), the vector of 
fixed effects controlled by the investigator (x; e.g., time and dose) and, if applicable, the 
vector z, containing patient-specific covariates which are also treated as fixed effects in 
the model. The random effects are described by the matrices Ω, Κ and Σ comprising 
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interindividual, interoccasion and residual variability parameters, respectively. In the 
following expression a NLME model is illustrated for a pharmacokinetic one-
compartment model with intravenous bolus administration: 
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where Cji is the jth measured concentration in subject i at time tj, D is the dose, θV and 
θCL are the typical volume of distribution and typical clearance in the population, 
respectively. The deviation of an individual value from the typical parameter value is 
described by ηi and the deviation from that at each occasion q, is denoted κq. εji is the 
discrepancy between the individual predicted concentration ( jiCˆ ) from the observation. 
η, κ and ε are random quantities with a mean value of 0 and the variances ω2, π2 and σ2, 
respectively. Collectively, Ω, Κ and Σ are the matrices of all the estimable variability 
parameters. 
The estimation algorithm implemented in NONMEM iteratively seeks for a set of 
model parameter values with the aim of maximizing the likelihood that the observations 
were derived from the model. Mathematically, the algorithm tries to find the global 
minimum of the extended least square objective function (OFELS, equation 3-3) [13]: 
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where yi is the vector of the observations for subject i and iyˆ  the vector of 
corresponding predictions, var(yi) is the variance matrix of yi, which in fact is a function 
containing all the variability parameters of the model. The logarithm penalty term on the 
right-hand side of equation 3-3 prevents the objective function from minimizing to 0 as 
the variance parameters increase to infinity. 
Since all random effects enter nonlinearly into the objective function, equation 3-3 has 
no closed-form solution and its minimum cannot be calculated analytically (as it would 
be the case for a simple linear regression model). In NONMEM a Taylor series 
approximation is used to account for this issue. A Taylor series is a high-order 
polynomial that approximates a function f at point x (i.e., f(x)) given the function value 
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and its derivatives (∂f(x)) at another point x0 [5]. In NONMEM the model function is 
linearized into a first-order polynomial of the function itself and its first partial 
derivatives with respect to the η’s (etas) [90]. Thus, the first-order Taylor approximation 
of the (simplified) model from equation 3-2 evaluated at η0 would be: 
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 equation 3-4
where f(…,η0) is the function value for the jth concentration in the ith subject with the ηs 
set to η0. The same applies to the partial derivates. Note that εji now also contains the 
error resulting from the approximation. Two principal methods are used in NONMEM: 
the first-order (FO) method where the Taylor series is evaluated at η0=0, and the more 
accurate FO conditional estimation (FOCE) method, where the approximation is done 
by setting η0 to the vector of the Bayesian estimates of the η’s. This means that at every 
iteration the estimates for all η’s are computed conditionally on the current Ω 
matrix [5,90]. A further refinement is the use of the interaction option, allowing ε to be 
dependent on η, which is particularly important when the residual error increases 
proportionally to the observed value (i.e., proportional error model, see next section). 
In this thesis only the first-order conditional estimation method (FOCE) with interaction 
was used. NONMEM runs were executed using Wings for NONMEM 
(version 6.14) [91] and compiled with the G77 Fortran compiler (version 2.95). 
3.1.2 Model Development 
Structural Model 
A PK or PD model is usually developed in a step-wise manner, beginning with the 
simplest model proceeding to more complex ones. Here the word “complex” refers to 
the number of model parameters. At every step, that is, with every intermediate model, 
it has to be decided, based on objective and subjective criteria (see section 3.1.3), how 
to proceed with the model development (e.g., adding or excluding model parameters or 
covariates). Usually model building should start with the structural model including 
only few random effects parameters right from the beginning. More variability 
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parameters are then continuously added, and, if it is an objective of the analysis, 
covariates on model parameters are included [5].   
The structural model should be able to characterize the central tendency of the observed 
data best. Different structural models were explored for the drugs that are subject to this 
thesis with details given in sections 3.2.5 and 3.2.6 for the venlafaxine example and 
sections 3.3.4 and 3.3.5 for the sunitinib example. 
The combined PK/PD models were developed in a sequential manner. First the PK 
model was completed. Individual PK parameter estimates obtained from this step were 
then used as input (together with the PD data) for the development of the PD part of the 
models. 
Interindividual Variability 
Interindividual variability was generally modeled as an exponential relationship: 
iePi
  equation 3-5
where Pi is the individual value of a model parameter (e.g., clearance), θ its typical 
value in the population and ηi is the difference between Pi and θ in the logarithmic 
domain. The interindividual variability is usually reported as a (geometric) coefficient 
of variation (CV) according to: 
1e100(%)CV
2    equation 3-6
For example, an estimate of ω2 of 0.1, denoting the variance of the model parameter in 
the logarithmic domain, would translate to a CV of approximately 32%. The 
exponential parameterization has the advantage that individual parameter estimates 
cannot be negative. Moreover, PK parameters often follow a right-skewed (log-normal) 
distribution which is better captured with the exponential model. 
Interindividual variability cannot always be estimated for every parameter in the model, 
especially when the number of subjects in the dataset is small. The decision if a 
variability parameter should be retained in the model or not, was mainly based on the 
estimated value itself and its contribution to the objective function value (OFV; see 
section 3.1.3.1). For example, if the estimated variance (or the CV) for a certain 
parameter was close to 0 it was removed from the model without any significant change 
of the OFV. It should be noted however, that this does not mean that the respective 
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parameter is free of variation. Rather it means that the given dataset does not contain 
sufficient information to support the quantification of the variability. 
In the sunitinib project the correlation of variance parameters was also explored by 
estimating the off-diagonal elements of the covariance matrix Ω: 

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
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 2
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1P  equation 3-7
where 21P and 21P  are the variances of the parameter P1 and P2 and 2P,1P  their 
covariance. The correlation coefficient (ρ) for the variances of the two parameters P1 
and P2 is then calculated according to: 
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
  equation 3-8
The estimation of a full covariance matrix is a numerically complex operation and often 
leads to unstable models (e.g., models that do not converge or are very sensitive to 
initial estimates). Therefore the estimation of off-diagonal elements of the covariance 
matrix was only considered when: (i) a scatter plot matrix of the empirical Bayes 
estimates indicated a strong correlation between random effects; (ii) the correlation was 
mechanistically/physiologically plausible; and (iii) inclusion into the model 
significantly improved the OFV. 
Interoccasion Variability  
Interoccasion variability was only applicable to the sunitinib project where observations 
from more than one study day were available. Guided by the principle of parsimony it 
was decided to test for interoccasion variability only on the mean transit time, a 
parameter describing the delayed absorption of sunitinib. This decision was based on 
the visual inspection of the observed concentration vs. time plots for each subject, 
where the delay in the absorption phase obviously differed in magnitude from one study 
day to the other, within the same individual.    
Similar to interindividual variability, an exponential relationship was applied for 
modeling interoccasion variability: 
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qieMTT MTTiq
  equation 3-9
where MTTiq is the mean transit time for the i-th subject on the q-th study day and θMTT 
describes the average value of this parameter in the study population. A CV for the 
interoccasion variability was calculated according to equation 3-6. 
Residual Variability 
Three different commonly used residual error models were applied in this thesis to 
account for the discrepancy between model predictions ( jiyˆ ) and observations ( jiy ):  
a) the additive model 
addjiji yˆy   equation 3-10
b) the proportional model 
)1(yˆy propjiji   equation 3-11
c) the combined model  
addpropjiji )1(yˆy   equation 3-12
where εadd and εprop are random quantities with mean 0 and variances 2addσ and 2propσ , 
respectively. Hence, 2propσ100  represents the coefficient of variation of the residual 
error (in %) and 2addσ its standard deviation (same unit as the observations). The 
additive error model can usually be applied if the assumption of homoscedasticy holds 
(i.e., constant variance independent of the magnitude of the measurement). This is often 
the case for PD data when the range of measured values is narrow (e.g., blood pressure). 
If, however, the measured values span several orders of magnitude (e.g., drug 
concentrations) the error usually increases proportionally with increasing values. The 
combined error model, often seen in PK models, merges the former two models, hence 
being the most flexible approach. 
3.1.3 Model Evaluation and Goodness-of-Fit 
The assessment of how good a model fits to a given set of data is important in all 
model-based data analyses. The agreement between observations and model predictions 
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is evaluated by numerical and graphical tools. In the following sections the evaluation 
techniques that were used in this thesis are described. Since some of these methods are 
very time-consuming (e.g., bootstrap, visual predictive checks) they were not routinely 
applied to every single intermediate model but were reserved for the evaluation of key 
models and final models.      
3.1.3.1 Metrics of Model Assessment 
Objective Function Value 
The value of the objective function (see section 3.1.1, equation 3-3) is a routine 
NONMEM output and serves as a metric to discriminate between competing models. 
Since the difference of the objective function value of two models (ΔOFV) is 
approximately χ2-distributed, parametric statistics can be applied to calculate a p-value 
for a given ΔOFV [5]. For example, if two models differ in the number of model 
parameters by one (degree of freedom [df] = 1) a ΔOFV of at least 3.84 would be 
necessary for the models to be significantly different from each other (p <0.05). This 
method is also known as the likelihood ratio test (LRT). Table 3-1 shows some 
commonly used levels of significance along with their associated ΔOFV for different 
degrees of freedom. 
 
Table 3-1 ΔOFV for various levels of significance (α) and degrees of 
freedom assuming a χ2-distribution 
Degrees of 
freedom α=0.05 α=0.01 α=0.001 
1 3.84 6.64 10.83 
2 5.99 9.21 13.82 
3 7.81 11.34 16.27 
4 9.49 13.28 18.47 
 
It should be noted that the LRT is strictly only valid for nested models, i.e. if one model 
is a hierarchical simplification of another [5]. A one-compartment model, for example is 
nested within a two-compartment model, whereas it is not a direct simplification of a 
model with nonlinear Michaelis-Menten elimination. However, in this thesis the ΔOFV 
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was also used for the assessment of non-nested models, although in such cases the LRT 
was never a single criterion for the discrimination between competing models.  
Epsilon Shrinkage 
Karlsson and Savic recently pointed to a problem that occurs especially in situations 
when individual data are sparse and lack sufficient information about model 
parameters [92]. Then individual predictions (IPRED) will “shrink” towards the actual 
observation. Goodness-of-fit plots of observations vs. IPRED will then suggest “a 
perfect fit” although the model may be misspecified, rendering this type of diagnostics 
useless to assess the model fit. A measure of informativeness of the individual 
predictions is ε-shrinkage. It is calculated as 100 × (1-σIWRES), where σIWRES stands for the 
standard deviation of the individual weighted residuals (IWRES). When ε-shrinkage is 
high (>20%) individual data are sparse in information and diagnostic plots using IPRED 
are of limited use [92].   
3.1.3.2 Bootstrap Method 
The bootstrap method, first described by Efron, is commonly seen in population PK 
data analyses as a tool to assess the precision of parameter estimates by calculating their 
nonparametric confidence intervals [93]. The procedure is a resampling technique 
where a sufficiently large number of new datasets is generated by randomly sampling 
with replacement individuals out of the original dataset. Parameter estimates are then 
obtained for each bootstrap dataset and summary statistics can be applied to the 
distribution of these estimates. In this thesis, whenever this method was applied, 1000 
bootstrap datasets were generated and each was evaluated using the respective PK or 
PD model. With the results from those estimation procedures (i.e., “runs”) where 
NONMEM was able to calculate the variance-covariance matrix (i.e., a successful 
covariance step), the 5th and 95th percentiles of the parameter distribution were derived 
representing the lower and the upper bound of a nonparametric 90% confidence interval. 
The bootstrap analysis was performed with PsN (Perl speaks NONMEM, versions 2.2.3 
to 2.3.1) [94]. 
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3.1.3.3 Standard Goodness-of-Fit Plots 
The graphical assessment of a model fit is very important to detect model 
misspecification and to discriminate between competing models, especially in situations 
when numerical methods are not reliable or not applicable. The following goodness-of-
fit plots were routinely inspected after every NONMEM run: 
 Observations vs. IPRED and population predictions (PRED)  
 Weighted residuals (WRES) vs. PRED 
 WRES vs. time (or time after dose) 
 Individual weighted residuals (IWRES) vs. IPRED 
IWRES are not a standard output of NONMEM but can be easily obtained as shown in 
equation 3-13 for a combined residual error model: 
2
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2
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2
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jiji
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)IPREDOBS(
IWRES

  
equation 3-13
where IWRESji is the ith IWRES for the jth subject, OBS the observation (e.g., 
concentration), σadd is the standard deviation and σprop the coefficient of variation of the 
additive and proportional components of the residual error model, respectively (see 
residual variability in section 3.1.2). 
For key models and the final models, PsN was used to calculate conditional weighted 
residuals (CWRES), which were then plotted against PRED or time. Unlike WRES, 
which were always calculated by a first-order linearization around the population mean 
of the random model parameters even though FOCE was used as estimation method, 
CWRES in contrast were calculated by linearization at each individual’s Bayesian 
estimates. Therefore, CWRES were thought to be more appropriate for model 
diagnostics when FOCE was the estimation method [92,95]. All goodness-of-fit plots 
were generated using the software Xpose (versions 4.0.1 to 4.0.3) [96]. 
3.1.3.4 Visual Predictive Check 
The visual predictive check (VPC) is a simulation-based diagnostic tool increasingly 
used in order to assess if simulations from a model resemble the observations with 
which the model was developed [92,97]. A VPC is further useful to graphically assess 
how model simulations compare with data which were not used for model building (e.g., 
external validation, comparison with literature). 
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For the preparation of the VPCs 1000 simulations were performed with the final models 
under the original study design (e.g., dose, dosing interval, sampling times). With the 5th 
and 95th percentiles of the simulated values a 90% prediction interval was constructed 
and plotted along with the observations and the median of the simulated values [98]. 
Ideally, the median of the simulations should reflect the central tendency of the 
observations without any systematic deviation. Variability is well captured by the model 
if, at every sampling time point, 5% of the observations are above (below) the 95th (5th) 
percentile of the simulations. It is therefore recommended to plot also the respective 
percentiles of the observations and compare these with those obtained from the 
simulations [97]. However, since the number of subjects in either project was only 12 
(i.e., maximal 12 observations per time point), the 5th and 95th percentiles were not 
regarded meaningful and were not calculated.  
In the sunitinib example simulated and observed values of the biomarkers were 
normalized to their respective baseline values. 
All VPCs shown in this thesis were generated using PsN and Xpose. 
3.1.3.5 Sensitivity Analysis 
In order to assess the influence and appropriateness of fixed parameters (i.e., model 
parameters that were not estimated but fixed to some predefined value), sensitivity 
analyses were performed. That is, each fixed model parameter value was changed in 
steps of 10% from -50% to +50% of its original value. The results were assessed in 
terms of changes of the estimated parameters and the OFV with respect to the original 
run. Differing from this procedure, R, the value for the relative potency of 
O-desmethylvenlafaxine compared to venlafaxine and Rsl, the relative contribution of 
the transduced signal with respect to the immediate signal of sunitinib’s effect on blood 
pressure were changed from 0 to 1.0 by a step size of 0.1. Similarly, the value of Kd, the 
dissociation constant used in the sunitinib PD models, was changed from 1 to 10 by a 
step size of 1. The fraction of sunitinib transformed to SU12662 (fm) was varied from 
0.1 to 0.9 by a step size of 0.1. 
3.1.4 Simulations 
Most simulations performed in this thesis were stochastic simulations, either to perform 
VPCs (see section 3.1.3.4), to compare the models with data from literature (see section 
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3.3.6.1), or to predict the outcome of a dose individualization study (see section 3.3.6.2). 
For this kind of simulation, also known as Monte Carlo simulation, a number of sets of 
model parameters are randomly sampled from a multivariate distribution, determined by 
the typical parameter values and their associated variability. For each set of parameters 
the model response (e.g., drug or biomarker concentrations) is then calculated. This 
method permits inference not only on the typical model response (e.g., average 
concentration-time profile) but also on the expected variability in a population. All 
stochastic simulations were performed with NONMEM, except for the dose 
individualization study which was done with the R software (version 2.7.2) [99]. 
Deterministic simulations were performed to assess the influence of the mean 
absorption time (MAT) of venlafaxine on the pupillographic response and the plasma 
concentrations of venlafaxine and its metabolite. For this, the model code and all typical 
parameter values were entered into the software Berkeley Madonna (version 8.3.14) and 
the average model response of the amplitude was simulated for different values of MAT 
without taking into account parameter variability. 
3.1.5 Statistical Analyses 
For the descriptive presentation of the data and the results, different measures of central 
tendency (median, arithmetic or geometric mean) and dispersion (standard deviation, 
variance, coefficient of variation) were employed as appropriate. Calculations were 
usually performed using Microsoft® Excel 2002 or the R software. 
For the statistical analysis of the survival data generated in the clinical trial simulation 
(see section 3.3.6.2) a Cox proportional hazard model was used. This model is 
frequently used for the statistical comparison of time-to-event data from different 
treatment groups (e.g., drug A vs. placebo). “Treatment group” is included as a 
dichotomous covariate (0=control, 1=treatment) and related to the hazard rate (equation 
3-14). The hazard rate may be interpreted as an instantaneous rate of death at any time t:   
)groupb(
0 e)t(h)t(h
  equation 3-14
where h0(t) is the hazard rate of the control group (note: when group=0 then exp(0)=1); 
b is a regression coefficient. The hazard ratio (HR) can than be calculated according to: 
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A HR <1 means that the treatment is associated with an increased survival compared to 
the control group, whereas a value >1 means decreased survival. 
A statistical test often applied to survival data is the log-rank test. Under the null 
hypothesis that the risk of death in two groups is the same (i.e., survival is not different), 
the expected number of events per group at each observed event time in ranked order is 
calculated. From the sums of the observed and the expected events (deaths) of each 
group (A and B) a test statistic Z can be derived:  
   
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EOZ   equation 3-16
where OA and OB are the sums of the observed number of events and EA and EB are the 
sums of the expected number of events. Z approximately follows a χ2-distribution from 
which a p-value can be calculated.  
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3.2 Venlafaxine Study 
3.2.1 Study Description 
The study was designed as a randomized, double-blind, placebo-controlled crossover 
trial. The subjects received either 37.5 mg venlafaxine twice daily (manufactured as 
Trevilor® tablets by Wyeth, Münster, Germany; to preserve blinding tablets were 
pulverized and filled into hard gelatine capsules by the Pharmacy of the University 
Hospital Dresden, Germany) or placebo from day 1 to 7. From day 8 to 14 they received 
either 75 mg venlafaxine twice daily or placebo. After a 14-day washout phase the two 
groups were crossed over according to the protocol. A scheme of the study design, 
including sampling times, is shown in Figure 3-1. Subjects were not allowed to smoke 
or to consume alcohol or caffeine containing beverages during the study. The study was 
conducted at the facilities of the Institute of Clinical Pharmacology at the Medical 
Faculty of the University of Dresden under supervision of Prof. Dr. Dr. W. Kirch and 
Prof. Dr. M. Siepmann.  
3.2.2 Subjects 
Twelve healthy male volunteers, ageing between 23 and 32 years (mean  SD: 26  3 
years), weighing between 67 and 85 kg (75  6 kg) and between 176 and 192 cm (183  
5 cm) in height, were enrolled in the study. The subjects were included after a standard 
physical examination, routine clinical laboratory tests and a 12-lead ECG. The study 
was conducted according to the Declaration of Helsinki (Edinburgh Amendment 2000) 
and German regulations. Written informed consent from the subjects and approval from 
the University Hospital Ethics Committee (Dresden, Germany) were obtained.  
3.2.3 Blood Sampling 
Blood samples were taken from a cubital vein on day 14 immediately before the last 
dose of venlafaxine or placebo was given as well as 0.5, 2, 3, 4, 5, 7, 8, 10, 12, 14, 18 
and 24 hours afterwards (Figure 3-1). Blood was left to clot for 90 min at room 
temperature, followed by centrifugation. The serum samples were then stored at -20°C 
until analysis. 
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Figure 3-1 
 
Scheduled time points of blood sampling and pupillographic 
measurement sessions. Time is given in hours. The numbers in 
parenthesis represent the time relative to dosing on day 14. 
 
3.2.4 Analytical Methods 
3.2.4.1 Determination of Venlafaxine and O-Desmethylvenlafaxine 
Concentrations 
Concentrations of venlafaxine and O-desmethylvenlafaxine in serum were measured 
with a validated high-performance liquid chromatography assay with fluorescence 
detection at the Institute of Clinical Pharmacology at the Medical Faculty of the 
University of Dresden by Dr. Reinhard Oertel. The procedure was validated according 
to previously published method descriptions [100-102]. The lower limit of 
quantification was 28.1 nmol/L for venlafaxine and 29.6 nmol/L for 
O-desmethylvenlafaxine. Coefficients of variation expressing precision and relative 
errors expressing analytical accuracy ranged from 2.9 to 10.1% and from -3.1 to 3.1% 
for venlafaxine and from 2.6 to 5.7% and -6.0 to 4.6% for O-desmethylvenlafaxine, 
respectively. 
3.2.4.2 Pupillography 
Measurement of pupillary light reflex was done before the first dose on day 1 and 0.5, 3, 
5, 7 hours after the last dose on day 14 of every treatment period (Figure 3-1). An 
infrared monocular pupillographic camera device (CIP, AMTech, Weinheim, 
Germany) was used for recording of the pupillary light reflex. The procedure was 
described in more detail elsewhere [103]. In brief, in a shaded room a light flash of 
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200 ms duration was used to provoke miosis of the subject’s pupil. The light-induced 
constriction and subsequent redilatation of the pupil was recorded by the camera device. 
The amplitude and 33% recovery time as response parameters were subject to the 
present analysis.    
3.2.5 Pharmacokinetic Model 
For the simultaneous estimation of venlafaxine and its major metabolite 
O-desmethylvenlafaxine a PK model previously described by Taft et al. [104] was 
adapted. This model includes a liver compartment accounting for the presystemic 
formation of O-desmethylvenlafaxine via the CYP2D6 enzyme system. According to a 
similar model developed for artemisinin [105], which also includes a liver compartment, 
the hepatic plasma flow (QH) was fixed to 0.63 L/h × body weight (in kg) and the 
volume of the liver compartment to 1 L. Different models describing the absorption 
phase were explored: first- and zero-order absorption with and without a time-lag 
parameter, as well as a system of serial transit compartments, previously reported for 
modeling the absorption kinetics of cyclosporine [106,107]. Mathematically this is a 
special case of the distribution function f(t) shown in equation 3-17: 
)tk(1N
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tr tret
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k
)t(f    equation 3-17
where N is the number of transit compartments, ktr the transfer rate constant and Γ(N) 
represents the gamma function of N. When N is an integer number the function f(t) is 
known as Erlang distribution function. The number of transfer compartments was set 
equal for all subjects and was estimated by successively introducing an additional 
transfer compartment into the model until the objective function value (OFV) did not 
improve anymore. The mean absorption time (MAT) was calculated as N/ktr. 
In principle, the fraction of venlafaxine metabolized to O-desmethylvenlafaxine (fm) and 
the volume of distribution of venlafaxine (VVEN) are not separately identifiable in the 
absence of data for other routes of elimination (e.g., concentrations in urine/feces). This 
was accounted for by fixing the volume of distribution of O-desmethylvenlafaxine 
(VODV) to 210 L a value that was reported in a previous study where 
O-desmethylvenlafaxine was administered intravenously to healthy subjects [107]. 
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An exponential variance model was used to describe interindividual variability in the 
PK parameters except for fm. Since this parameter is naturally constrained to lie between 
0 and 1 a logit model was applied [108]: 
i))pop,mf1/(pop,mfln(e1
1f i,m 

  
equation 3-18
fm,i denotes the parameter estimate for individual i, fm,pop is the typical value for fm in the 
population and ηi represents a random quantity with mean 0 and variance ω2. The 
coefficient of variation of the interindividual variability in fm,pop can be approximated by 
equation 3-19:  
100)f1(%CV pop,m   equation 3-19
where ω denotes the standard deviation of ηi. 
The residual variability for venlafaxine and O-desmethylvenlafaxine was estimated by 
two separate error models. Each error model consisted of a proportional and an additive 
component (i.e., a combined error model).  
3.2.6 Pharmacodynamic Models 
Prior to the model building, plots of pharmacodynamic effect vs. active concentration 
were generated to get a first impression of the behavior of the pharmacodynamic system. 
Based on preclinical data O-desmethylvenlafaxine was assumed to be half as potent as 
venlafaxine in inhibiting norepinephrine uptake [109]. Thus the active concentration 
was calculated as 0.5×CODV +CVEN. Different values for the relative potency of 
O-desmethylvenlafaxine were however tested as part of a sensitivity analysis.  
Different structural pharmacodynamic models were explored: Linear and log-linear 
models, simple and sigmoid Emax models [8], indirect response models [110] and 
different kinds of tolerance models (see model development summary in Table 9-2 in 
the appendix) [9,111-117]. 
The interindividual variability in the PD parameters was described by an exponential 
error model. Additive, proportional and combined error models were tested for 
modeling the residual variability in the amplitude and the 33% recovery time. 
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3.2.7 Optimal Study Design and Simulations 
The final PK/PD model for the amplitude (see section 4.1.2) was introduced in the D-
optimal design software WinPOPT (version 1.2). The program evaluates the Fisher 
information matrix (FIM) of a given nonlinear mixed effects model and uses the 
determinant of this matrix as the optimization criterion (D-optimal). Since the inverse of 
the FIM is the covariance matrix of the model parameters, maximizing the determinant 
of the FIM results in improved precision of the parameter estimates (i.e., smaller 
standard errors) [118]. Two algorithms are available in the software, the exchange 
algorithm and simulated annealing. In this thesis only the exchange algorithm was used. 
On each iteration a single sampling time was exchanged with one from a list of possible 
sampling times (0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours) that provides the 
same or a better value of the determinant of the FIM. Possible designs with 4 to 8 
samples per subject were evaluated and the expected standard errors of the 
pharmacodynamic parameters as well as the determinant of the FIM were recorded. The 
baseline measurement at time 0 hours was always included and not subject to 
optimization. The number of subjects was always 12, receiving a single dose of 75 mg 
venlafaxine, except for the scenario with 5 sampling times, which was also evaluated 
for 24 subjects. The sampling times for a possible extended release formulation were 
calculated by setting the mean absorption time to 4 hours.  
To numerically compare the different study designs, the relative efficiency (Erel) was 
calculated according to: 
k
reference,FIM
ealternativ,FIM
rel D
D
*100(%)E   equation 3-20
where k is the number of evaluated model parameters, DFIM,alternative and DFIM,reference are 
the determinants of the FIMs for an alternative design and the reference design, 
respectively. The sampling schedule of the original venlafaxine study described in 
section 3.2.4.2 was applied to a single-dose study and chosen as the reference design 
(i.e., sampling at 0, 0.5, 3, 5, 7 hours). 
To determine the influence of the venlafaxine formulation on the pharmacodynamic 
response, different values of mean absorption time (1, 2, 4, 8 hours) were used to 
simulate the typical response profile after a single dose of 75 mg. 
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3.3 Sunitinib Study 
3.3.1 Study Description 
The study was approved by the ethics committee of the Medical Faculty of the 
University of Cologne, Germany, and was conducted according to the Declaration of 
Helsinki and corresponding European and international guidelines. It was divided in a 
first part with 4 participants taking capsules containing 50 mg sunitinib (Sutent®; Pfizer 
Inc.) on each of 3 consecutive days (at 8:00 AM) and a later, second part with 8 subjects 
and drug administration on 5 consecutive days. Before the first drug administration 
subjects had to stay at the study site for 24 hours to evaluate possible diurnal changes of 
the drug-free (i.e., baseline) biomarker response. The rest of the study was conducted in 
an ambulatory manner at the facilities of the Department of Pharmacology of the 
Hospital of the University of Cologne under supervision of Prof. Dr. Uwe Fuhr. 
3.3.1.1 Sampling Schedule 
Blood samples were drawn on the day before the first dose was administered (day 0) at 
8:00 AM, noon, 4:00 PM, 8:00 PM, midnight, 4:00 AM and 8:00 AM. After the first dose 
was given, blood sampling for the determination of plasma biomarker concentrations 
(i.e., VEGF-A, VEGF-C, soluble VEGFR-2) as well as sunitinib and SU12662 
concentrations was carried out at 1, 2, 4, 6, 8, 10, 12, 24, 25, 36, 48, 49, 60, 72, 96, 120, 
240, 288, 336, and 384 hours. In the second part additional blood sampling was 
performed 0.5, 24.5, 48.5, 72.5, 73, 84, 96.5, 97, 98, 100, 102, 104, 106, 108, 144, 168, 
and 432 hours after the first dose. Figure 3-2 provides a schematic representation of the 
dosing and sampling schedule. The samples were collected in EDTA tubes and 
immediately centrifuged for 15 min at 4 °C with 780 g in the first part and 1000 g in the 
second part of the study. 
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Figure 3-2 
 
Blood sampling schedule in the first (a) and second (b) study part. Grey 
boxes indicate dosing events. Sampling times are given in hours relative 
to the first dosing event. 
 
3.3.2 Subjects 
Six healthy males and six healthy females (Caucasian, nonsmokers), ageing between 27 
and 54 years (mean  SD: 40  5.5 years), weighing between 60 and 90 kg 
(72  10.8 kg) and between 163 and 192 cm (175  8 cm) in height, were included. All 
subjects gave their written informed consent prior to their participation. 
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3.3.3 Analytical Methods 
3.3.3.1 Determination of Sunitinib and N-Desethylsunitinib  
Sunitinib and SU12662 concentrations in human plasma were determined by high-
performance liquid chromatography coupled with mass spectrometry (LC-MS/MS, 
Applied Biosystems/MDS Sciex API5000 LC/MS/MS) by Dr. Martina Kinzig at the 
Institute for Biomedical and Pharmaceutical Research (IMBP) under supervision of Prof. 
Dr. Fritz Sörgel. The method used d5-sunitinib as an internal standard which was 
synthesized by Dr. Paul Elsinghorst under supervision of Prof. Dr. Michael Gütschow at 
the Institute of Pharmacy at the University of Bonn [119]. The response from 
calibration standards of sunitinib and SU12662 was linear from 0.06 to 100 ng/mL. The 
lower limit of quantification for plasma samples was 0.06 ng/mL for both analytes. 
Coefficients of variation (CV) expressing precision and relative errors (RE) expressing 
analytical accuracy ranged from 1.0 to 5.3% and +0.9 to +5.6% for sunitinib and from 
2.9 to 3.9% and −2.2 to +3.9% for SU12662, respectively. 
3.3.3.2 Determination of VEGF-A, VEGF-C and sVEGFR-2 
Plasma concentrations of VEGF-A, VEGF-C and sVEGFR-2 were determined using 
commercially available enzyme-linked immunosorbent assay kits from R&D Systems 
(Minneapolis, USA). All assays were validated by the manufacturer for their use with 
plasma samples. The qualification of these assays, in terms of precision and accuracy, 
and the determination of biomarker levels in the samples were performed by Friederike 
Kanefendt and Cathleen Krambeer at the Institute of Pharmacy at the University of 
Bonn. Table 3-2 compares the precision and accuracy of the assays determined “in-
house” to the manufacturer specifications. The detailed analytical procedure is 
described in the diploma thesis of Krambeer [120].  
Table 3-2 Intra-assay precision and accuracy of the immunoassays 
 Precision (CV) Accuracy (RE) 
 Manufacturer In-house Manufacturer In-house 
VEGF-A (QuantiGlo®) 2.8 - 7.9% 1.5 - 6.4% -2 - 10% 0.5 -15.3% 
VEGF-C (Quantikine®) 3.5 - 6.6% 2.7 - 6.1% -4 - 10% -17.1 to -6.8%
sVEGFR-2 (Quantikine®) 2.9 - 4.2%  2.2 - 4.3% -8 - 4%a  – b 
a  Determined in cell culture media. 
b  Could not be reliably determined in plasma. 
CV: coefficient of variation; RE: relative error.  
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Accuracy of the sVEGFR-2 assay was not established in plasma by the manufacturer 
and failed to be reliably determined “in-house”. Nevertheless, results obtained with this 
assay are valid as long as relative changes of this biomarker and not absolute values are 
of interest. 
3.3.3.3 Blood Pressure 
Blood pressure was measured with an automated device (Dinamap; Criticon, Tampa, 
USA) shortly before blood sampling and after the subjects had been resting for at least 
5 min in a supine position. 
3.3.4 Pharmacokinetic Model 
Sunitinib and SU12662 pharmacokinetics were simultaneously estimated using a model 
that accounted for systemic and presystemic formation of the metabolite. The fraction of 
parent drug converted to metabolite (fm) was set to 21%, a value previously 
reported [121].  
Given that: 
sys,mpre,mpre,mm f)f1(ff   equation 3-21
the ratio of the fraction formed presystemically (fm,pre) to the fraction formed 
systemically (fm,sys) is: 
sys,m
pre,m
f
f
RPS   equation 3-22
Under the condition that fm,pre, fm,sys and fm are always <1 the above equations can be 
solved for fm,pre, allowing the RPS being estimated as primary parameter: 
m
2 fRPS4-RPSRPS21  5.0RPS5.05.0f pre,m  equation 3-23 
The unknown bioavailability of sunitinib is the product of the fraction of a dose that is 
absorbed from the gut (fa) and the fraction not metabolized presystemically (1- fm,pre). 
Since no PK information from intravenously administered sunitinib was available fa 
could not be estimated and was fixed to 1. 
Like in the venlafaxine project, it was explored if the inclusion of a transit compartment 
model of absorption would improve the fit [122]. However, differing from the 
procedure described in section 3.2.5 the number of transit compartments was not 
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constrained to an integer value but was estimated as a model parameter. For both 
sunitinib and SU12662 one and two distribution compartments were tested. The residual 
variability was estimated separately for sunitinib and SU12662 using a combined error 
model. 
3.3.5 Pharmacodynamic Models 
For all biomarkers, possible diurnal baseline changes were evaluated by one or two 
cosine functions based on data from the 24 hours before the first dose was given (day 0). 
First, it was tested if a model describing time-dependent baseline values improved the 
model fit with data from day 0 only. In the affirmative, it was included in the PD model 
and was only retained if it also significantly improved the model fit on the whole dataset. 
To describe the concentration-effect relationship of the different biomarkers a 
mechanism-based approach was applied, linking the drug-specific part (i.e., drug-
receptor interaction) to the biological system-specific part (i.e., biomarker signal) with a 
unique transducer function for each biomarker (Figure 3-3). Danhof et al. extensively 
reviewed this approach in a recent publication [123].  
Since for sunitinib and SU12662 equal potency has been reported [62], the active 
moiety used in the model was the sum of unbound sunitinib and SU12662 
concentrations (active unbound concentration, ACub). To calculate the ACub 95 and 
90 % protein binding were assumed for sunitinib and SU12662, respectively [59]. 
The drug-specific part was described by a simple hyperbolic function (Figure 3-3 and 
equation 3-24) relating the ACub to the fractional tyrosine kinase inhibition (INH): 
ubd
ub
ACK
ACINH   equation 3-24
The dissociation constant Kd was fixed to 4 ng/ml. Mendel et al. [124] reported this 
value for the VEGF-dependent inhibition of VEGFR-2 tyrosine kinase phosphorylation 
by sunitinib in vitro. Different transducer functions (e.g., linear, hyperbolic, power) 
relating the INH to the measured biomarker signal were explored during model 
development. 
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Increasing systolic and diastolic blood pressure values were modeled simultaneously 
each with a separate additive residual error model. Because of the simultaneous 
mechanisms of action that are discussed for this effect (see section 1.4.2) [87], it was 
tested if the inclusion of a second, slower mechanism could improve the model fit. 
A possible time delay in VEGF-A response relative to drug concentration was tested for 
by including a transduction component in the model [125]. Differences in VEGF-A 
levels between subjects in the first part and the second part of the study, caused by two 
Figure 3-3 
 
Relationship between drug concentration and biomarker response in a 
mechanism-based pharmacodynamic model. The drug-specific tyrosine kinase 
inhibition (a) is linked to the system-specific biomarker response by a transducer 
function. b Hyperbolic relationship, c inverse linear relationship, d power 
function. Note that when γ equals 1 the relationship is linear. The dotted line 
represents the baseline value of the biomarker.  
Kd: dissociation constant; BR: biomarker response; BL: baseline; α: intrinsic 
activity parameter; INH50: INH that elicits 50% of the maximal biomarker 
response; γ: exponent of the power function. 
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different centrifugation speeds at which plasma samples were generated, were 
accounted for by including the study part as a covariate on baseline VEGF-A levels 
(BLVEGF-A, equation 3-25): 
 IND 1PARTAVEGF1A,PARTVEGF BLBL    equation 3-25
where θPART1 represents a factor adjusting for systematic differences in VEGF-A 
concentrations between the two study parts and IND is an indicator variable taking a 
value of 1 for subjects in the first part and 0 otherwise.  
Changes in sVEGFR-2 concentrations were described by an indirect response 
model [110] with the INH affecting the zero-order release rate (Kin) of this biomarker. 
Proportional residual error models were applied for VEGF-A and sVEGFR-2.  
3.3.6 Simulations 
3.3.6.1 Comparison with Literature 
To compare predictions from the pharmacodynamic models with previously reported 
biomarker data, 1000 individuals receiving a typical sunitinib treatment (1 cycle: 
50 mg/day over 4 weeks, then 2 weeks off treatment) were simulated. Two treatment 
cycles were simulated to compare predicted blood pressure with blood pressure vs. time 
profiles from a study in 7 normotensive patients with metastatic renal cell carcinoma 
(mRCC) [74]. To compare model-predicted variability with the standard deviations 
(SD) shown in the original graph, a 68% prediction interval (approximately equal to the 
interval embraced by ±1 SD) of the simulated data was calculated.  
Four cycles were simulated for the comparison of predicted changes in circulating 
biomarkers with the biomarker response reported in studies with patients suffering from 
breast cancer [75], mRCC [76,77], and gastrointestinal stromal tumor (GIST) [78].  
For all simulations the final model parameter estimates were used, except that the mean 
systolic and diastolic baseline blood pressure values were set to 120 and 72.3 mmHg 
(the baseline values from the Azizi-study [74]), respectively, to compensate for baseline 
differences between the subjects in the present study and the patients in the report.  
The biomarker data were graphically extracted from biomarker vs. time plots in the 
above mentioned publications using the measurement tool included in Adobe Acrobat 
Pro, version 9.1.2 (Adobe Systems, San Jose, USA). 
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3.3.6.2 Clinical Trial Simulation: Dose Individualization Based on 
Blood Pressure Increase 
To explore the hypothesis that dose adjustments based on individual blood pressure 
measurements could be beneficial in terms of clinical outcome, various clinical trial 
scenarios were simulated comparing a standard dose group with a group where the dose 
was adjusted based on individual blood pressure measurements. Since the present study 
was conducted in healthy volunteers, a model for clinical outcome could obviously not 
be developed with the data at hand. However, such a model relating sunitinib exposure 
(i.e., AUC) to an outcome measurement (overall survival) has recently been published 
by Houk et al. [126] They used a parametric Weibull distribution function (equation 
3-26) to describe the survival data of 146 patients with mRCC.  
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equation 3-26
where S(t) is the survival function giving the proportion of patients alive at time t, γ is a 
shape parameter and φ is the median survival time, modeled as a function of exposure: 
φ=baseline+slope×exposure. The following parameter estimates were reported by Houk 
et al. and used for the simulations in the present thesis: γ: 1.78, baseline: 110 days, 
slope: 485 days/mg·h/L. The probability of dying in an interval of length tinter is 
calculated by multiplying the hazard rate h(t) with tint as shown in the following 
equation [127]: 
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 equation 3-27
where PDF(t) is the probability density function of the survival function from equation 
3-26 at time t. As a measurement of exposure they used the average daily steady-state 
AUC of sunitinib during a treatment cycle (AUCdaily) calculated according to equation 
3-30 (the authors stated that similar results were obtained using the AUC of the total 
drug [sunitinib+metabolite], in their final model, however, they only used the AUCdaily 
of sunitinb). 
During the treatment with sunitinib patients often suffer from side effects with fatigue 
being the most dominant in clinical practice. Severe fatigue often requires a dose 
reduction and should therefore be considered in a realistic simulation scenario. A 
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logistic regression model relating the frequency of grade 3 or 4 fatigue (according to 
Common Terminology Criteria for Adverse Events of the National Cancer Institute 
version 3.0) to sunitinib exposure was developed by the Pharmacometrics Department 
of the FDA during the approval process of sunitinib [128]. Their analysis included data 
from 516 patients with different tumor types who were treated with sunitinb in clinical 
trials. According to this report, the probability of occurrence of grade 3/4 fatigue 
P(fatigue) is related to the sum of sunitinib and SU12662 exposure (AUCsum) as shown 
in equation 3-28: 
3.2164)-AUC(0.5144- sume1 
1)fatigue(P  equation 3-28
From the above equation it can be calculated that for each unit increase of AUCsum the 
probability of occurrence of severe fatigue increases 1.7-fold (i.e., odds ratio). This 
model only predicts the total probability of experiencing severe fatigue during the entire 
study duration and not the incidence of fatigue in one treatment cycle. This, however, 
was important to properly simulate dose reduction events per cycle. Assuming that the 
risk of suffering from fatigue is the same in every treatment cycle, P(fatigue) can be 
split into smaller probabilities of equal size. The 516 patients used in the FDA analysis 
were treated for approximately 17 cycles, thus the probability of having a fatigue event 
in one cycle P(fatigue,cyc) is: 
17 )fatigue(P11)cyc,fatigue(P   equation 3-29
Houk et al. showed in their analysis that the risk of experiencing fatigue increases 
during the treatment with sunitinib, reaching a maximum probability (plateau) already 
after one treatment cycle [126]. Thus, assuming equal probability of fatigue in every 
cycle (including the first one) may only produce a minor overestimation of the 
occurrence of fatigue.  
From the final PK and blood pressure model (see section 4.2.1 and 4.2.2.1) individual 
parameters were simulated for 75 virtual patients per treatment group. The individual 
clearance of sunitinib (CL/Fsunitinib) and SU12662 (CL/fa,SU12662) were used to calculate 
AUCdaily (equation 3-30) and AUCsum (equation 3-31). The fraction of the dose 
converted to SU12662 was fixed to 0.21 as described in section 3.3.4. 
  
     
49Material and Methods 
(42) cycle per days total
(28) treatment on days
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To calculate diastolic blood pressure at steady state, first the active unbound 
concentration at steady state was calculated according to equation 3-32: 
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The fractional tyrosine kinase inhibition at steady state (INHss) was then calculated as 
previously shown in equation 3-24. After 28 days of treatment not only the 
pharmacokinetic system can be assumed to having reached equilibrium but also the 
pharmacodynamic system. The time-delay component included in the final blood 
pressure model was therefore not considered in these simulations and diastolic blood 
pressure at day 28 was calculated from the final blood pressure model (equation 4-6), 
setting the immediate signal and the transduced signal both equal to INHss. It was 
further assumed that blood pressure measurements were always performed at the same 
time of day and circadian variations in diastolic blood pressure were not taken into 
account. Since diastolic and systolic blood pressure are highly correlated and diastolic 
blood pressure is closely related to vascular resistance, only the diastolic value was 
considered in this simulation study. 
The study duration in the virtual trials was 960 days (20 treatment cycles). The cycle 
length was 6 weeks (42 days) according to the approved 4-weeks-on/2-weeks-off 
treatment schedule. At the end of every 4-weeks-on treatment period a “clinical 
assessment” was scheduled where diastolic blood pressure and the probabilities of death 
and severe fatigue were calculated for every individual based on the current dose he 
received. The individual probabilities of death or experiencing fatigue in a given cycle 
were used to generate a dichotomous variable with a value of 1 for “alive” or “fatigue” 
and 0 for “dead” or “no fatigue”. For example, if the probability of experiencing fatigue 
for a given individual was 0.10, a random draw from a virtual urn containing 10 balls 
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marked “fatigue” and 90 balls marked “no fatigue” was made. In mathematical terms, 
this is sampling at random from a binomial distribution. Figure 3-4 illustrates the 
treatment schedule. 
Figure 3-4 
 
Treatment schedule used for the virtual trial. Whether a patient died or 
experienced fatigue since the last assessment was calculated from the individual 
probabilities as explained in the text. The dose for the next cycle was changed 
according to the algorithm shown in Figure 3-5. 
dBP: diastolic blood pressure. 
 
Then a decision was made if and how the dose should be adjusted for the subsequent 
cycle. The starting dose for both groups was 50 mg/day and, in accordance with the 
Sutent® prescribing information [129], dose adjustments were only allowed between 
25 mg/day and 87.5 mg/day. In both groups the dose was reduced by 12.5 mg if severe 
fatigue occurred. In the individualized dose group the dose was augmented by 12.5 mg 
if the increase in diastolic blood pressure (relative to the pretreatment value) did not 
reach a predefined target.  
Initially, a 16% increase in diastolic blood pressure was chosen as a target, 
corresponding to an INHss of 0.55. However, other target values ranging from 11.6% to 
20.3% were also explored (see below). To make the simulations more realistic, it was 
also considered that the rise in blood pressure may reach values demanding intervention 
with an antihypertensive drug. This was assumed to occur when the simulated diastolic 
blood pressure was greater than 100 mmHg. In this case, no further dose increment was 
allowed for the rest of the study. Dose reductions, however, remained possible. This 
treatment algorithm for the individualized dose group is illustrated in Figure 3-5.  
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Start dose: 50 mg/d 
4-weeks-on, 2-weeks-off
Grade 3/4 
fatigue ?
Dose >25 mg ?
Antihypertensive 
treatment ?
Increase in
dBP >16% ?
Dose ≥87.5 mg ?
Diastolic BP 
>100 mmHg ?
Day 28 of each cycle
Reduce dose 
by 12.5 mg Increase dose 
by 12.5 mg
Maintain 
dose
Start / continue
antihypertensive 
treatment
Yes
No
No
No
No
Yes
Yes
Yes
Yes Yes
No
No
 
Figure 3-5 
 
Treatment algorithm used for the simulation of a clinical trial with blood pressure 
controlled dose adjustments. 
dBP: diastolic blood pressure. 
 
The following modifications of the initial study design were also investigated: 
 Different number of patients per group (25, 50, 100, 150, 200, 250) 
 Different target values for the increase in diastolic blood pressure (11.6%, 
13.0%, 14.5%, 17.4%, 18.9%, 20.3%; corresponding to INHss values of 0.40, 
0.45, 0.50, 0.60, 0.65, 0.70) 
Median time to death and frequency of severe fatigue were recorded as outcome 
parameters of the simulated trials. Each scenario was repeatedly simulated 500 times. In 
each of the 500 trial replicates a Cox proportional hazard model was applied to calculate 
the hazard ratio and the log-rank p-value, analyzing the difference in the median time to 
death (i.e., overall survival) between the two groups. The statistical power to detect a 
significant difference between the two groups was then calculated as the percentage of 
trial replicates with p <0.05. The 2.5th and 97.5th percentiles of the distribution of an 
outcome parameter across the trial replicates were derived, representing the lower and 
the upper bound of a 95% confidence interval. The last dose level a patient received at 
the end of the study (or at the time of his death) and the frequency of antihypertensive 
treatment was also recorded.  
The simulations were performed with R (version 2.7.2) [99]. The code can be found in 
the appendix (Code 9-8).  
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4 Results 
4.1 Venlafaxine Study 
4.1.1 Pharmacokinetic Model 
Plasma concentration-time data of venlafaxine and its metabolite were successfully 
described by a model with one-compartment disposition for both analytes (Figure 4-1). 
Inclusion of additional disposition compartments did not improve the model fit. The 
absorption process described by a system of 3 transit compartments was superior to 
other tested absorption models, including first- and zero-order absorption with and 
without a lag-time parameter. The application of an absorption model where the number 
of transit compartments is an estimable parameter (like in the sunitinib project) was not 
feasible in the present analysis due to excessive NONMEM runtimes.   
Important steps of the model development are summarized in Table 9-1 in the appendix.  
 
Figure 4-1 
 
Pharmacokinetic model for the simultaneous prediction of venlafaxine 
and O-desmethylvenlafaxine concentrations. After oral administration 
venlafaxine passes the 3 transit compartments of absorption (T1, T2, T3) 
and enters the liver where it is metabolized to O-desmethylvenlafaxine. 
ktr: transit rate constant; MAT: mean absorption time; VVEN: volume of 
distribution of venlafaxine’s central compartment; VODV: volume of 
distribution of O-desmethylvenlafaxine’s central compartment; VL: 
volume of the liver compartment; fm: fraction of venlafaxine metabolized 
to O-desmethylvenlafaxine; CLint,VEN: intrinsic clearance of venlafaxine; 
CLODV: clearance of O-desmethylvenlafaxine; QH: liver plasma flow. 
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Although it was previously shown, that about 5% of venlafaxine is renally 
excreted [50,130], this fact was neglected during the model building process, since the 
introduction of a renal clearance parameter did not improve the model fit. The model 
performed well in terms of precision of the parameter estimates, as suggested by the 
relatively narrow bootstrap confidence intervals (Table 4-1). Only CLint,VEN and its 
interindividual variability showed a wider confidence interval. This is likely due to the 
fact that one subject had a very high clearance of venlafaxine compared to the 
population mean (652 L/h vs. 99.9 L/h). It was only possible to estimate interindividual 
variability in MAT, CLint,VEN, and fm. Inclusion of more variability parameters did not 
improve the model fit (see summary of the model development in Table 9-1 in the 
appendix). This is not uncommon in nonlinear mixed-effects modeling when the 
number of subjects is small while the number of model parameters is high. 
 
Table 4-1 Pharmacokinetic parameter estimates and bootstrap confidence intervals 
Parameter Estimate (90% CI) IIV, CV% (90% CI) 
VVEN (L) 178 (164 - 203) - 
CLint,VEN (L/h) 99.9 (69.9 - 150) 94.8 (46.1 - 146.4) 
fm 0.746 (0.613 - 0.855) 34.5 (20.4 - 47.5) 
CLODV (L/h) 17.7 (16.8 - 18.9) - 
MAT (h) 1.03 (0.843 - 1.24) 38.9 (17.0 - 50.9) 
σprop,VEN (%) 18.5 (12.2 - 29.7) - 
σadd,VEN (nmol/L) 26.4 (10.0 - 38.6) - 
σprop,ODV (%) 8.86 (6.51 - 11.9) - 
σadd,ODV (nmol/L) 54.8 (20.8 - 79.3) - 
IIV: interindividual variability; CV: coefficient of variation; VVEN: venlafaxine‘s volume of 
distribution; CLint,VEN: intrinsic clearance of venlafaxine; fm: fraction of venlafaxine 
metabolized to O-desmethylvenlafaxine; CLODV: clearance of O-desmethylvenlafaxine; 
MAT: mean absorption time; σprop: proportional residual variability (CV); σadd: additive 
residual variability (standard deviation). 
The sensitivity analysis (Figure 9-5, appendix) revealed that changing the value of QH 
caused VVEN to vary between 110 and 228 L but led at the same time to higher OFVs 
compared to the original run. Setting the QH at a value hat corresponds to the hepatic 
blood flow (1.2 L/h × bodyweight) resulted in an estimate of VVEN of 258 L and an 
increase of the OFV by 12 units. Varying the volume of the liver compartment from 0.5 
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to 1.5 L did neither affect the parameter estimates nor the OFV (Figure 9-6, appendix). 
When changing the fixed value for VODV the OFV increased and the estimates for 
CLODV and fm varied between 9 to 21 L/h and 0.34 to 0.87, respectively (Figure 9-7, 
appendix).  
The visual predictive checks for venlafaxine and O-desmethylvenlafaxine are shown in 
Figure 4-2. The majority of the observations were located within the prediction interval 
and there is no systematic misspecification. 
 
Figure 4-2 Visual predictive check for (a) venlafaxine and (b) O-desmethylvenlafaxine. 
The 5th and 95th percentiles (dashed lines) and the median (solid red line) 
obtained from 1000 simulations are shown together with the actual 
observations (black circles). 
 
The goodness-of-fit plots shown in the appendix (Figure 9-1 and Figure 9-2) also 
demonstrate that the model described the data reasonably well. No obvious model 
misspecification was detected.  
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The NONMEM code of the PK model is provided in the appendix (Code 9-1). 
Table 4-2 compares pharmacokinetic parameters calculated with the present model with 
values previously reported in the literature.  
Table 4-2 Comparison of estimated pharmacokinetic parameters with literature values 
Parametera NONMEMb 
n=12 
Effexor® 
Prescribing 
Information[46]c 
Klamerus     
et al.[51]c 
n=18 
Troy et al.[130]c 
n=18 
VVEN/F/BW (L/kg) 8.0 (65.9%) 7.5 (49.3%) 8.1 (37.0%) 8.3 (47.0%) 
CLint,VEN/BW (L/h/kg) 1.3 (97.0%) 1.3 (46.1%) 1.73 (56.1%) 2.1 (67.3%) 
VODV /fm/BW (L/kg) 4.5 (44.7%) 5.7 (31.5%) 4.6 (23.9%) 6.0 (61.7%) 
CLODV/fm/BW (L/h/kg) 0.4 (44.7%) 0.4 (50.0%) 0.3 (21.9%) 0.4 (41.7%) 
a   Estimates were normalized to body weight (BW) for comparison reasons only. 
b   Values are expressed as geometric mean (geometric coefficient of variation, CV) and were       
calculated from individual Bayes estimates. 
c   Values are expressed as arithmetic mean (CV). 
VVEN: venlafaxine‘s volume of distribution; F: bioavailability; CLint,VEN: intrinsic clearance of 
venlafaxine; fm: fraction of venlafaxine metabolized to O-desmethylvenlafaxine; VODV: 
O-desmethylvenlafaxine’s volume of distribution; CLODV: clearance of O-desmethylvenlafaxine. 
 
Mean parameter values were very similar to previous findings except for the variability 
in CLint,VEN which strongly depends on the composition of the study population in terms 
of their metabolic performance. For the purpose of comparability, the pharmacokinetic 
parameters in Table 4-2 are presented per kg of body weight. Since exponential models 
were used in this study to describe the interindividual variability in the parameters this 
study, the geometric means and associated coefficients of variations are presented. 
The hepatic extraction ratio of venlafaxine (EH) can be calculated as follows: 
)CLQ(
CL
E
VENint,H
VENint,
H   equation 4-1
resulting in a value of 68% (for a person weighing 75 kg).  
The fraction of venlafaxine metabolized to O-desmethylvenlafaxine (fm) was estimated 
to be 75% with an interindividual variability of 35% (CV). Results from a mass balance 
study with radioactive marked venlafaxine showed that at least 60% of absorbed 
venlafaxine is transformed to O-desmethylvenlafaxine [50].  
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4.1.2 Pharmacodynamic Models 
There was no clear hint from the placebo period of this trial (Figure 4-3 b and d) - nor 
from other studies investigating the effects of various antidepressants (i.e., venlafaxine, 
paroxetine, desipramine and reboxetine) on pupillary light reflex for up to six weeks - 
that this measure varies over time without administration of active drug [58]. The data 
from the placebo period of the present study were therefore not further considered in the 
analysis.  
Shortly after administration of the drug, the amplitude was found to be decreased and 
the 33% recovery time was reduced compared to their respective baseline values (Figure 
4-3 a and c).  
 
Figure 4-3 
 
Individual time course of the amplitude and 33% recovery time after 
administration of venlafaxine (a and c) and during the placebo period (b and d). 
The thick red line represents the mean response. 
 
The maximum decrease in the amplitude and the maximum reduction of the 33% 
recovery time were estimated to occur about 1 hour after administration, whereas the 
peak concentration of the active drug was about 2-3 hours after administration. 
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In Figure 4-4 the mean amplitude and the mean 33% recovery time are plotted against 
mean plasma concentrations of the active moiety. A decrease of the effect over time, 
despite equal plasma concentrations, can be seen. This phenomenon is known as 
proteresis and is indicative of the development of acute tolerance to the drug regarding 
the amplitude and the 33% recovery time. 
 
 
Figure 4-4 
 
Mean pharmacodynamic effect vs. mean plasma concentration (blue triangles) 
of the active moiety (i.e., CVEN + 0.5 × CODV) for (a) amplitude and (b) 33% 
recovery time. The arrows represent the progression of time, the red dotted lines 
indicate the mean baseline effect. The sampling times are also shown. 
D1: Day 1; D14: day 14.  
 
This behavior was best described by a modified version of a model that 
Porchet et al. [116] used for the analysis of the effect of nicotine on the heart rate. The 
same model was used for the amplitude and the 33% recovery time. Other PD models 
that were tested (linear and log-linear models, simple and sigmoid Emax models, indirect 
response models and different kinds of tolerance models) did not converge successfully 
and/or resulted in imprecise parameter estimates and higher OFVs (see summary of the 
model development in Table 9-2 and Table 9-3 in the appendix).  
The model is similar to the effect compartment model developed by Sheiner et al. [131], 
including an additional compartment, referred to here as the “tolerance” compartment. 
In this tolerance compartment, a hypothetical mediator M is generated, which acts as a 
contrary force opposing the effects of venlafaxine and O-desmethylvenlafaxine. The 
rate of change of the concentration of the mediator (CM) in the tolerance compartment 
can be expressed as in equation 4-2: 
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M0tolVENODVtol1
M Ck)CCR(k
d
dC 
t equation 4-2
where R is the relative potency of O-desmethylvenlafaxine (fixed to 0.5); kt1ol is the first-
order rate constant at which the concentration of M in the tolerance compartment rises, 
driven by the concentration of venlafaxine and O-desmethylvenlafaxine; and ktol0 is the 
rate constant at which the concentration of M declines. 
Since k1tol and ktol0 are not separately identifiable they were set equal (k1tol=ktol0=ktol ). 
Thus ktol describes the rate of appearance or disappearance of tolerance, whichever is 
the slower process, and represents the delay in the development of tolerance. Finally, 
the observed effect (E, amplitude or 33% recovery time) is described by a linear 
relationship: 
MTVENODVE CS)CCR(SBLE  equation 4-3
where BL denotes the baseline effect, SE is the slope (i.e., the potency) of the drug effect 
model and ST is the slope of the tolerance model. Note that SE and ST contribute with 
different signs to the overall effect. Model parameters were precisely estimated as 
shown in Table 4-3. 
The visual predictive checks for the amplitude and the 33% recovery time are shown in 
Figure 4-5. The majority of the observations were located within the prediction interval. 
No systematic misspecification was seen for the 33% recovery time. The amplitude 
however, tended to be slightly underestimated at later time points after administration of 
the drug. Goodness-of-fit plots shown in the appendix (Figure 9-3 and Figure 9-4) 
support this finding. 
The NONMEM codes of the final model for the amplitude and the 33% recovery time 
are also provided in the appendix (Code 9-2 and Code 9-3).  
The sensitivity analysis (Figure 9-8 and Figure 9-9 in the appendix) showed that when 
setting R at values of 0 to 0.4, the OFV and the residual variability in both the amplitude 
and the 33% recovery time increased. Values of R between 0.6 and 1 affected neither 
the OFV nor the residual variability relevantly. Fixing R at 1, that is, assuming equal 
potency of venlafaxine and O-desmethylvenlafaxine, reduced the estimates for the SE 
and ST by about 20%, while the ktol changed by only about 10%. Thus fixing R at 0.5 is 
not supposed to introduce much bias in the parameter estimates. 
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 Table 4-3 Parameter estimates and bootstrap confidence intervals for 
pharmacodynamic model 
Parameter Estimate (90% CI) IIV, %CV (90% CI) 
Amplitude   
BLamplitude (µm) 1600 (1490 - 1740) 11.6 (5.79 - 15.6) 
SE (µm·L/nmol) 1.86 (1.48 - 2.54) - 
ST (µm·L/nmol) 1.52 (1.32 - 2.13) - 
Ktol (1/h) 1.38 (0.74 - 2.53) - 
t1/2tol (min) 30.1 (16.4 - 56.2) - 
σprop (%) 16.2 (13.4 - 17.8) - 
33% Recovery time   
BLrecovery (msec) 1420 (1370 - 1470) 6.80 (4.54 - 8.46) 
SE (msec·L/nmol) 0.497 (0.372 - 0.834) - 
ST (msec·L/nmol) 0.376 (0.256 - 0.695) - 
ktol (1/h) 1.04 (0.631 - 2.00) - 
t1/2tol (min) 40.0 (20.8 - 65.9) - 
σprop (%) 4.97 (3.99 - 5.76) - 
IIV: interindividual variability; CV: coefficient of variation; BL: baseline value; SE: slope 
of the effect model; ST: slope of the tolerance model; ktol: rate constant of development 
or disappearance of tolerance (i.e., tolerance delay); t1/2tol: half-life of development or 
disappearance of tolerance (=ln2/ktol); σprop: proportional residual variability (CV). 
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Figure 4-5 
 
Visual predictive checks for (a) amplitude and (b) 33% recovery time. The open 
circles are the observations. The 5th and 95th percentiles (dashed lines) and the 
median (solid red line) obtained from 1000 simulations are shown together with the 
actual observations (black circles). Note the break in the x-axes. 
 
4.1.3 Optimal Study Design  
All tested sampling schedules for a possible single-dose study on the pupillographic 
response (amplitude) to immediate-released venlafaxine were more efficient than the 
reference design and the original sampling design with sampling at steady state (Table 
4-4). The original design of the venlafaxine study, with samples obtained at steady state, 
was only marginally superior to the single-dose reference design which used the same 
sampling times relative to dosing. The predicted relative standard errors (RSE) of the 
fixed effects parameters for optimized schedules with 5 to 8 measurements per subject 
were lower than 20%. Even a design with only 4 pupillographic measurements per 
subject would be approximately 19% more efficient and would result in more precise 
parameter estimates than the reference schedule with 5 samples. 
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Table 4-4 Predicted performance of different sampling schedules  
Predicted relative standard errors 
(%)  
Number of 
Samples Sampling times BL SE ST ktol IIV(BL) Erel (%) 
5 0, 0.5, 3, 5, 7 
(Reference design) 
3.44 28.5 33.0 25.9 42.3 100.0 
5 0, 312.5, 315, 317, 319 
(original sampling times, 
dosing at 312 h) 
3.44 27.4 31.9 24.9 42.4 104.8 
8 0, 0.5, 1.5, 2.5, 3, 5, 6, 7 3.43 15.0 16.5 14.4 41.6 150.6 
7 0, 0.5, 1.5, 2.5, 3, 5, 6 3.43 15.6 16.9 15.4 41.7 144.3 
6 0, 0.5, 1.5, 3, 5, 6 3.43 16.0 17.6 17.0 41.7 137.1 
5 0, 0.5, 1.5, 3, 6 3.43 16.2 17.8 17.8 41.8 126.6 
4 0, 2, 3, 6 3.44 19.0 21.1 20.8 42.1 119.2 
5 
(24 subj.) 
0, 0.5, 1.5, 3, 6 2.43 11.5 12.6 12.6 29.6 253.2 
5 
(MAT=4) 
0, 2, 5, 11, 12 3.44 46.8 56.0 43.5 42.0 63.2 
BL: baseline value; SE: slope of the effect model; ST: slope of the tolerance model; ktol: rate 
constant of development and disappearance of tolerance; IIV(BL): interindividual variability in 
BL; Erel: relative efficiency of a sampling schedule with respect to the original schedule, MAT: 
mean absorption time. 
 
The baseline response (BL) would be precisely estimated (RSE: <4%) in all designs, 
since this parameter is mostly determined by the measurement at 0 hours. The precision 
with which the interindividual variability in BL can be estimated depends on the 
number of subjects studied. Doubling the number of subjects to 24 reduced the 
predicted RSE of the IIV(BL) from 42% to 30% and would be two-times more efficient. 
As might have been expected, optimal sampling times for an extended release 
formulation were at later time points than for an immediate release formulation. 
However, in this scenario pharmacodynamic parameters (except BL) would be 
estimated with only poor precision (RSE: >40%). 
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4.1.4 Influence of the Absorption Time on the Response 
A slower absorption (i.e., longer MAT) had a considerable impact on the typical 
response vs. time profiles. Figure 4-6 shows how different values of the MAT influence 
the plasma concentration-time curves of venlafaxine and O-desmethylvenlafaxine. 
 
Figure 4-6 
 
Typical concentration-time profiles of venlafaxine (a) and 
O-desmethylvenlafaxine (b) simulated with different values of the mean 
absorption time (MAT). The liberation rate of an extended release 
formulation of venlafaxine approximately corresponds to a MAT of 4 to 8 
hours. 
 
Changes in the concentration-time profile of the drug directly affect the 
pharmacodynamic response parameters (Figure 4-7). Obviously, the longer the MAT 
the smaller is the peak response and that the maximum response is shifted towards later 
time points.  
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Figure 4-7 
 
Typical amplitude (a) and 33% recovery time (b) response simulated with 
different values of the mean absorption time (MAT). The liberation rate of an 
extended release formulation of venlafaxine approximately corresponds to a 
MAT of 4 to 8 hours. 
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4.2 Sunitinib Study 
4.2.1 Pharmacokinetic Model 
The final pharmacokinetic model (Figure 4-8) included a one- and two-compartment 
disposition for SU12662 and sunitinib, respectively. Inclusion of the second disposition 
compartment for sunitinib reduced the objective function value (OFV) significantly by 
114 units (p <0.001), whereas an additional compartment for SU12662 did not improve 
the model fit. Important steps of the model building process are summarized in Table 
9-4 in the appendix. 
 
Figure 4-8 
 
Pharmacokinetic model for the simultaneous prediction of sunitinib and 
SU12662 concentrations. After oral administration sunitinib passes the 
transit compartments T1 to TN mimicking delayed absorption. The 
number of transit compartments (N) and the mean transit time (MTT) 
were estimated as model parameters. The transit rate constant (ktr) is a 
secondary parameter. From the absorption compartment sunitinb 
enters systemic circulation unchanged or is metabolized to its major 
active metabolite SU12662. fa is the fraction of drug that is absorbed 
from the gut; fm,pre and fm,sys are the fractions of sunitinib metabolized to 
SU12662 either systemically or presystemically. 
CL: clearance; Q: intercompartmental clearance; V: volume of 
distribution. 
Random effects of apparent volumes and clearances for both sunitinib and SU12662 
were all highly correlated and estimation of covariances between these parameters 
significantly reduced the objective function (ΔOFV: 91 units, p <0.001). The ratio of 
presystemic to systemic metabolite formation was 1.91, indicating that metabolite 
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formation is mainly attributable to a first-pass effect. Accounting for delayed absorption 
with a system of transit compartments considerably improved the fit compared to a 
model with immediate first-order absorption (ΔOFV: 564 units). Although the 
estimation of the interindividual variability in the mean transit time had no impact on 
the fit, inclusion of interoccasion variability in this parameter reduced the OFV by 74 
units. The sensitivity analysis (Figure 9-16, appendix) showed that setting fm to different 
values had no important influence on the OFV or estimated model parameters - except, 
of course, on the volume of distribution and the clearance of SU12662, demonstrating 
that these parameters are not separately identifiable.  
No systematic misspecification was evident from the VPCs for sunitinib and SU12662 
plasma concentrations (Figure 4-9) or from the goodness-of-fit plots (Figure 9-10 and 
Figure 9-11, appendix). 
 
 
Figure 4-9 Visual predictive checks (VPCs) for (a) sunitinib and (b) SU12662 plasma 
concentrations. The 5th and 95th percentiles (dashed lines) and the median 
(solid red line) obtained from 1000 simulations are shown together with the 
actual observations (black circles). For subjects who only received 3 
doses the VPCs for time points >72 h are shown separately. The arrows 
indicate dosing events. 
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Pharmacokinetic parameter estimates and their bootstrap confidence intervals are 
summarized in Table 4-5.  
 
Table 4-5 Parameter estimates and their bootstrap confidence intervals (CI) from 
the pharmacokinetic model 
Parameter Estimate (90% CI) IIV, %CV (90% CI) 
RPS 1.91 (1.66 - 4.60) - 
MTT (h) 1.48 (1.25 - 2.06) -a 
N 1.46 (0.88 - 1.87) 61 (28 - 82) 
ka (h-1) 0.54 (0.48 - 0.66) 26 (1.7 - 39) 
CL/Fsunitinib (L/h) 32.4 (28.8 - 37.8) 28 (20 - 36) 
V1/Fsunitinib (L) 1720 (1397 - 2003) 33 (24 - 43) 
Q/Fsunitinib (L/h) 3.3 (2.5 - 15.3) - 
V2/Fsunitinib (L) 221 (190 - 386) - 
CL/fa,SU12662 (L/h) 14.6 (12 -18) 43 (35 - 66) 
V1/fa,SU12662 (L) 1410 (1141 - 1855) 47 (38 - 66) 
Correlations   
ρ(CL/Fsunitinib,V1/Fsunitinib) 0.88 (0.80 - 0.96) - 
ρ(CL/Fsunitinib,CL/fa,SU12662) 0.70 (0.50 - 0.93) - 
ρ(CL/Fsunitinib,V1/fa,SU12662) 0.67 (0.41 - 0.93) - 
ρ(V1/Fsunitinib,CL/fa,SU12662) 0.90 (0.84 - 0.99) - 
ρ(V1/Fsunitinib,V1/fa,SU12662) 0.90 (0.93 - 0.99) - 
ρ(CL/fa,SU12662,V1/fa,SU12662) 0.99 (0.99 - 1.00) - 
Residual error 
  
σadd,sunitinib (ng/mL) 0.07 (0.02 - 0.17) - 
σprop,sunitinb (%) 11 (8.8 - 12) - 
σadd,SU12662 (ng/mL) 0.36 (0.13 - 0.39) - 
σprop,SU12662 (%) 11 (9.3 - 13) - 
IIV: interindividual variability; CV: coefficient of variation (%); RPS: ratio of 
presystemic to systemic metabolite formation; MTT: mean transit time; N: number of 
transit compartments; ka: absorption rate constant; CL: clearance; V1: volume of 
distribution of the central compartment; Q: intercompartmental clearance; V2: volume 
of distribution of the peripheral compartment; F: bioavailability (fa•[1-fm,pre]); fa: fraction 
of absorbed dose (fixed to 1); ρ: correlation coefficient; σadd: additive residual 
variability (standard deviation); σprop: proportional residual variability (CV). 
a  Interoccasion variability in MTT was estimated at 111% (90%CI: 77 - 138). 
 
The NONMEM code of the final model is provided in the appendix (Code 9-4). 
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4.2.2 Pharmacodynamic Models 
4.2.2.1 Blood pressure 
A time-dependent variation in baseline systolic and diastolic blood pressure 
(BL(T)systolic,diastolic) was found to be best described by a function including two cosine 
terms (equation 4-4) previously used by Hempel et al. [132]: 
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4-4
where BL(24)systolic,diastolic is the mean systolic or diastolic blood pressure during a 24-
hour period, AMP1 and AMP2 are the amplitudes of each cosine term, PS1 and PS2 are 
the phase shifts of the functions relative to time (T) determining when a maximum or 
minimum occurs. The periods of the two cosine terms were 24 and 12 hours, 
respectively. The estimate for PS1 was close to zero and fixed to this value in the final 
model with no impact on the OFV. Based on individual parameter estimates, blood 
pressure was calculated to be 2.2 to 8.1% higher in the evening (~10:00 PM) and ~2.4 to 
8.3% lower in the afternoon (~2:00 PM) compared to the individual BL(24)systolic,diastolic 
estimate. At 8:00 AM the relative deviation from the individual BL(24)systolic,diastolic value 
ranged from -3 to +3%. Figure 4-10 shows the predicted diastolic blood pressure during 
24 hours for the subjects in the present study. 
 
Figure 4-10 Individual predictions of diastolic blood pressure of the 12 subjects 
during a 24-hour (drug-free) interval. The dashed line marks the 
average 24-hour baseline diastolic blood pressure in this population. 
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Estimation of separate amplitudes or phase shifts for systolic and diastolic blood 
pressure did not improve the fit or resulted in unstable models (see Table 9-5 in the 
appendix). 
The increase in systolic and diastolic blood pressure observed after sunitinib 
administration (Figure 4-11), was found to be well described by equation 4-5 and 
equation 4-6 including an immediate signal (ISIG), which was set equal to the fractional 
tyrosine kinase inhibition (INH, see section 3.3.5) and a slower, transduced signal 
(TSIG).  
 
Figure 4-11 
 
Mean systolic (red) and diastolic (blue) blood pressure vs. mean 
fractional tyrosine kinase inhibition (INH) (a). On the right-hand side (b) 
the blood pressure response is presented as ratio to baseline (i.e., the 
mean of all measurements on day 0). The arrows indicate the 
progression of time; the dashed line marks the baseline blood pressure. 
placeholder 
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equation 4-6
where αsystolic,diastolic is the intrinsic activity denoting the power of the drug to produce a 
response in diastolic or systolic blood pressure and τBP is the transduction time 
describing the time delay for the slower signal. Rsl denotes the proportional contribution 
of this slower signal to the overall effect. It was estimated to be close to 1 and finally 
fixed to this value without affecting the OFV. In fact, the sensitivity analysis showed, 
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that setting Rsl to values <1 led to higher OFVs (Figure 9-17, appendix). Of the fixed-
effects parameters only τBP was sensitive to changes in Rsl which appears logical given 
that both parameters describe the transduced signal and may be correlated. Setting the 
dissociation constant Kd to values >4 ng/mL had almost no effect on the OFV or the 
random-effects parameters. αsystolic, αdiastolic and τBP changed by 20-30% for every unit 
change of Kd (Figure 9-18, appendix). 
τBP was estimated to be 121 h showing a considerably delayed response to the slower 
process. Although the inclusion of this parameter was associated with a significant 
reduction of the OFV of 13 units (p <0.001), its 90% confidence interval (CI), however, 
was fairly wide (12.2–541 h). Estimates and 90% CIs for all other parameters are given 
in Table 4-6. 
Table 4-6 Parameter estimates and their bootstrap confidence intervals (CI) from 
the sunitinib blood pressure models 
Parameter Estimate (90% CI) IIV, %CV (90% CI) 
BL(24)systolic (mmHg) 118 (115 - 121) 6.7(4.6 - 7.7) 
BL(24)diastolic (mmHg) 67.6 (65.1 - 70.5) 8.7 (6.3 - 9.6) 
AMP1 0.025 (0.014 - 0.036) 75 (32 - 137) 
PS1 0 fixed - 
AMP2 -0.016 (-0.023 to -0.006) 78 (36 - 200) 
PS2 1.4 (1.1 - 1.6) - 
αsystolic 0.078 (0.035 - 0.142) 135 (65 - 257) 
αdiastolic 0.145 (0.082 - 0.221) 71 (42 - 104) 
Rsl 1 fixed - 
τBP (h)  121 (12.2 - 541) - 
Correlations   
ρ(BL(24)systolic,BL(24)diastolic) 0.70 (0.49 - 0.92) - 
ρ(αsystolic,αdiastolic) 0.88 (0.29 - 0.98) - 
Residual error   
σadd,systolic (mmHg) 7.4 (6.6 - 8.1) - 
σadd,diastolic (mmHg) 6.6 (5.9 - 7.1) - 
IIV: interindividual variability; CV: coefficient of variation; BL(24)systolic,diastolic: average 
systolic or diastolic blood pressure over 24 hours; BL: baseline value; 
AMP1,2: amplitude of the first or second cosine term; PS1,2: phase shift of the first or 
second cosine term; α: intrinsic activity parameter; Rsl: relative contribution of the 
transduced signal to the effect; τ: transduction time; ρ: correlation coefficient; 
σadd: additive residual variability (standard deviation). 
 
  
     
71Results 
The visual predictive checks (Figure 4-12) demonstrate that the model predicted the 
observed data reasonably well. Variability, however, appears to be slightly 
overestimated especially at later time points. Goodness-of-fit plots, shown in the 
appendix, support this finding (Figure 9-12 and Figure 9-13). 
 
 
Figure 4-12 
 
Visual predictive checks (VPCs) for (a) systolic and (b) diastolic blood 
pressure. The 5th and 95th percentiles (dashed lines) and the median (solid 
red line) obtained from 1000 simulations are shown together with the 
actual observations (black circles) normalized to their respective baseline 
estimates. For subjects who only received 3 doses the VPCs for time 
points >72 h are shown separately. The arrows indicate dosing events. 
 
The NONMEM code of the final blood pressure model is provided in the appendix 
(Code 9-5). 
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4.2.2.2 VEGF-A 
None of the tested cosine models for diurnal variations in VEGF-A levels were 
significantly different from the mean baseline value.  
From Figure 4-13 it is evident that the relationship between the fractional tyrosine 
kinase inhibition (INH) and VEGF-A concentrations is not linear.  
 
 
Figure 4-13 
 
Mean VEGF-A concentrations vs. mean fractional tyrosine kinase 
inhibition (INH) grouped by study part (Part 1: red, Part 2: blue). In b 
the VEGF-A concentrations are normalized to the baseline 
concentration (i.e., the mean of all measurements on day 0). The 
arrows indicate the progression of time; the dashed line marks the 
baseline. 
 
A power function including a signal transduction component was found to best describe 
this relationship (equation 4-7 and equation 4-8). A summary of the model building 
process is provided in Table 9-6 in the appendix. 
 TSIGINH1
d
dTSIG
AVEGF


t
 equation 4-7 
)TSIG1(BLAVEGF AVEGFAVEGF    equation 4-8 
where αVEGF-A is the intrinsic activity and γ is a shape parameter describing the signal 
modification during the transduction process (see Figure 3-3); TSIG denotes the 
transduced signal and τVEGF-A the transduction time. Exclusion of γ from the model (i.e., 
fixing it to 1) worsened the OFV by 85 units. The inclusion of a signal transduction 
function to account for a time delay in VEGF-A response improved the OFV by 73 
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units. The signaling process of VEGF-A was slightly delayed as indicated by a 
transduction time of only ~12 hours in a typical subject. However, in two subjects 
individual estimates of τVEGF-A were considerably longer (85 and 327 h) explaining the 
high interindividual variability (CV: 373%) associated with this parameter. The baseline 
estimate of VEGF-A (BLVEGF-A) in the first part of the study was 1.76 times higher than 
in the second part (p <0.05). This is most likely due to the differences in the 
centrifugation speed (780 g in the first, and 1000 g in the second part) at which plasma 
samples were prepared. The sensitivity analysis (Figure 9-19, appendix) is not very 
conclusive. The values of τVEGF-A, the interindividual variability (IIV) in τVEGF-A and 
αVEGF-A are quite sensitive to changes in Kd, however, without a consistent pattern. This 
may be due to the relatively low precision with which these parameters could be 
estimated (i.e., wide confidence intervals, see Table 4-7). 
 
Table 4-7 Parameter estimates and their bootstrap confidence intervals (CI) from 
the sunitinib VEGF-A model 
Parameter Estimate (90% CI) IIV, %CV (90% CI) 
BLVEGF-A (pg/ml) 80.1 (66.1 - 99.6) 33 (14 - 41) 
θPART1 on BLVEGF-A 1.76 (1.35 - 2.27) - 
γ 4.3 (3.4 - 6.7) - 
αVEGF-A 10.2 (5.1 - 57) 68 (29 - 99) 
τVEGF-A (h) 11.8 (3.4 - 45.4) 373 (94 - 2143) 
Residual error   
σprop,VEGF-A (%) 18 (17 - 20) - 
IIV: interindividual variability; CV: coefficient of variation; BL: baseline value; θPART1: 
baseline adjustment for subjects from the first part of the study; γ: shape parameter; 
α: intrinsic activity parameter; τ: transduction time; σprop: proportional residual variability 
(CV).  
 
The visual predictive check (Figure 4-14) indicated some overestimation of the 
variability between 30 and 100 hours after the first dose. Overall, however, the model 
fitted reasonably well to the observed data, which is also supported by the goodness-of-
fit plots shown in the appendix (Figure 9-14).  
The NONMEM code of the VEGF-A model is provided in the appendix (Code 9-6). 
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Figure 4-14 
 
Visual predictive check for VEGF-A. The 5th and 95th percentiles 
(dashed lines) and the median (solid line) obtained from 1000 
simulations are shown together with the actual observations (black 
circles) normalized to their respective baseline estimates. For subjects 
who only received 3 doses the VPC for time points >72 h is shown 
separately. The arrows indicate dosing events. 
 
4.2.2.3 VEGF-C 
VEGF-C concentrations did not show any consistent change over time (Figure 4-15), 
nor were they related to the fractional tyrosine kinase inhibition (Figure 4-16). The 
development of a PK/PD model was therefore not considered for this biomarker. From 
Figure 4-16 (a) it is evident that plasma concentrations differed between the two study 
parts. As with VEGF-A, the different centrifugation speeds are likely to be responsible 
for this observation. 
 
Figure 4-15 
 
Individual VEGF-C concentrations plotted against time (a). The right 
panel (b) shows the VEGF-C concentrations normalized to the 
baseline concentration (i.e., the mean of all measurements on day 0). 
The arrows indicate dosing events. 
PlaceholderLik  
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Figure 4-16 
 
Mean VEGF-C concentrations vs. mean fractional tyrosine kinase 
inhibition (INH) grouped by study part (Part 1: red, Part 2: blue). In b 
the VEGF-C concentrations are normalized to the baseline 
concentration (i.e., the mean of all measurements on day 0). The 
arrows indicate the progression of time; the dashed line marks the 
baseline. 
 
4.2.2.4 sVEGFR-2 
Inclusion of a cosine function describing diurnal variation in baseline sVEGFR-2 levels 
did not improve the model fit.  
An indirect response model (equation 4-9) with the fractional tyrosine kinase inhibition 
(INH) reducing the zero-order release rate (Kin) of sVEGFR-2 best described the data:  
2sVEGFRk
)INH1(
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d
2dsVEGFR
out
2sVEGFR
in 




t
 equation 4-9
where αsVEGFR-2 is the intrinsic activity and Kin was assumed to equal BLsVEGFR-2×kout.  
Other functional relationships were also tested and are summarized in Table 9-7 in the 
appendix. 
The first-order rate constant kout may be interpreted as the elimination rate constant of 
sVEGFR-2 from plasma. Hence, the typical half-life (ln2/kout) of this soluble receptor 
was ~4 days. The delayed response of sVEGFR-2 is evident from Figure 4-17 where 
mean concentrations are plotted against the INH – the clockwise hysteresis loop 
indicates that the response is time-dependent.  
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Figure 4-17 
 
Mean VEGFR-2 concentrations vs. mean fractional tyrosine kinase 
inhibition (INH). In b the VEGFR-2 concentrations are normalized to 
the baseline concentration (i.e., the mean of all measurements on day 
0). The arrows indicate the progression of time; the dashed line marks 
the baseline. 
 
The sensitivity analysis (Figure 9-20, in the appendix) showed that setting the 
dissociation constant (Kd) to different values had only little impact on most of the 
parameter estimates. Only αsVEGFR-2 changed by about 20% for every unit change in Kd. 
This, however, is not surprising, since αsVEGFR-2 and Kd are interdependent parameters 
that are not separately identifiable. Values of Kd <4 ng/mL increased the OFV, whereas 
with greater values of Kd the OFV slightly decreased.   
The visual predictive check (Figure 4-18) shows that the median prediction matches the 
observed concentrations and that the variability was reasonably described. Standard 
goodness-of-fit plots are provided in the appendix (Figure 9-15). Parameter estimates 
and 90% CIs are presented in Table 4-8. 
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Figure 4-18 
 
Visual predictive check for VEGF-A. The 5th and 95th percentiles (dashed 
lines) and the median (solid red line) obtained from 1000 simulations are 
shown together with the actual observations (black circles) normalized to 
their respective baseline estimates. For subjects who only received 3 
doses the VPC for time points >72 h is shown separately. The arrows 
indicate dosing events. 
Placeholder 
Table 4-8 Parameter estimates and their bootstrap confidence intervals (CI) from 
the sVEGFR-2 model 
Parameter Estimate (90% CI) IIV, %CV (90% CI) 
BLsVEGFR-2 (pg/mL) 9060 (8620 - 9470) 10 (5.3 - 13) 
αsVEGFR-2 0.50 (0.28 - 0.80) 70 (18 - 200) 
kout,sVEGFR-2 (d-1) 0.175 (0.103 - 0.259) 66 (21 - 131) 
Residual error   
σprop,sVEGFR-2 (%) 6.5 (6.2 - 6.9) - 
IIV: interindividual variability; CV: coefficient of variation; BL: baseline value; 
α: intrinsic activity parameter; kout: rate of loss of biomarker response; σprop: 
proportional residual variability (CV). 
 
The NONMEM code can be found in the appendix (Code 9-7). 
4.2.3 Comparison with Data from Literature 
The average predictions from the blood pressure model matched closely the data 
reported by Azizi et al. [74] for the normotensive mRCC patients (Figure 4-19). The 
variability in the simulated values is, however, higher than in the original report. In 
Figure 4-20 the mean predicted changes in VEGF-A and sVEGFR-2 levels are 
compared with data from previously reported investigations in cancer patients [75-78]. 
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The present models predicted consistently smaller mean changes in VEGF-A or 
sVEGFR-2 levels from baseline compared to average observations in cancer patients. 
 
 
Figure 4-19 
 
Comparison of model-simulated time courses of the blood pressure response 
with data extracted from graphs in a previous publication. The mean values 
(dashed line) and the 68% prediction interval (blue area) of simulated systolic 
and diastolic blood pressure are compared to mean values (filled squares) 
and standard deviation (SD) (vertical bars) reported by Azizi et al. [74].  
Placeholder 
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Figure 4-20 Simulated mean changes (dashed lines) of (a) VEGF-A, and (b) sVEGF-
2 levels are shown together with mean changes reported in studies in 
patients with GIST ( , Norden-Zfoni et al. [78]), breast cancer ( , 
Burstein et al. [75]), and mRCC ( , Deprimo et al. [76] and , 
Kontovinis et al. [77]). The blue area represents the 90% prediction 
interval of the simulations. For the sake of clarity and because a measure 
of variability (e.g., SD) was not provided in all studies, no error bars are 
shown. 
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4.2.4 Clinical Trial Simulation 
In the initial simulation scenario, with 75 patients per group and a target increase of 
diastolic blood pressure of 16%, the median overall survival (OS) in the standard dose 
group was 574 days (95% CI, 490 - 700) and 784 days (95% CI, 616 - 826) in the 
individualized dose group (hazard ratio: 0.64 [95% CI, 0.40 – 0.92], power: 62.2% 
[95% CI, 57.8 – 66.4]). The incidence of grade 3/4 fatigue was 10.7% (95% CI, 4.0 – 
17.0) in the standard dose group and 17.3% (95% CI, 10.6 - 26.7) in the individualized 
dose group. In the standard dose group 24.0% (95% CI, 15.3 – 33.3) of the patients 
needed antihypertensive treatment compared to 28% (95% CI, 17.3 – 37.3) in the 
individualized dose group. The distribution of the dose levels patients received in their 
final treatment cycle is shown in Figure 4-21. Almost half of the patients in the 
individual dose group ended up with the highest dose allowed of 87.5 mg. 
 
Figure 4-21 
 
Frequency distribution of the final dose level the patients 
received in the trial. The error bars represent the 95% confidence 
interval. 
Figure 4-22 shows the simulated survival curves. Statistical power to detect a 
significantly longer median OS in relation to the number of patients studied or the target 
blood pressure increase are shown in Figure 4-23. Table 4-9 summarizes the simulation 
results for different values of the target increase in diastolic blood pressure. 
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Figure 4-22 
 
Simulated median survival curves in patients with mRCC for the 
standard treatment group (black solid line) and the individualized dose 
group (red line). The shaded areas are the 95% confidence intervals 
around the respective survival curves. 
Placeholder 
 
 
Figure 4-23 
 
Statistical power to detect a significantly longer median overall survival in 
relation to the total number of patients studied (a, target dBP increase fixed to 
16%) or target dBP increase (b, number of patients fixed to 150). Vertical bars 
represent the 95% confidence intervals. dBP: diastolic blood pressure. 
placeholder 
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Table 4-9 Impact of target blood pressure on the overall survival and the incidence 
of fatigue 
 Median                   overall survival (days)  
Incidence of  
grade 3/4 fatigue (%) 
Target      
blood pressure 
increase (%) 
Individualized 
dose group 
Standard  
dose group 
Individualized  
dose group 
Standard 
dose group 
11.6  742 574 17.3 10.7 
13.0 742 574 17.3 10.7 
14.5 742 574 17.3 10.7 
16.0 784 574 17.3 10.7 
17.4 784 574 18.7 10.7 
18.9 784 574 18.7 10.7 
20.3 784 574 18.7 10.7 
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5 Discussion 
5.1 Venlafaxine Study 
5.1.1 Pharmacokinetic Model 
The pharmacokinetic model adequately described the plasma concentration-time 
profiles of venlafaxine and O-desmethylvenlafaxine and was able to account for the 
presystemic formation of this metabolite in the liver (i.e., first-pass effect). This could 
be achieved by integrating a physiological body compartment, the liver, and using liver 
plasma flow and liver volume as fixed physiological parameters. Taft et al. [104] were 
the first who applied such a model to describe venlafaxine and O-desmethylvenlafaxine 
plasma concentrations. The present model is a modification of the one they used and 
differs mainly in two aspects. First, a system of transit compartments was applied to 
account for a delayed absorption of venlafaxine. It was recently demonstrated that this 
approach gives mathematically more stable models and also provides more precise 
parameter estimates as, for example, the inclusion of an absorption lag-time [122]. 
Second, in contrast to Taft et al. [104], who fixed the fraction metabolized (fm) to a 
value obtained from literature in order to estimate the volume of distribution of 
O-desmethylvenlafaxine (VODV) and its clearance (CLODV), in the present work VODV 
was fixed to 210 L, in order to estimate fm and its interindividual variability. Because 
venlafaxine is exclusively metabolized to O-desmethylvenlafaxine via the CYP2D6 
enzyme system, which is subject to genetic polymorphism [133], it seemed reasonable 
that fm varies more between healthy subjects than VODV and CLODV. A disadvantage of 
this approach is that the interindividual variability in fm cannot be fully separated from 
the variability in VODV and CLODV. This means that the estimate for the interindividual 
variability in fm (CV: 34.5%) also contains the variability in VODV and CLODV to some 
(unknown) extent. However, this weakness apparently did not lead to erroneous results 
since parameter estimates from the present model are consistent with values previously 
reported (Table 4-2).  
Numerous researchers have described the highly variable metabolism of venlafaxine 
due to CYP2D6 polymorphism [133-139]. Consistent with these findings, a high value 
for the interindividual variability in the intrinsic clearance of venlafaxine (CLint(VEN); 
CV: 94.8%) was estimated in the present work.  
  
84 Discussion
Another feature of the model is its ability to estimate the hepatic extraction ratio EH, 
which was calculated to be 68% and is indicative for a moderate to high extraction drug. 
Based on the results from a crossover trial with orally and intravenously administered 
venlafaxine, Patat et al. [49] calculated an EH of 55 to 60%.  
Although several assumptions had to be made for model building (e.g., fixing QH, VODV, 
and the volume of the liver compartment) precise and reasonable parameter estimates 
could be obtained. All assumptions are physiologically reasonable and are based on 
previous findings. A sensitivity analysis showed that changing the value of fixed 
parameters had either no relevant influence on other model parameters or worsened the 
model fit in terms of OFV. Setting the QH, for example, at a value corresponding to the 
hepatic blood flow (1.2 L/h/kg) worsened the model fit in terms of the OFV. This is 
interesting, since the hepatic elimination of drugs is usually limited by the hepatic blood 
flow [140]. During the passage through the liver, drug molecules associated with or 
distributed into blood cells normally redistribute rapidly back into the plasma when 
concentrations decline there due to metabolism. In the case of venlafaxine, an 
explanation could be that the distribution of this drug from erythrocytes to the plasma is 
very slow. Then the hepatic clearance may not exceed the hepatic plasma flow.  
Nevertheless, the present study endorses the conclusion drawn by Taft et al. [104], that 
this kind of semi-physiological model provides useful information on the disposition of 
drugs that undergo hepatic metabolism.   
5.1.2 Pharmacodynamic Models 
The shortening of the 33% recovery time of the pupillary light reflex induced by 
venlafaxine and O-desmethylvenlafaxine is presumably reflecting sympathetic 
potentiation in the iris due to the inhibition of norepinephrine (NE) reuptake from the 
synaptic gap. Venlafaxine and O-desmethylvenlafaxine have no relevant affinity to 
muscarinergic receptors of the iris [54]. Therefore, the decrease in the amplitude of the 
pupillary light reflex induced by venlafaxine and O-desmethylvenlafaxine is assumed to 
be caused by NE-mediated inhibition of central parasympathetic (Edinger-Westphal) 
neurons, again due to NE reuptake blockade [58].  
In the present analysis, a smaller effect (i.e., the shortening of the 33% recovery time 
and the decrease of the amplitude) was observed at the end of a dosing interval than at 
the beginning, despite equal plasma concentrations of the active drug (Figure 4-4). This 
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indicates the development of acute tolerance of the pharmacodynamic response. In 
general, there are several possible mechanisms for the development of tolerance: 
counter-regulation by an endogenous substance, receptor desensitization, receptor 
downregulation, and depletion of an endogenous precursor pool. In this case, the most 
likely explanation for the acute tolerance is rapid desensitization of β-adrenoceptors, 
since it has been demonstrated in vivo that a single administration of venlafaxine and 
O-desmethylvenlafaxine led to reduced cyclic adenosine monophosphate (cAMP) 
response to isoproterenol in the pineal gland of rats [141]. Franklin et al. later confirmed 
this result and showed that the reduction of responsiveness is not due to a decrease in 
NE concentration (similar to a precursor pool depletion) but most likely a result of β-
adrenoceptor desensitization [142]. 
Models, similar to the one applied here, including a tolerance compartment have already 
successfully been used to describe the effect of nicotine on heart rate [116], the 
antinociceptive effect of morphine [115], and the effect of caffeine on blood 
pressure [117]. It is, of course, a simplification of the true underlying mechanism, which 
is undoubtedly more complex. However, more mechanistic models (e.g., negative 
feedback model [113], precursor pool model [112]) were tested but did not show 
superiority in terms of model fit. Moreover, because more complex models need more 
parameters to be estimated, they resulted in imprecise estimates due to 
overparameterization.  
Nevertheless, the model is justified by its ability to describe the concentration-effect 
relationship and the time course of the effect of venlafaxine and 
O-desmethylvenlafaxine on the pupillary light reflex parameters, amplitude and 33% 
recovery time. An interesting parameter that can be derived from the analysis is the 
half-life of development or disappearance of tolerance (t1/2tol). The estimates of t1/2tol 
were similar for both amplitude and 33% recovery time (30 min and 40 min, 
respectively) and suggest that after about 3 hours (~5 half-lives), full sensitivity to 
venlafaxine should be regained. 
It could be argued that a predose value for the PD measurements at day 14 should have 
been determined and used for model building instead of, or in addition to, the baseline 
value at day 0. However, the last PD measurements on day 14 (7 hours after the last 
dose and 5 hours before the end of the dosing interval) did not differ from their baseline 
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values at day 1 ([meanSD] 1.64  0.25 vs. 1.60  0.33 mm for amplitude and 
1.39  0.14 vs. 1.42  0.10 sec for 33% recovery time). This indicates that the drug 
effect returns to baseline within a dosing interval of 12 hours and no “accumulation” of 
the drug effect occurs. Thus, it is unlikely that inclusion of predose PD values at day 14 
would have altered the modeling results much. 
No PK and PD measurements after the first dose were performed, since the aim of the 
present study was to investigate the time course of the effect of venlafaxine and 
O-desmethylvenlafaxine under steady-state conditions, as this was considered to be of 
more clinical relevance. However, PK and PD measurements after a single dose of 
venlafaxine and the influence of different doses could be studied in future trials in order 
to characterize the kinetic complexities of the tolerance phenomenon in more detail by 
developing a more mechanistic model.  
5.1.3 Optimal Study Design 
As an example of the utility of model-based data analysis, the model for the amplitude 
was used for the optimization of pupillographic measurement times. The single-dose 
reference design was only slightly inferior to the original design used in the venlafaxine 
study where sampling was performed at steady-state (same sampling times relative to 
the preceding dose event). In this case, sampling at steady state offers no relevant 
advantage over sampling after the first administration. 
All optimal sampling schedules with 4 to 8 measurements per subject were more 
efficient than the reference design with 5 measurements per subject. Most interestingly, 
designs with the same number of samples per subject or even one less outperformed the 
reference design. This demonstrates the importance of selecting the most informative 
sampling times in order to obtain precise parameter estimates in later analysis. The 
exploration of different sampling schedules permits the rational planning of future 
studies taking into account costs and other limitations. In the case of a single-dose study 
with 12 subjects it could be shown that a schedule with 8 samples would only slightly 
improve parameter precision compared to an optimal design with 5 samples per subject. 
However, if the (precise) determination of interindividual variability is an objective, 
than more subjects would have to be included. 
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5.1.4 Influence of Absorption Time on the Response 
Since venlafaxine is also offered as an extended release formulation (Effexor XR®), it 
was of interest how a slower release (represented by a longer mean absorption time, 
MAT) would influence the pharmacodynamic response.  
Simulations showed that a longer MAT would lead to reduced maximal plasma 
concentrations of venlafaxine and O-desmethylvenlafaxine occurring later in time. 
Correspondingly, the peak response of the amplitude and the 33% recovery time would 
also be smaller and would be shifted towards later time points. This is of importance, as 
the response is weaker for a longer MAT, it may happen that in a study with the 
extended release formulation the pupillographic response is not easily distinguishable 
from the placebo response. Furthermore, sampling times optimal for a study with the 
immediate release formulation would be inadequate for slow-released venlafaxine (see 
Table 4-4). 
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5.2 Sunitinib Study 
5.2.1 Pharmacokinetic Model 
Plasma concentration-time profiles for sunitinib and SU12662 were successfully 
described by a pharmacokinetic model simultaneously accounting for presystemic and 
systemic metabolite formation. This type of model was previously used for a variety of 
drugs that undergo a significant first-pass metabolism [143-145], but had not been used 
for sunitinb. Volume and clearance estimates from the model compare well to previous 
reports in healthy volunteers [146]. The high correlations that were estimated for 
random effects on apparent volume and clearance terms of sunitinib and SU12662 
(correlation coefficients ranging from 0.67 to 0.99) reflect the interdependence of these 
parameters caused by the fraction absorbed (fa) and the fraction metabolized (fm) as 
common, however unknown, sources of variability. Accounting for delayed absorption 
greatly improved the model fit. However, its impact on steady-state concentrations may 
be negligible, given the long half-lives of sunitinib and SU12662 (~55 and ~73 h, 
respectively) in relation to the mean transit time (MTT) of only ~1.5 h. Likewise, the 
interoccasion variability in the MTT, although substantial (CV: 111%), is not expected 
to affect plasma concentrations at equilibrium.  
5.2.2 Pharmacodynamic Models 
A mechanism-based approach that permits the separation between drug-specific 
(tyrosine kinase inhibition) and biological system-specific components (biomarker 
signal) was successfully applied to relate drug concentrations to biomarker response.  
The drug-specific part of the model consisted of a function relating free drug 
concentration to VEGFR-2 tyrosine kinase inhibition based on in vitro data for protein 
binding [59] and kinase inhibition [124]. An important assumption was that all 
measured biomarker effects are triggered solely by the inhibition of the VEGFR-2 
tyrosine kinase. Although sunitinib targets several other tyrosine kinases (see section 
1.4.1), for the biomarkers studied here, it is likely that this assumption holds true, since 
signaling via VEGFR-2 is predominantly responsible for angiogenesis, and similar 
effects on biomarkers had been described also for other drugs targeting VEGFR-2 [71].  
A limitation of the present study was the small number of subjects leading to less 
precise estimates of interindividual variability parameters. Moreover, for ethical reasons, 
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only up to five doses of sunitinib were given. However, because of the long half-lives of 
sunitinib and SU12662 steady state is not reached until ~12 days after treatment start. 
This might explain, why parameters describing a time delay (τBP, τVEGF-A, kout,sVEGFR-2) 
could not be estimated precisely.  
5.2.2.1 Blood Pressure 
The dual mechanism of action that was incorporated in the blood pressure model is 
compatible with the theory of how hypertension is caused by antiangiogenic therapy: (i) 
reduction in endothelial nitric oxide synthase (eNOS) expression which is controlled by 
VEGF signaling [147], and (ii) vascular rarefaction [85], that is, a decrease in perfused 
microvessels and a reduction in capillary density both controlling peripheral vascular 
resistance. A reduction in eNOS expression and the subsequent decline in nitric oxide 
production are likely to be more rapid than functional and morphological alterations to 
the vasculature. It is intriguing how closely model simulations compare to the 
observations that Azizi et al. reported for patient with metastatic renal cell carcinoma 
(mRCC) (Figure 4-19) [74]. Thus, drug effects on blood pressure may not be decisively 
influenced by this disease.  
It is known that blood pressure is subject to diurnal variations [148] and accounting for 
a circadian rhythm improved the model fit in the present analysis. Therefore, for future 
studies it may be advisable to either account for diurnal blood pressure changes by a 
model, or to obtain measurements always at the same time of day.  
5.2.2.2 Circulating Biomarkers 
A relatively quick rise in VEGF-A concentrations was observed and a slow decline in 
sVEGFR-2 levels. Given the short plasma half-life of VEGF-A of ~13 min [149], it was 
assumed that the small delay in VEGF-A response is likely due to a slow signal 
transduction process, rather than rate-limiting elimination from plasma. By contrast, the 
calculated half-life for sVEGFR-2 of ~4 days is of the same order as the half-life (~7 
days) that was reported for VEGF-trap, a soluble analogue of VEGFR-1 [149]. Thus, 
rate-limiting elimination may likely be the reason for the delayed sVEGFR-2 response. 
Subjects in the first part of the study had significantly higher VEGF-A and VEGF-C 
levels than subjects in the second part. This is very likely due to the different 
centrifugation speeds used for sample preparation in the two parts. VEGF-A (and 
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VEGF-C) is present within platelets, thus at lower rotation speeds more platelets remain 
in the plasma supernatant and any VEGF-A (or –C) released from these will also be 
measured [150-152]. This difference, however, could be successfully accounted for by 
including “study part” as a covariate on the baseline estimate for VEGF-A (BLVEGF-A). 
VEGFR-2 concentrations were not affected by this difference.  
No changes in VEGF-C levels in relation to sunitinib concentrations were observed in 
this study. The reason for this is not quite clear, since in a study with mRCC patients a 
23% reduction in VEGF-C levels during the first cycle was reported [153]. It might be, 
that changes of VEGF-C levels are not directly related to tyrosine kinase inhibition but 
rather occur secondary to effects on a tumor and are therefore not observable in healthy 
subjects. An alternative explanation could be that the effect on VEGF-C might be too 
weak to be obvious after only 5 doses of sunitinib.      
5.2.3 Comparison with Data from Literature 
The simulations suggested that the change in VEGF-A levels from baseline is smaller in 
healthy subjects than in cancer patients (Figure 4-19 a). Moreover, changes in this 
biomarker seem to be more pronounced in patients with mRCC or breast cancer than 
with GIST. Similarly, changes in simulated sVEGFR-2 levels were smaller than 
observations in patients, with GIST patients exhibiting the least fold-change (Figure 
4-19 b). It may be concluded that VEGF-A released from tumor cells adds substantially 
to VEGF-A derived from other body cells. Likewise, the inhibition of sVEGFR-2 
release into circulation by sunitinib may be more affected in tumor tissue than in 
healthy ones. This would be in accordance with preclinical observations in tumor-
bearing and healthy mice [73]. Moreover, it appears that the magnitude of biomarker 
release (or inhibition of release) depends on the type of tumor.  
This is in line with the theory that mRCC is more susceptible to angiogenesis inhibition 
than is GIST [80]. In GIST, sunitinib’s affinity to KIT seems to be of higher relevance 
for the antitumor effect than inhibition of angiogenesis [81]. In this context it is 
important to note, that VEGF receptors are also overexpressed in breast cancer 
tissue [154].  
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5.2.4 Clinical Trial Simulation 
The results from the clinical trial simulations showed that adjusting the dose based on 
individual diastolic blood pressure measurements could relevantly prolong overall 
survival (OS). However, the benefit of the estimated 210 days of longer survival comes 
at the cost of a higher risk to suffer from severe fatigue. Since fatigue is a manageable 
and reversible side effect this may be clinically acceptable. Variation of the target 
increase in diastolic blood pressure suggested, that an increase of 16%, may be the most 
useful target. Higher target values only led to an increased incidence of severe fatigue 
but did not prolong survival any further. 
With clinical trial simulations it is possible to estimate the probability that a trial will be 
successful and the influence of different design factors (e.g., study size) on this 
probability can be investigated. This was done by repeatedly simulating the trial and 
counting the number of times the null hypothesis (no difference between the two 
groups) was declared false. This number divided by the total number of simulation 
replicates represents the statistical power of the trial [16]. 
Not surprisingly, the statistical power to demonstrate a significant difference in OS was 
related to the number of patients studied. Figure 4-23 suggests that about 125 patients 
per group may be needed to achieve a power greater than 80%. However, it should be 
noted that the results from the power analysis may be overly optimistic since important 
factors such as dropouts, noncompliance, occurrence of adverse events others than 
fatigue leading to dose reductions, treatment interruption, death unrelated to tumor etc., 
were not considered in the present simulations. In fact, in a large phase III trial a 
reduction of the dose was necessary in about 50% of the patients [155]. 
The purpose of this clinical trial simulation was to give an impression of the potential 
that dose individualization of sunitinb may have and to show the usefulness of modeling 
and simulation as a tool to explore this. More exhaustive simulations including the 
above-mentioned factors will be required when a real clinical trial is to be planned. 
Especially a (logistic regression) model relating the probability of having a dose 
reduction or a treatment interruption to some measure of drug exposure would be useful.  
Despite the limitations of this simulation study, the benefit of dose individualization 
based on blood pressure measurements is obvious and in line with previous findings. 
Several retrospective analyses showed that elevated blood pressure has the potential to 
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be predictive for treatment outcome with antiangiogenic agents [79,156,157]. Rixe et 
al. [79], found that hypertension of >grade 2 was an independent predictor for a better 
clinical response in patients with mRCC treated with sunitinib. Moreover, a tremendous 
survival benefit was observed in phase II studies of axitinib, a selective inhibitor of 
VEGF receptors 1, 2, and 3, where patients with recorded diastolic blood pressure ≥90 
mmHg lived about 90 weeks (!) longer than patients without blood pressure 
increase [158]. This probably led to the decision to apply a special dose-titration scheme 
based on blood pressure control for the phase III program of this drug [70,158]. 
Although not published yet, it is very likely that the company developing axitinib 
(Pfizer Inc.) used modeling and simulation techniques to support this decision. 
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6 Conclusions and Perspectives 
 
Although the two drugs sunitinib and venlafaxine come from unrelated therapeutic 
fields, oncology and central nervous system diseases, the approach of PK/PD modeling 
and simulation using biomarkers could be successfully applied to both of them. In fact, 
these two therapeutic areas are among the ones with the highest failure rates of drug 
development programs. Most likely this is due to the lack of robust and early 
responding biomarkers, capable of quantifying efficacy in proof-of-concept 
studies [159].  
Even though a correlation between pupillary light reflex parameters and the clinical 
effect of antidepressant drugs has not been established yet, pupillography has the 
potential of generating biomarkers that are useful in the clinical development of this 
kind of drugs. In this thesis it was shown, that light reflex parameters changed in a 
concentration-dependent manner, and parameters describing venlafaxine’s 
pharmacological potency (SE) were derived from PK/PD models. Given this, a company 
investigating on norepinephrine reuptake inhibitors could conduct a small crossover 
study in healthy subjects where different doses of the candidate drug(s), placebo and the 
marketed competitor are administered. The results would indicate the most potent 
candidate, permit early comparison with the competitor, and facilitate dose selection for 
the phase II studies. All this is extremely valuable information, obtained from only one, 
relatively inexpensive study in a short period of time. 
If pupillographic response could ultimately be related to clinical response, this 
biomarker may also be used for dose adjustments early in the course of the treatment. 
For instance, a pupillographic assessment could be scheduled a few days after treatment 
initiation and a dose adjustment would be made according to the results, instead of 
waiting several weeks until changes of clinical symptoms are observed. 
The data used in this thesis originated from small studies in healthy volunteers, 
excluding the possibility to establish a relationship between biomarker response and 
clinical outcome. The models developed in here may, however, serve as a starting point 
for further investigations in patients where establishing such a relationship is an 
objective. One such starting point is the planning of sampling times at which biomarker 
observations should ideally be scheduled in a clinical study. PK/PD models can be used 
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for this task as it was illustrated in the venlafaxine project. Informative sampling times 
are a prerequisite for a meaningful analysis of biomarker data. Furthermore, simulations 
can be used to assess how a different formulation (e.g., extended release) would 
influence the PD response. 
In the sunitinib project simulations suggested that the circulating biomarkers behave 
differently in healthy subjects and patients and that the biomarker response may also 
depend on the tumor entity. It would be interesting to conduct a population PK/PD 
meta-analysis on biomarker data from studies in patients with different tumor entities. 
The present models would provide the basis with “tumor type” being investigated as a 
covariate on, for example, the intrinsic activity parameters αVEGF-A or αsVEGFR-2. In 
patients, biomarker response may not be constant over weeks and months of treatment. 
Indeed, in a study with continuous daily sunitinib administration, VEGF-A levels kept 
increasing over 4 months of treatment without reaching a plateau [81]. This, however, 
could be easily incorporated in a model and might reflect disease progression. With 
biomarker data from large patient populations the influence of additional patient 
specific covariates on biomarker response, such as age, sex, disease state, tumor size, 
concurrent medication, previous treatment etc., could be explored, thus gaining more 
insight into the complexities of the disease and the biomarker response itself. In the end, 
this may help to earlier identify patients not responding to the drug and would give 
some guidance how treatment should be continued (e.g., dose increase, switch to 
another drug of the same class, change drug class, etc.).  
The predictive value of circulating biomarkers with respect to the outcome of an 
antiangiogenic therapy is still a matter of debate [160,161]. Evidence for blood pressure 
as a predictor of clinical response, however, is much stronger [79,158,160,162,163]. In 
this thesis simulations were performed combining the developed blood pressure model 
with a published survival model and a model accounting for the risk of severe fatigue. 
The results suggested that individualizing the dose of sunitinib based on blood pressure 
measurements has the potential to prolong survival by 7 months. The real value of this 
kind of dose individualization has to be confirmed prospectively, like it is currently 
done for axitinib [70], before it can be routinely applied in clinical practice. However, it 
was exemplified how modeling and simulation could be used for the planning of such a 
prospective clinical trial. 
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In summary, biomarkers are of great utility for the development of new drugs and the 
optimization of drug treatment. They can be used to support the selection of the most 
effective (and least toxic) candidate compound, are helpful in finding the most 
appropriate dose or dosing schedule, and may support regulatory approval. This will 
make the development process more efficient and important new drugs will be available 
earlier. 
In clinical practice biomarkers offer the possibility to adjust treatment modalities based 
on the patients’ individual biomarker response, providing the physician with a potent 
tool to improve drug treatment 
PK/PD modeling and simulation will play a central role in biomarker research, 
establishing the link between dose and biomarker response. This will help us to 
understand the complexities of a pharmacological response in a quantitative way.  
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7 Summary 
 
In this thesis the concept of pharmacokinetic/pharmacodynamic modeling using 
biomarkers for the description of concentration-effect relationships was illustrated on 
the example of two projects with drugs from different therapeutic areas.  
As first example venlafaxine, an antidepressant selectively inhibiting serotonin and 
norepinephrine reuptake from the synaptic gap, was investigated. The inhibition of 
norepinephrine uptake is assumed to enhance antidepressant efficacy when venlafaxine 
is given at higher therapeutic doses. Therefore the investigation of the concentration-
response relationship of noradrenergic effects is of clinical interest. A useful test system 
to measure noradrenergic response is pupillography since the pupillary light reflex is 
controlled, in part, by the sympathetic nervous system. In a randomized-controlled 
crossover trial, 12 healthy volunteers received placebo or up to 75 mg venlafaxine twice 
daily for 14 days. On day 14 blood samples were drawn to determine serum 
concentrations of venlafaxine and its major active metabolite O-desmethylvenlafaxine. 
Together with data from serial pupillographic measurements in these volunteers, a 
pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the time 
course of the noradrenergic response.  
The PK part of the model was simultaneously fit to venlafaxine and 
O-desmethylvenlafaxine concentration-time data, yielding precise parameter estimates 
that are similar to published results. A rapid development of tolerance of the pupillary 
light reflex parameters, amplitude and 33% recovery time, was seen, most probably due 
to desensitization of β-adrenoceptors. This was successfully accounted for in the PD 
part of the model. The half-life of development and regression of tolerance was 
estimated to be 30 min for the amplitude and 40 min for the 33% recovery time. 
As examples of possible applications of the model, optimal pupillographic sampling 
times for a hypothetical single-dose study were calculated based on the modeling results. 
Using simulations it was investigated how an oral formulation with a slower drug 
release (extended release) would influence the PD response-time profile. 
In the second project sunitinib, a multitargeted tyrosine kinase inhibitor with 
antiangiogenic properties, was investigated. The effects on blood pressure, plasma 
concentrations of vascular endothelial growth factor A and C (VEGF-A and -C) and its 
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soluble receptor-2 (sVEGFR-2) in response to administration of 50 mg sunitinib on 3 to 
5 consecutive days were studied in 12 healthy volunteers. PK/PD models were 
developed to quantify changes of these biomarkers in relation to plasma concentrations 
of sunitinib and its active metabolite. 
Increasing blood pressure and VEGF-A levels were observed shortly after the first dose 
while a decrease in sVEGFR-2 occurred with substantial delay. No concentration-
dependent changes of VEGF-C levels were observed in this study. The models 
predicted a percent change (relative to baseline) in systolic and diastolic blood pressure, 
VEGF-A, and sVEGFR-2 levels, of 10%, 18%, 124%, and -24% respectively, for a 
typical subject after 4 weeks of sunitinib treatment with 50 mg/day. Simulated blood 
pressure-time courses excellently compared to published patient data, whereas changes 
in circulating biomarkers were greater in patients than simulations suggested for healthy 
subjects. With the model for blood pressure changes, and published models for survival 
and incidence of fatigue, clinical trials were simulated showing that blood pressure-
guided dose individualization could potentially prolong the median survival time by 210 
days, compared to the standard dosing regimen. 
The approach of PK/PD modeling and simulation using biomarkers was successfully 
applied in both projects and more insight into the concentration-response relationship of 
venlafaxine and sunitinib was obtained. Biomarkers will play an increasingly important 
role in drug development and pharmacotherapy. They will guide important decisions 
regarding candidate selection, dose finding and regulatory approval and will improve 
our understanding of complex diseases like cancer and mental disorders. Modeling and 
simulation are extremely useful tools to fully exploit the potential of biomarkers in this 
context. 
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9 Appendix 
9.1 Venlafaxine Study 
9.1.1 Tables 
Table 9-1 Model building summary - Important steps of the venlafaxine PK model 
development 
Model 
number Model description Random effects  
Number of 
parameters 
(fixed/random) 
OFV 
1 1 compartment VEN, 
1 compartment ODV, 
first-order absorption 
IIV(CLint,VEN) 
IIV(CLODV) 
IIV(ka) 
6/7 2990.1 
2 2 compartment VEN, 
1 compartment ODV, 
first-order absorption 
Like model #1 8/7 2984.1 
3 Structural model #1 
+ lag time 
Like model #2 7/7 2973.8 
4 1 compartment VEN, 
1 compartment ODV, 
zero-order absorption 
IIV(CLint,VEN) 
IIV(CLODV) 
IIV(k0) 
6/7 2961.4 
5 Structural model #4 
+ lag time 
Like model #3 7/7 2953.5 
6 Structural model #1 
2 transit compartments  
of absorption 
IIV(CLint,VEN) 
IIV(CLODV) 
IIV(MAT) 
6/7 2965.8 
7 Structural model #1 
3 transit compartments  
of absorption 
Like model #6 6/7 2957.8 
8 Structural model #1 
4 transit compartments  
of absorption 
Like model #6 6/7 2957.5 
9 Structural model #7 Like model #6 + 
IIV(fm) 
6/8 2913.0 
10 Structural model #7 
 
Like model #6 + 
IIV(fm)IIV(VVEN) 
6/9 2912.8 
11 Structural model #7 
(Final model) 
Like model #9 6/7 2916.5 
12 Structural model #7 
+ nonhepatic clearance 
Like model #9 7/7 2916.6 
13 Structural model #5 IIV(CLint,VEN) 
IIV(CLODV) 
IIV(fm),IIV(k0) 
7/7 2914.1 
OFV: objective function value; IIV: interindividual variability; VEN: venlafaxine; ODV: 
O-desmethylvenlafaxine; CLint,VEN: intrinsic clearance of venlafaxine; CLODV: clearance of 
O-desmethylvenlafaxine; ka: first-order absorption rate constant; k0: zero-order 
absorption rate; VVEN: volume of distribution of venlafaxine’s central compartment; fm: 
fraction of venlafaxine metabolized to O-desmethylvenlafaxine. 
placeholder 
placeholder 
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Table 9-2 Model building summary - Important steps of the amplitude model development 
Model 
number Model description 
Random 
effects  
Number of 
parameters 
(fixed/random) 
OFV 
1 Null model 
(only BL is estimated) 
IIV(BL)  
proportional 
residual error 
1/2 -76.8 
2 Structural model #1 IIV(BL)  
additive 
residual error 
1/2 -76.7 
3 Structural model #1 IIV(BL)  
additive + 
proportional 
residual error 
1/3 -76.9 
4 CA~E 
linear relationship 
Like model #1 2/2 -86.7 
5 CA~E 
log-linear relationship 
Like model #1 2/2 -85.7 
6 Emax model Like model #1 3/2 -87.5 
7 Sigmoid Emax model Like model #1 4/2 -87.5 
8 Indirect response model (inhibition of 
kin) 
Like model #1 3/2 -87.5 
9 Indirect response model 
(stimulation of kout) 
Like model #1 3/2 -87.5 
10 Tolerance compartment model 
(Porchet et al. [116]) 
50
M
AE
MAtol
M
TC
C1
CSBLE
)CC(k
dt
dC



 
Like model #1 4/2 -94.1 
11 Indirect counter-regulation (Bauer et 
al. [114]) 
TCSBLE
TkMk
dt
dT
MkCSk
dt
dM
AE
T,out2
2AE1



 
Like model #1 5/2 -101.6 
12* Negative feedback model (Mandema 
et al. [113]) 
TBLCS
dt
dE
)TE(kG
dt
dT
AE
tol


 
 
Like model #1 4/2 -105.8 
continued on next page 
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Table 9-2 continued 
 
Model 
number Model description 
Random 
effects  
Number of 
parameters 
(fixed/random) 
OFV 
13 Precursor pool model (Movin-
Osswald et al. [112])  
Ek
CS1
1Pk
dt
dE
CS1
1Pkk
dt
dP
out
AE
in
AE
in0

  
Like model #1 4/2 -86.5 
14** Receptor inactivation model 
(Kenakin[111]) 
IRFRAR
AREBLE
IRkARkCFRk
dt
dFR
IRkARk
dt
dIR
AR)kk(CFRk
dt
dAR
max
4offAon
43
3offAon




 
Like model #1 6/2 - 
15 Modified Porchet model  
MTAE
MAtol
M
CSCSBLE
)CC(k
dt
dC

  
(Final model) 
Like model #1 4/2 -101.7 
16 Structural model #15 Like model #1 
+ IIV(SE) 
4/3 -102.8 
17 Structural model #15 Like model #1 
+ IIV(ST) 
4/3 -102.4 
18 Structural model #15 Like model #1 
+ IIV(ktol) 
4/3 -101.7 
OFV: objective function value; IIV: interindividual variability; BL: baseline value; kin: zero-order 
rate of production of response; kout: first-order rate constant of loss of response; CM: 
concentration of the mediator in the tolerance compartment; CA: concentration of the active 
moiety (R·CODV+CVEN); ktol: rate constant of development and disappearance of tolerance (i.e., 
tolerance delay); E: effect (i.e., amplitude); SE: slope of the effect model; TC50: concentration at 
half the maximal tolerance; M: mediator; k1,2: first-order rate constants describing the kinetics of 
the mediator; T: tolerance; kout,T: first-order rate constant of loss of tolerance; G: extent of 
tolerance development; k0: production rate of the pool; AR: activated receptors; FR: free 
receptors; IR; inactive receptors; kon: second-order receptor association rate constant; koff: first-
order receptor dissociation constant; k3,4: first-order rate constants of production and loss of 
inactive receptors; Emax: maximal effect. 
* Estimate of G close to 0, ktol unrealistically high. 
** Not converged.    
placeholder 
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Table 9-3 Model building summary - Important steps of the 33% recovery time model 
development 
Model 
number Model description 
Random 
effects  
Number of 
parameters 
(fixed/random) 
OFV 
1 Null model 
(only BL is estimated) 
IIV(BL)  
proportional 
residual error 
1/2 -76.8 
2 Structural model #1 IIV(BL)  
additive 
residual error 
1/2 -76.7 
3 Structural model #1 IIV(BL)  
additive + 
proportional 
residual error 
1/3 -206.5 
4 CA~E 
linear relationship 
Like model #1 2/2 -207.6 
5 CA~E 
log-linear relationship 
Like model #1 2/2 -207.6 
6 Emax model Like model #1 3/2 -224.4 
7 Sigmoid Emax model Like model #1 4/2 -220.1 
8 Indirect response model (inhibition of 
kin) 
Like model #1 3/2 -225.0 
9 Indirect response model 
(stimulation of kout) 
Like model #1 3/2 -225.1 
10 Tolerance compartment model 
(Porchet et al. [116]) 
50
M
AE
MAtol
M
TC
C1
CSBLE
)CC(k
dt
dC



 
Like model #1 4/2 -225.0 
11 Indirect counter-regulation (Bauer et 
al. [114]) 
TCSBLE
TkMk
dt
dT
MkCSk
dt
dM
AE
T,out2
2AE1



 
Like model #1 5/2 -225.0 
12* Negative feedback model (Mandema 
et al. [113]) 
TBLCS
dt
dE
)TE(kG
dt
dT
AE
tol


 
 
Like model #1 4/2 -228.5 
continued on next page 
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Table 9-3 continued 
 
Model 
number Model description 
Random 
effects  
Number of 
parameters 
(fixed/random) 
OFV 
13 Precursor pool model (Movin-
Osswald et al. [112])  
Ek
CS1
1Pk
dt
dE
CS1
1Pkk
dt
dP
out
AE
in
AE
in0

  
Like model #1 4/2 -221.8 
14** Receptor inactivation model 
(Kenakin[111]) 
IRFRAR
AREBLE
IRkARkCFRk
dt
dFR
IRkARk
dt
dIR
AR)kk(CFRk
dt
dAR
max
4offAon
43
3offAon




 
Like model #1  - 
15 Modified Porchet model  
MTAE
MAtol
M
CSCSBLE
)CC(k
dt
dC

  
(Final model) 
Like model #1 4/2 -235.9 
16 Structural model #15 Like model #1 
+ IIV(SE) 
4/3 -236.0 
17 Structural model #15 Like model #1 
+ IIV(ST) 
4/3 -236.2 
18 Structural model #15 Like model #1 
+ IIV(ktol) 
4/3 -233.9 
OFV: objective function value; IIV: interindividual variability; BL: baseline value; kin: zero-order 
rate of production of response; kout: first-order rate constant of loss of response; CM: 
concentration of the mediator in the tolerance compartment; CA: concentration of the active 
moiety (R·CODV+CVEN); ktol: rate constant of development and disappearance of tolerance (i.e., 
tolerance delay); E: effect (i.e., 33% recovery time); SE: slope of the effect model; TC50: 
concentration at half the maximal tolerance; M: mediator; k1,2: first-order rate constants 
describing the kinetics of the mediator; T: tolerance; kout,T: first-order rate constant of loss of 
tolerance; G: extent of tolerance development; k0: production rate of the pool; AR: activated 
receptors; FR: free receptors; IR; inactive receptors; kon: second-order receptor association rate 
constant; koff: first-order receptor dissociation constant; k3,4: first-order rate constants of 
production and loss of inactive receptors; Emax: maximal effect. 
* Very high relative standard errors for ktol and G (>180%). 
** Not converged.    
placeholder 
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9.1.2 Figures 
9.1.2.1 Goodness-of-fit Plots 
 
Figure 9-1 
 
Standard goodness-of-fit plots for the prediction of venlafaxine plasma 
concentrations. ε-shrinkage was 6.2%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-2 
 
Standard goodness-of-fit plots for the prediction of O-desmethylvenlafaxine 
plasma concentrations. ε-shrinkage was 4.2%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-3 
 
Standard goodness-of-fit plots for the prediction of the amplitude. ε-shrinkage was 
7.1%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-4 
 
Standard goodness-of-fit plots for the prediction of the 33% recovery time.  
ε-shrinkage was 8.8%. The grey line is a lowess smoother. 
placeholder 
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9.1.2.2 Sensitivity Analysis 
Placeholder 
Figure 9-5 
 
Sensitivity analysis of the liver plasma flow (QH). The graphs illustrate how 
different values of QH (0.32 to 0.95 L/h/kg) influence fixed-effect parameters 
(a), random-effects parameters (b) and the objective function (c) of the 
venlafaxine PK model. The vertical dotted line marks the fixed value of QH 
used in the final model. 
IIV: interindividual variability; VVEN: venlafaxine‘s volume of distribution; 
CLint,VEN: intrinsic clearance of venlafaxine; fm: fraction of venlafaxine 
metabolized to O-desmethylvenlafaxine; CLODV: clearance of O-
desmethylvenlafaxine; MAT: mean absorption time; σprop: proportional 
residual variability; σadd: additive residual variability. 
placeholder 
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Figure 9-6 
 
Sensitivity analysis of the volume of the liver compartment (VL). The graphs 
illustrate how different values of VL (0.5 to 1.5 L) influence fixed-effect parameters 
(a), random-effects parameters (b) and the objective function (c) of the 
venlafaxine PK model. The vertical dotted line marks the fixed value of VL used 
in the final model. Symbols see Figure 9-5. 
Placeholder 
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Figure 9-7 
 
Sensitivity analysis of the volume of distribution of O-desmethylvenlafaxine 
(VODV). The graphs illustrate how different values of VODV (105 to 315 L) 
influence fixed-effect parameters (a), random-effects parameters (b) and the 
objective function (c) of the venlafaxine PK model. The vertical dotted line 
marks the fixed value of VODV used in the final model. Symbols see Figure 9-5. 
 
Figure 9-8 
 
Sensitivity analysis of the relative potency (R) of O-desmethylvenlafaxine. The 
graphs illustrate how different values of R (0 to 1) influence fixed-effect and 
random-effects parameters (a) and the objective function (b) of the amplitude 
model. The vertical dotted line marks the fixed value of R used in the final 
model. 
IIV: interindividual variability; CV: coefficient of variation; BL: baseline value; 
SE: slope of the effect model; ST: slope of the tolerance model; ktol: rate 
constant of development and disappearance of tolerance (i.e., tolerance delay); 
σprop: proportional residual variability.   
placeholder 
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Figure 9-9 
 
Sensitivity analysis of the relative potency (R) of O-desmethylvenlafaxine. 
The graphs illustrate how different values of R (0 to 1) influence fixed-effect 
and random-effects parameters (a) and the objective function (b) of the 33% 
recovery time model. The vertical dotted line marks the fixed value of R 
used in the final model. Symbols see Figure 9-8. 
Placeholder 
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9.1.3 NONMEM Codes 
 
Code 9-1 NONMEM control stream for the venlafaxine pharmacokinetic model 
$PROBLEM Venlafaxine - PK model 
 
;------------------------- 
;  UNITS                 | 
;  TIME - HOURS          | 
;  DOSE - NMOL           | 
;  CP  - NMOL/L          | 
;  CLEARANCES - L/HOUR   | 
;  VOLUMES - L           | 
;  LOQ - 28 NMOL/L       | 
;------------------------- 
  
$INPUT ID TIME AMT ADDL II DV CMT EVID AGE HGT KG 
       ;ADDL=Additional doses, II=dosing interval (see NONMEM Users Guide) 
        
$DATA Data_input_file_PKven.csv 
 
$SUBROUTINE ADVAN5 
$MODEL       
NCOMP=6 
COMP(DEPOT1)   ;Transit compartment 1 
COMP(DEPOT2)   ;Transit compartment 2 
COMP(DEPOT3)   ;Transit compartment 3 
COMP(LIVER)    ;Liver compartment 
COMP(VEN)      ;Venlafaxine (VEN) compartment 
COMP(ODV)      ;O-desmethylvenlafaxine (ODV) compartment 
 
;INITIAL VALUES 
$THETA   
(0,200)      ; THVVEN    - Volume of distribution (Vd) of VEN 
(0,100)      ; THCLVEN   - Intrinsic clearance of VEN 
(0,0.7)      ; THFM      - Fraction metabolized to ODV 
(210 FIX)    ; THVODV    - Vd of ODV 
(0,18)       ; THCLODV   - Clearance of ODV 
(0,1)        ; THMAT     - Mean absorption time 
(0,30)       ; SD_VEN    - Additive residual error VEN 
(0,0.2)      ; CV_VEN    - Proportional residual error VEN 
(0,50)       ; SD_ODV    - Additive residual error ODV 
(0,0.1)      ; CV_ODV    - Proportional residual error ODV 
 
$OMEGA 0.1   ; ETACLVEN  - Interindividual variability (IIV) of CLVEN 
$OMEGA 0.1   ; ETAFM     - IIV of FM 
$OMEGA 0.1   ; ETAMAT    - IIV of MAT 
 
$SIGMA 1 FIX 
 
$PK 
 
;ERLANG ABSORPTION  
 MAT   = THETA(6)*EXP(ETA(6))       
 N     = 3                              ;Number of transit compartment 
 KTR   = N/MAT                          ;Transit rate constant 
 
;DISPOSITION AND METABOLISM 
 VL    = 1                              ;Liver volume 
 QL    = 0.63*KG                        ;Liver plasma flow 
  
 VVEN  = THVVEN        
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Code 9-1 continued  
 CLVE  = THCLVEN * EXP(ETACLVEN)      
TERM  =  EXP(LOG(THFM/(1-THFM))+ETAFM) ;Logit transformation            
 FM    =  TERM/(1+TERM)                   
 
 CLFM  = FM*CLVE                        ;Clearance of formation of ODV 
 CLO   = CLVE-CLM                       ;Clearance of formation of other metabolites 
 VODV  = THVODV      
 CLOD  = THCLODV*EXP(ETA(5))        
 
;Definition of volumes and rate constants of the ADVAN5 compartment system 
 K12   = KTR 
 K23   = KTR 
 K34   = KTR 
 K40   = CLO/VL 
 K46   = CLFM/VL 
 K60   = CLOD/VODV 
 K45   = QL/VL 
 K54   = QL/VVEN 
  
 S4    = VL      
 S5    = VVEN 
 S6    = VODV    
     
$ERROR  
;PREDICTIONS AND RESIDUAL ERROR 
IF (CMT.EQ.5) THEN               
 IPRE  = A(5)/VVEN                           ;Individual predicted VEN concentration    
 IRES  = DV - IPRE                           ;Individual residuals  
 W     = SQRT(SD_VEN**2+CV_VEN**2*IPRE**2)   ;Combined residual error VEN 
 Y     = IPRE+ERR(1)*W 
ELSE 
 IPRE  = A(6)/VODV                           ;Individual predicted ODV concentration   
 IRES  = DV - IPRE                           ;Individual residuals 
 W     = SQRT(SD_VEN**2+CV_VEN**2*IPRE**2)   ;Combined residual error ODV 
 Y     = IPRE+ERR(1)*W 
ENDIF 
 DEL            = 0 
 IF(W.EQ.0) DEL = 1                          ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)               ;Individual weighted residuals 
 
$ESTIMATION SIG=3 PRINT=1 METHOD=1 MAXEVAL=9999 NOABORT INTER MSFO=msfo.msf 
$COVARIANCE PRINT=E 
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Code 9-2 NONMEM control stream for the venlafaxine amplitude model 
$PROBLEM  Venlafaxine - Amplitude model 
 
;------------------------- 
;  UNITS                 | 
;  TIME - HOURS          | 
;  DOSE - NMOL           | 
;  CP  - NMOL/L          | 
;  CLEARANCES - L/HOUR   | 
;  VOLUMES - L           | 
;  AMP - MM              | 
;------------------------- 
 
$INPUT ID TIME AMT ADDL II DV AGE HGT KG  
       MATx VVENx CLVEx VODVx CLODVx FMx ;Individual parameters from the previous PK 
step 
       ;DV=Amplitude 
        
$DATA Data_input_file_AMP.csv 
 
$SUBROUTINE ADVAN5 
$MODEL       
NCOMP=6 
COMP(DEPOT1)   ;Transit compartment 1 
COMP(DEPOT2)   ;Transit compartment 2 
COMP(DEPOT3)   ;Transit compartment 3 
COMP(LIVER)    ;Liver compartment 
COMP(VEN)      ;Venlafaxine (VEN) compartment 
COMP(ODV)      ;O-desmethylvenlafaxine (ODV) compartment 
COMP(T1)       ;Tolerance compartment for VEN 
COMP(T2)       ;Tolerance compartment for ODV 
 
;INITIAL VALUES 
$THETA  
(0,1600)        ; THBL    - Baseline amplitude 
(0,1.86)        ; THSE    - Slope of effect model 
(0,1.52)        ; THST    - Slope of tolerance model 
(0,1.38)        ; THKT0L  - Tolerance delay 
(0.5 FIX)       ; THR     - Relative potency of ODV 
(0,0.1)         ; CV_AMP  - Proportional residual error 
 
$OMEGA 0.02     ; ETABL   - Interindividual variability in BL 
 
$SIGMA 1 FIX 
 
$PK  
;PD-PART 
 BL   = THBL/1000*EXP(ETABL)  ;Division by 1000 converts mm to µm in the results 
 SE   = THSE/1000 
 ST   = THST/1000 
 KT0L = THKTOL 
 R    = THR  
    
;PK-PART  
 MAT   = MATx      ;Description see PK model 
 N     = 3                               
 KTR   = N/MAT                          
 VL    = 1                              
 QL    = 0.63*KG                        
 VVEN  = VVENx                       
 CLVE  = CLVEx               
 FM    = FMx               
 CLFM  = FM*CLVE      
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Code 9-2 continued                    
 CLO   = CLVE-CLM                        
 VODV  = VODVx     
 CLOD  = CLODVx        
 
;Definition of volumes and rate constants of the ADVAN5 compartment system 
 K12   = KTR 
 K23   = KTR 
 K34   = KTR 
 K40   = CLO/VL 
 K46   = CLFM/VL 
 K60   = CLOD/VODV 
 K45   = QL/VL 
 K54   = QL/VVEN 
  
 S4    = VL      
 S5    = VVEN 
 S6    = VODV      
 S7    = V7 
 S8    = V8 
 
;TOLERANCE COMPARTMENTS 
 ;For technical reasons in ADVAN5 two tolerance compartments had to be used, one for 
each compound.  
 ;This is however equivalent to the differential equation shown in equation 3-2. 
  
 V7 = 0.0001 ;Negligible volume of the tolerance compartments  
 V8 = 0.0001  
  
 K67 = V7*KT0/VVEN     
 K76 = KT0L  
 K58 = V8*KT0/VODV      
 K85 = KT0L   
        
$ERROR 
;Plasma concentrations of VEN and ODV 
 CVEN = A(5)/VVEN       ; VEN concentration 
 CODV = A(6)/VODV       ; ODV concentration 
 CA   = CVEN+R*CODV     ; Active concentration 
    
;Concentration of the hypothetical tolerance mediator(CM) 
 CM1 = A(8)/V7          
 CM2 = A(7)/V8  
 CM  = CM1+R*CM2   
 
;Individual response and residual error     
 IPRE   = BL-SE*CA+ST*CM        ;Individual predicted amplitude 
   
 IRES   = DV - IPRED            ;Individual residuals 
 W      = CV_AMP*IPRED          ;Proportional residual error 
 Y      = IPRED+ERR(1)*W 
   
 DEL            = 0 
 IF(W.EQ.0) DEL = 1             ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)  ;Individual weighted residuals 
 
$ESTIMATION SIG=3 PRINT=1 METHOD=1 MAXEVAL=9999 NOABORT INTER 
$COVARIANCE 
placeholder  
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Code 9-3 NONMEM control stream for the venlafaxine 33% recovery time model 
 
$PROBLEM  Venlafaxine - 33% Recovery time model 
 
;------------------------- 
;  UNITS                 | 
;  TIME - HOURS          | 
;  DOSE - NMOL           | 
;  CP  - NMOL/L          | 
;  CLEARANCES - L/HOUR   | 
;  VOLUMES - L           | 
;  REC - SEC             | 
;------------------------- 
 
$INPUT ID TIME AMT ADDL II DV AGE HGT KG  
       MATx VVENx CLVEx VODVx CLODVx FMx ;Individual parameters from the previous PK 
step 
       ;DV=33% Recovery time 
        
$DATA Data_input_file_REC.csv 
 
$SUBROUTINE ADVAN5 
$MODEL       
NCOMP=6 
COMP(DEPOT1)   ;Transit compartment 1 
COMP(DEPOT2)   ;Transit compartment 2 
COMP(DEPOT3)   ;Transit compartment 3 
COMP(LIVER)    ;Liver compartment 
COMP(VEN)      ;Venlafaxine (VEN) compartment 
COMP(ODV)      ;O-desmethylvenlafaxine (ODV) compartment 
COMP(T1)       ;Tolerance compartment for VEN 
COMP(T2)       ;Tolerance compartment for ODV 
 
;INITIAL VALUES 
$THETA  
(0,1400)        ; THBL    - Baseline 33% recovery time 
(0,1.86)        ; THSE    - Slope of effect model 
(0,1.52)        ; THST    - Slope of tolerance model 
(0,1.38)        ; THKT0L  - Tolerance delay 
(0.5 FIX)       ; THR     - Relative potency of ODV 
(0,0.1)         ; CV_REC  - Proportional residual error 
 
$OMEGA 0.02     ; ETABL   - Interindividual variability in BL 
 
$SIGMA 1 FIX 
 
$PK  
;PD-PART 
 BL   = THBL/1000*EXP(ETABL)  ;Division by 1000 converts sec to msec in the results 
 SE   = THSE/1000 
 ST   = THST/1000 
 KT0L = THKTOL 
 R    = THR  
    
;PK-PART  
 MAT   = MATx      ;Description see PK model 
 N     = 3                               
 KTR   = N/MAT                          
 VL    = 1                              
 QL    = 0.63*KG                        
 VVEN  = VVENx                       
 CLVE  = CLVEx               
 FM    = FMx        
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Code 9-3 continued        
 CLFM  = FM*CLVE                         
 CLO   = CLVE-CLM                        
 VODV  = VODVx     
 CLOD  = CLODVx        
 
;Definition of volumes and rate constants of the ADVAN5 compartment system 
 K12   = KTR 
 K23   = KTR 
 K34   = KTR 
 K40   = CLO/VL 
 K46   = CLFM/VL 
 K60   = CLOD/VODV 
 K45   = QL/VL 
 K54   = QL/VVEN 
  
 S4    = VL      
 S5    = VVEN 
 S6    = VODV      
 S7    = V7 
 S8    = V8 
 
;TOLERANCE COMPARTMENTS 
 ;For technical reasons in ADVAN5 two tolerance compartments had to be used, one for 
each compound.  
 ;This is however equivalent to the differential equation shown in equation 3-2. 
  
 V7 = 0.0001 ;Negligible volume of the tolerance compartments  
 V8 = 0.0001  
  
 K67 = V7*KT0/VVEN     
 K76 = KT0L  
 K58 = V8*KT0/VODV      
 K85 = KT0L   
        
$ERROR 
;Plasma concentrations of VEN and ODV 
 CVEN = A(5)/VVEN       ; VEN concentration 
 CODV = A(6)/VODV       ; ODV concentration 
 CA   = CVEN+R*CODV     ; Active concentration 
    
;Concentration of the hypothetical tolerance mediator(CM) 
 CM1 = A(8)/V7          
 CM2 = A(7)/V8  
 CM  = CM1+R*CM2   
 
;Individual response and residual error     
 IPRE   = BL-SE*CA+ST*CM        ;Individual predicted 33% recovery time 
   
 IRES   = DV - IPRED            ;Individual residuals 
 W      = CV_REC*IPRED          ;Proportional residual error 
 Y      = IPRED+ERR(1)*W 
   
 DEL            = 0 
 IF(W.EQ.0) DEL = 1             ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)  ;Individual weighted residuals 
 
$ESTIMATION SIG=3 PRINT=1 METHOD=1 MAXEVAL=9999 NOABORT INTER 
$COVARIANCE 
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9.2 Sunitinib Study 
9.2.1 Tables 
Table 9-4 Model building summary - Important steps of the sunitinib PK model 
development 
Model 
number Model description Random effects  
Number of 
parameters 
(fixed/random) 
OFV 
1 1 compartment Sunitinib  
1 compartment SU12662 
Transit absorption  
IIV(ka) 
IIV(CL/Fsunitinib) 
IIV(CL/fa,SU12662) 
additive+ prop. 
residual error 
8/7 2948.4 
2 2 compartments Sunitinib  
1 compartment SU12662 
Transit absorption 
Like model #1 
 
10/7 2478.5 
3 2 compartments Sunitinib  
2 compartments SU12662 
Transit absorption 
Like model #1 
 
12/7 2686.6 
4 Structural model #2 Like model #1 + 
IIV(V1/Fsunitinib)  
10/8 2439.8 
5 Structural model #2 Like model #4 + 
IIV(V1/fa,SU12662) 
10/9 1821.0 
6 Structural model #2 Like model #5 + 
IIV(V2/Fsunitinib)  
10/10 1820.9 
7 Structural model #2 Like model #5 + 
IIV(Q/Fsunitinib)  
10/10 1821.0 
8 Structural model #2 Like model #5 + 
IIV(N) 
10/10 1764.7 
9 Structural model #2 Like model #5 + 
IIV(MTT) 
10/11 1721.9 
10 Structural model #2 Like model #9 + 
IOV(MTT) 
10/12 1635.5 
11 Structural model #2 Like model #10 + 
OMEGA BLOCKa 
10/18 1545.2 
12 Structural model #2 Like model #11 
without 
IOV(MTT) 
10/17 1618.7 
13 Structural model #2 
(Final Model) 
Like model #11 
without IIV(MTT) 
10/17 1545.2 
14 Structural model #2 
 
Like model #13 + 
IIV(RPS) 
10/18 1541.2 
15 1 compartment Sunitinib  
1 compartment SU12662 
Transit absorption 
Like model #13 8/17 1659.6 
16 2 compartments Sunitinib  
1 compartment SU12662 
First-order absorption 
Like model #7 + 
OMEGA BLOCKa 
8/15 2109.3 
a   Covariance of volume and clearance parameters was estimated. 
OFV: objective function value; IIV: interindividual variability; IOV: Interoccasion 
variability; RPS: ratio of presystemic to systemic metabolite formation; MTT: mean 
transit time; N: number of transit compartments; ka: absorption rate constant; CL: 
clearance; V1: volume of distribution of the central compartment; Q: intercompartmental 
clearance; V2: volume of distribution of the peripheral compartment; F: bioavailability 
(fa•[1-fm,pre]); fa: fraction of absorbed dose. 
  
     
133Appendix 
Table 9-5 Model building summary - Important steps of the sunitinib blood pressure 
model development 
Model 
number Model description Random effects  
Number of 
parameters 
(fixed/random) 
OFV 
Day 0 dataset    
1 Null model  
(only BL is estimated 
IIV(BLsystolic) 
IIV(BLdiastolic) 
2/4 877.3 
2 Structural model #1 Like model #1 
COV(BLsystolic,BLdiastolic) 
2/5 867.9 
3 1 cosine term  
(AMP1, PS1) 
Like model #2 4/5 863.0 
4 2 cosine terms,  
(AMP1, AMP2, PS1) 
Like model #2 5/5 860.7 
5 2 cosine terms,  
(AMP1, AMP2, PS1, PS2) 
Like model #2 6/5 854.7 
6* Structural model #5 with 
separate cosine terms for 
systolic and diastolic BP 
Like model #2 8/5 - 
7 Structural model #4 with 
separate cosine terms for 
systolic and diastolic BP 
Like model #2 10/5 852.5 
8 Structural model #5 
 
Like model #2 + 
IIV(AMP1) 
6/6 850.6 
9 Structural model #5 
 
Like model #2 + 
IIV(AMP1), IIV(AMP2) 
6/7 846.2 
Full dataset    
10 INH~BM  
linear relationship 
IIV(BLsystolic) 
IIV(BLdiastolic) 
COV(BLsystolic,BLdiastolic) 
IIV(αsystolic), IIV(αdiastolic) 
4/5 4623.9 
11 Structural model #10 
+ baseline model #9 
Like model #10 +  
IIV(AMP1), IIV(AMP2) 
8/7 4576.1 
12 Structural model #11 Like model #10 + 
COV(αsystolic,αdiastolic) 
8/8 4548.3 
13 INH~BM 
power function 
Like model #12 9/10 4546.7 
14 INH~BM 
hyperbolic relationship 
Like model #12 9/10 4552.9 
15 Structural model #11 
+slow signal transduction 
Like model #12 9/10 4534.9 
16* Structural model #11 Like model #12 + IIV(τ) 9/11 - 
17 Structural model #11 
without PS1, Rsl fixed to 1 
(Final model) 
Like model #12 8/10 4535.9 
OFV: objective function value; IIV: interindividual variability; BL: baseline value; BP: blood 
pressure; AMP1,2: amplitude of the first or second cosine term; PS1,2: phase shift of the first 
or second cosine term; α: intrinsic efficacy parameter; τ: transduction time; 
COV: covariance; Rsl:relative contribution of the slow signal transduction. 
* Not converged. 
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Table 9-6 Model building summary - Important steps of the sunitinib VEGF-A model 
development 
Model 
number Model description Random effects  
Number of 
parameters 
(fixed/random) 
OFV 
Day 0 dataset    
1 Null model  
(only BL is estimated) 
IIV(BL) 
proportional 
residual error  
1/2 581.6 
2 1 cosine term  
(AMP1, PS1)  
Like model #1 3/2 576.8 
3 2 cosine terms,  
(AMP1, AMP2, PS1) 
Like model #1 4/2 576.6 
4 2 cosine terms,  
(AMP1, AMP2, PS1, PS2) 
Like model #1 5/2 574.8 
Full dataset    
5 INH~BM  
linear relationship  
IIV (BL) 
IIV(α) 
2/3 3120.7 
6 INH~BM 
hyperbolic relationship 
Like model #5 3/3 3148.6 
7 INH~BM 
power function 
Like model #5 3/3 3028.3 
8 Structural model #7 
+ signal transduction 
Like model #5 4/3 3016.7 
9 Structural model #8 Like model #5 + 
IIV(τ) 
4/4 2941.2 
10 Structural model #8 Like model #9 + 
IIV(γ) 
4/5 2941.2 
11 Structural model #8 
+ study part as covariate 
(Final model) 
Like model #9 5/4 2937.3 
12 Structural model #11 
γ fixed to 1 
Like model #9 4/4 3022.9 
13 Structural model #11 Like model #9 
without IIV(τ) 
5/3 3010.5 
14 Structural model #11 
without signal 
transduction 
Like model #5 4/3 3022.5 
OFV: objective function value; IIV: interindividual variability; BL: baseline value; 
AMP1,2: amplitude of the first or second cosine term; PS1,2: phase shift of the first or 
second cosine term; INH: fractional tyrosine kinase inhibition; BM: biomarker; α: intrinsic 
activity parameter; τ: transduction time; γ: shape parameter of the power function. 
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Table 9-7 Model building summary - Important steps of the sunitinib sVEGFR-2 
model development 
Model 
number Model description Random effects  
Number of 
parameters 
(fixed/random) 
OFV 
Day 0 dataset    
1 Null model  
(only BL is estimated) 
IIV(BL) 
proportional 
residual error  
1/2 1167.5 
2 1 cosine term  
(AMP1, PS1)  
Like model #1 3/2 1152.8 
3 2 cosine terms,  
(AMP1, AMP2, PS1) 
Like model #1 4/2 1152.6 
4 2 cosine terms,  
(AMP1, AMP2, PS1, PS2) 
Like model #1 5/2 1152.1 
5 Structural model #2 Like model #1 + 
IIV(AMP1) 
3/3 1151.9 
Full dataset    
6 INH~BM  
inverse linear relationship 
IIV(BL) 
IIV(α) 
3/3 5691.8 
7 Structural model #6 
+ baseline model #2 
Like model #6 5/3 5688.7 
8 INH~BM  
inverse hyperbolic 
relationship 
Like model #6 4/3 5699.2 
9* INH~BM  
inverse power function 
Like model #6 4/3 5662.2 
10 Structural model #6 
(Final model) 
Like model #6 + 
IIV(kout) 
3/4 5684.2 
11 Structural model #6 
+ study part as covariate 
Like model #10 4/4 5682.9 
OFV: objective function value; IIV: interindividual variability; BL: baseline value; 
AMP1,2: amplitude of the first or second cosine term; PS1,2: phase shift of the first or 
second cosine term; INH: fractional tyrosine kinase inhibition; BM: biomarker; α: intrinsic 
activity parameter; kout: rate of loss of VEGFR-2 response. 
* Model overparameterized; large relative standard error of α (>400%); high correlation 
between fixed effect parameters. 
placeholder 
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9.2.2 Figures 
9.2.2.1 Goodness-of-fit Plots 
placeholder 
Figure 9-10 
 
Standard goodness-of-fit plots for the prediction of sunitinib plasma 
concentrations. ε-shrinkage was 7.7%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-11 
 
Standard goodness-of-fit plots for the prediction of SU12662 plasma 
concentrations. ε-shrinkage was 3.0%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-12 
 
Standard goodness-of-fit plots for the prediction of systolic blood pressure. 
ε-shrinkage was 2.8%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-13 
 
Standard goodness-of-fit plots for the prediction of diastolic blood pressure.  
ε-shrinkage was 2.0%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-14 
 
Standard goodness-of-fit plots for the prediction of VEGF-A plasma 
concentrations. ε-shrinkage was 3.1%. The grey line is a lowess smoother. 
placeholder 
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Figure 9-15 
 
Standard goodness-of-fit plots for the prediction of sVEGFR-2 plasma 
concentrations. ε-shrinkage was 3.2%. The grey line is a lowess smoother. 
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9.2.2.2 Sensitivity Analysis 
placeholder 
Figure 9-16 
 
Sensitivity analysis of the fraction metabolized to SU12662 (fm). The graphs 
illustrate how different values of fm (0.1 to 0.9) influence fixed-effect (a), random-
effects parameters (b) and the objective function (c) of the sunitinib PK model. 
The vertical dotted line marks the fixed value of fm used in the final model.  
IIV: interindividual variability; RPS: ratio of presystemic to systemic metabolite 
formation; MTT: mean transit time; N: number of transit compartments; ka: 
absorption rate constant; CL: clearance; V1: volume of distribution of the central 
compartment; Q: intercompartmental clearance; V2: volume of distribution of the 
peripheral compartment; F: bioavailability (fa•[1-fm,pre]); fa: fraction of absorbed 
dose; ρ: correlation coefficient; σadd: additive residual variability; σprop: 
proportional residual variability. 
placeholder 
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Figure 9-17 
 
Sensitivity analysis of the relative contribution of the slow, transduced signal to 
the effect (Rsl). The graphs illustrate how different values of Rsl (0 to 1) influence 
fixed-effect (a), random-effects parameters (b) and the objective function (c) of 
the sunitinib blood pressure model. The vertical dotted line marks the fixed 
value of Rsl used in the final model. Note: Runs with Rsl set to 0.1 and 0.2 did not 
converge. 
IIV: interindividual variability; BL(24)systolic,diastolic: average systolic or diastolic 
blood pressure over 24 hours; BL: baseline value; AMP1,2: amplitude of the first 
or second cosine term; PS2: phase shift of the second cosine term; α: intrinsic 
activity parameter; τ: transduction time; ρ: correlation coefficient; σadd: additive 
residual variability. 
placeholder 
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Figure 9-18 
 
Sensitivity analysis of the dissociation constant (Kd). The graphs illustrate how 
different values of Kd (4 to 10) influence fixed-effect (a), random-effects 
parameters (b) and the objective function (c) of the sunitinib blood pressure 
model. Note: Runs with Kd fixed to values <4 did not converge. Symbols see 
Figure 9-17. 
Placeholder 
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Figure 9-19 
 
Sensitivity analysis of the dissociation constant (Kd). The graphs illustrate how 
different values of Kd (1 to 10) influence fixed-effect (a), random-effects 
parameters (b) and the objective function (c) of the sunitinib VEGF-A model. 
The vertical dotted line marks the fixed value of Kd used in the final model. 
IIV: interindividual variability; BL: baseline value; θPART1: baseline adjustment 
for subjects from the first part of the study; γ: shape parameter; α: intrinsic 
activity parameter; τ: transduction time; σprop: proportional residual variability. 
placeholder 
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Figure 9-20 
 
Sensitivity analysis of the dissociation constant (Kd). The graphs illustrate how 
different values of Kd (1 to 10) influence fixed-effect (a), random-effects 
parameters (b) and the objective function (c) of the sunitinib sVEGFR-2 model. 
The vertical dotted line marks the fixed value of Kd used in the final model. 
IIV: interindividual variability; BL: baseline value; α: intrinsic activity parameter; 
kout: rate of loss of biomarker response; σprop: proportional residual variability. 
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9.2.3 NONMEM and R Codes 
Code 9-4 NONMEM control stream for the sunitinib pharmacokinetic model 
$PROBLEM Sunitinib - Pharmacokinetic model 
 
;----------------------------------------- 
;  UNITS                                  | 
;  TIME - HOURS                           | 
;  DOSE - UG                              | 
;  CP  - NG/ML  -> UG/L                   | 
;  LLOQ - 0.06 NG/ML                      | 
;  CL - L/HOUR                            | 
;  VOLUMES - L                            | 
;------------------------------------------ 
 
$INPUT ID TIME AMT DV EVID D1M2 BQL CMT OCC PART AGE BW HGT SEX 
       ;DV = sunitinib or SU12662 plasma concentrations 
          
$DATA Data_input_file_PKsun.csv 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL  
NCOMP=4 
COMP=(DEPOTD,DEFDOSE)  ;Dosing compartment 
COMP=(CENTRAL)         ;Sunitinib central compartment 
COMP=(PERIPH)          ;Sunitinib peripheral compartment 
COMP=(MET)             ;SU12662 central compartment 
 
;INITIAL VALUES 
$THETA 
(0,30)         ; THCL   - Clearance/F of sunitinib 
(0,1500)       ; THV1   - Central volume of distribution (Vd)/F of sunitinb 
(0,200)        ; THV2   - Peripheral Vd/F 
(0,2.5)        ; THQ    - Intercompartmental clearance/F of sunitinib 
(0.1,0.5)      ; THKA   - Absorption rate constant 
(0.001,1.3)    ; THMTT  - Mean transit time  
(0,1.3,5)      ; THN    - Number of transit compartments 
(0,2.0)        ; THRPS  - Ratio of presystemic to systemic metabolism 
(0.21 FIX)     ; THFM   - Fraction metabolized to SU12662 
(1 FIX)        ; THFABS - Fraction of dose absorbed 
(0,14)         ; THCLM  - Clearance/FABS of SU12662 
(0,1410)       ; THVM1  - Vd/FABS of SU12662 
(0,0.06)       ; SD_PAR - Additive residual error sunitinib 
(0,0.10)       ; CV_PAR - Proportional residual error sunitinib 
(0,0.06)       ; SD_MET - Additive residual error SU12662 
(0,0.10)       ; CV_MET - Proportional residual error SU12662 
 
$OMEGA BLOCK(4)  
0.074                  ; ETACL  - Interindividual variability (IIV) of CL 
0.0793 0.109           ; ETAV1  - IIV of V1 
0.02 0.02 0.168        ; ETACLM - IIV of CLM 
0.02 0.02 0.0185 0.205 ; ETAVM1 - IIV of VM1 (Covariances are the off-diagonal elements) 
 
$OMEGA 0.1             ; ETAN    - IIV of N 
$OMEGA 0.05            ; ETAKA   - IIV of KA 
$OMEGA  BLOCK(1) 0.95  ; KPMTT1  - Interoccasion variability in MTT 
$OMEGA  BLOCK(1) SAME  ; KPMTT2 
$OMEGA  BLOCK(1) SAME  ; KPMTT3 
$OMEGA  BLOCK(1) SAME  ; KPMTT4 
$OMEGA  BLOCK(1) SAME  ; KPMTT5 
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Code 9-4 continued 
$SIGMA 1 FIX 
 
$PK 
 
;Increase maximum number of integrations of the differential equations 
"FIRST 
" COMMON /PRCOMG/ IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" IMAX=99000000 
              
 FM    =  THFM    
 RPS   =  THRPS 
  
 ;The following function is needed for the calculation of FPRE and FSYSS  
 ;under the condition that FM=FPRE+(1-FPRE)*FSYSS and RPS=FPRE/FSYSS and FM,FSYS,FPRE<1 
  
 SQ   =  SQRT(1+2*RPS+RPS**2-4*RPS*FM)  
 FPRE =  0.5+0.5*RPS-0.5*SQ  
 FSYS =  FPRE/RPS             
 
 FABS = THFABS 
 FD   = (1-FPRE)*FABS       ;Bioavailability of sunitinib (FD=F) 
 
 KA   = THKA*EXP(ETAKA) 
 CL   = FD*THCL*EXP(ETACL) 
 V1   = FD*THV1*EXP(ETAV1) 
 V2   = FD*THV2 
 Q    = FD*THQ 
 CLM  = THCLM*EXP(ETACLM) 
 VM1  = THVM1*EXP(ETAVM1) 
   
;INTEROCASSION VARIABILITY IN MTT 
OCC1=0 
OCC2=0 
OCC3=0 
OCC4=0 
OCC5=0 
IF(OCC.EQ.1) OCC1=1 
IF(OCC.EQ.2) OCC2=1 
IF(OCC.EQ.3) OCC3=1 
IF(OCC.EQ.4) OCC4=1 
IF(OCC.EQ.5) OCC5=1 
 
IOV=OCC1*KPMTT1+OCC2*KPMTT2+OCC3*KPMTT3+OCC4*KPMTT4+OCC5*KPMTT5 
MTT=THMTT*EXP(IOV)    
   
 N  = THN*EXP(ETAN)          
 KTR=(N+1)/MTT              ;Transit rate constant 
  
 S2=V1 
 S3=V2  
 S4=VM1 
 
;SETTING UP THE DOSE  
IF(NEWIND.NE.2) THEN  
 TDOS=0                ;For every new individual the time of the first dose is set to 0 
 DOSE=0                ;Reset dose 
ENDIF                 
 
;TIME AFTER DOSE 
IF(AMT.GT.0) THEN      ;If a dosing event is found in the data file 
 TDOS=TIME             ;time of dosing and the dose are set accordingly 
 DOSE=AMT*FABS       
ENDIF 
 TAD=TIME-TDOS         ;Time after dose 
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Code 9-4 continued 
 
;DELETE NONMEMS DOSE RECORD 
 F1=0                 ;This necessary for the transit model to work 
  
;STERLING APPROXIMATION OF (LOG) FACULTY N (see Savic et al. 2007) 
 L=LOG(2.5066)+(N+0.5)*LOG(N)-N 
  
$DES 
 X=0.00001  ;To avoid LOG(0) when DOSE=0 
 
;TRANSIT COMPARTMENTS OF ABSORPTION (see Savic et al. 2007) 
IF(T.GE.TDOS)THEN ; IF CURRENT TIME GREATER THAN TDOS 
 DADT(1)=EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*(T-TDOS)+X)-KTR*(T-TDOS)-L)-(1-
FPRE)*KA*A(1)-(FPRE)*KA*A(1) 
ELSE 
 DADT(1)=EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*T +X)-KTR*T-L)-(1-FPRE)*KA*A(1)-
(FPRE)*KA*A(1) 
ENDIF 
 
;DISPOSITION 
 DADT(2)= (1-FPRE)*KA*A(1)-Q/V1*A(2)+Q/V2*A(3)-CL/V1*A(2) ;Sunitinib central compartment 
 DADT(3)=                 +Q/V1*A(2)-Q/V2*A(3)         ;Sunitinib peripheral compartment 
 DADT(4)=     FPRE*KA*A(1)-CLM/VM1*A(4)       +CL/V1*A(2)*FSYS ;SU12662 central 
compartment 
 
  
$ERROR 
;PREDICTIONS AND RESIDUAL ERROR 
IF (CMT.EQ.2) THEN               
 IPRE  = A(2)/V1                             ;Individual predicted sunitinib 
concentration    
 IRES  = DV - IPRE                           ;Individual residuals  
 W     = SQRT(SD_PAR**2+CV_PAR**2*IPRE**2)   ;Combined residual error sunitinib 
 Y     = IPRE+ERR(1)*W 
ELSE 
 IPRE  = A(4)/VM1                            ;Individual predicted SU12662 concentration   
 IRES  = DV - IPRE                           ;Individual residuals 
 W     = SQRT(SD_MET**2+CV_MET**2*IPRE**2)   ;Combined residual error sunitinib 
 Y     = IPRE+ERR(1)*W 
ENDIF 
 DEL            = 0 
 IF(W.EQ.0) DEL = 1                          ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)               ;Individual weighted residuals 
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT MSFO=msfo.msf 
$COVARIANCE PRINT=E 
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Code 9-5 NONMEM control stream for the sunitinib blood pressure model 
$PROBLEM Sunitinib - Blood pressure model 
 
;----------------------------------------- 
;  UNITS                                  | 
;  TIME - HOURS                           | 
;  DOSE - UG                              | 
;  CP  - NG/ML  -> UG/L                   | 
;  VOLUMES - L                            | 
;  BP - mmHg                              | 
;------------------------------------------ 
                                  
$INPUT ID TIME AMT DV EVID CMT PART AGE BW HGT SEX  
       KAx MTTx Nx RPSx FM=DROP CLx V1x Qx V2x CLMx VM1x ;Individual parameters from the 
previous PK step 
          ;TIME relative to 6 AM on Day 0 - this is necessary in order to include  
          ;the baseline measurements of day 0  
          ;DV = systolic or diastolic blood pressure       
 
$DATA Data_input_file_BP.csv 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL  
NCOMP=7 
COMP=(DEPOTD,DEFDOSE)  ;Dosing compartment 
COMP=(CENTRAL)         ;Sunitinib central compartment 
COMP=(PERIPH)          ;Sunitinib peripheral compartment 
COMP=(MET)             ;SU12662 central compartment 
COMP=(SYS)             ;Systolic blood pressure (BP) 
COMP=(DIA)             ;Diastolic BP 
COMP=(SST)             ;Slow signal transduction 
 
;INITIAL VALUES 
$THETA 
(0,118)        ; THBLS      - Average baseline systolic BP over 24 hours 
(0,68)         ; THBLD      - Average baseline diastolic BP over 24 hours 
(0.125)        ; THALSY     - Intrinsic activity (alpha) for systolic BP 
(0.217)        ; THALDI     - Intrinsic activity (alpha) for diastolic BP 
(4 FIX)        ; THKD       - Dissociation constant 
(0,100)        ; THTAU      - Signal transduction time for slow signal 
(0 FIX)        ; THPS1      - Phase shift 1 
(1.31)         ; THPS2      - Phase shift 2 
(0.0177)       ; THAMP1     - Amplitude of first cosine term   
(-0.0209)      ; THAMP2     - Amplitude of second cosine term 
(0,7.37)       ; ADD_SYS    - Additive residual error systolic BP 
(0,6.63)       ; ADD_DIA    - Additive residual error diastolic BP 
 
$OMEGA BLOCK(2) 
0.00474            ; ETABLS  - Interindividual variability (IIV) of BLS 
0.00420 0.00764    ; ETABLD  - IIV of BLD (covariance is the off-diagonal element) 
$OMEGA BLOCK(2) 
0.517              ; ETAALSY - IIV of ALSY 
0.31 0.294         ; ETAALDI - IIV of ALSY (covariance is the off-diagonal element) 
$OMEGA 0.63        ; ETAAMP1 - IIV of AMP1 
$OMEGA 0.368       ; ETAAMP2 - IIV of AMP2 
 
$SIGMA 1 FIX 
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Code 9-5 continued 
$PK 
 
;Increase maximum number of integrations of the differential equations 
"FIRST 
" COMMON /PRCOMG/ IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" IMAX=99000000 
 
;DRUG SPECIFIC 
 KD   = THKD          
 
;SYSTEM SPECIFIC                    
 BLS   = THBLS*EXP(ETABLS) 
 BLD   = THBLD*EXP(ETABLD) 
 ALDI  = THALDI*EXP(ETAALDI) 
 ALSY  = THALSY*EXP(ETAALSY) 
 TAU   = THTAU  
 
;CIRCADIAN VARIATION 
 PS1   = THPS1 
 AMP1  = THAMP1*EXP(ETAAMP1)                                  
  
 PS2   = THPS2 
 AMP2  = THAMP2*EXP(ETAAMP2)           
 
;PK PART   
 FABS  =  1                   ;Fraction absorbed          
 FM    =  0.21                ;Fraction metabolized 
 RPS   =  RPSx                ;Ratio FPRE/FSYS 
 
 SQ   =  SQRT(1+2*RPS+RPS**2-4*RPS*FM) 
 FPRE =  0.5+0.5*RPS-0.5*SQ   ;Fraction metabolized presystemically 
 FSYS =  FPRE/RPS             ;Fraction metabolized systemically 
 
 KA  = KAx                    ;Description see PK model 
 CL  = CLx 
 V1  = V1x 
 V2  = V2x 
 Q   = Qx 
 CLM = CLMx 
 VM1 = VM1x 
 MTT = MTTx 
 N   = Nx 
 KTR=(NN+1)/MTT               ;Transit rate constant 
  
 S2=V1 
 S3=V2  
 S4=VM1 
 
;SETTING UP THE DOSE  
IF(NEWIND.NE.2) THEN  
 TDOS=26               ;For every new individual the time of the first dose is set to 
 ON=0                  ;to 26h after 6 AM on day 0 
 DOSE=0                ;Reset dose 
ENDIF                 
 
;TIME AFTER DOSE 
IF(AMT.GT.0) THEN      ;If a dosing event is found in the data file 
 TDOS=TIME             ;time of dosing and the dose are set accordingly 
 ON=1                  ;Switch on the transit compartments when a dose is given 
 DOSE=AMT*FABS       
ENDIF 
TAD=TIME-TDOS        ;Time after dose 
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Code 9-5 continued 
 ;DELETE NONMEMS DOSE RECORD 
 F1=0                 ;This necessary for the transit model to work 
  
;STERLING APPROXIMATION OF (LOG) FACULTY N (see Savic et al. 2007) 
 L=LOG(2.5066)+(N+0.5)*LOG(N)-N 
 
;INITIALIZATION OF SLOW TRANSDUCTION COMPARTMENT 
 A_0(7)=0 
 
$DES 
 X=0.00001  ;To avoid LOG(0) when DOSE=0 
 
;TRANSIT COMPARTMENTS OF ABSORPTION (see Savic et al. 2007) 
IF(T.GE.TDOS)THEN  
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*(T-TDOS)+X)-KTR*(T-TDOS)-L)-(1-
FPRE)*KA*A(1)-(FPRE)*KA*A(1) 
ELSE 
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*T +X)-KTR*T-L)-(1-FPRE)*KA*A(1)-
(FPRE)*KA*A(1) 
ENDIF 
 
;DISPOSITION 
 DADT(2)= (1-FPRE)*KA*A(1)-Q/V1*A(2)+Q/V2*A(3)-CL/V1*A(2)      ;Sunitinib central 
compartment 
 DADT(3)=                 +Q/V1*A(2)-Q/V2*A(3)                 ;Sunitinib peripheral 
compartment 
 DADT(4)=     FPRE*KA*A(1)-CLM/VM1*A(4)       +CL/V1*A(2)*FSYS ;SU12662 central 
compartment 
 
;TYROSINE KINASE INHIBITION  
 AC= A(4)/VM1*(1-0.90)+A(2)/V1*(1-0.95)      ;Unbound active concentration (outside of 
$DES) 
 IF(AC.LE.0) AC=0                            ; 95% PB sunitinib, 90% PB SU12662 
   
 INH   = FC/(KD+FC)                          ;Fractional tyrosine kinase inhibition 
 DADT(7)=1/TAU*INH-1/TAU*A(7)                ;Slow signal transduction 
 
$ERROR 
 ACx    = A(4)/VM1*(1-0.90)+A(2)/V1*(1-0.95) ;Unbound active concentration  
 INHx   = ACx/(KD+ACx)                       ;Fractional tyrosine kinase inhibition 
   
;CIRCADIAN VARIATION 
 ;TIME+6 because clock time is 6 AM when TIME=0  
 CBLS  =BLS*(1+(AMP1*COS((TIME+6)*6.283/24-PS1)+AMP2*COS((TIME+6)*6.283/12-PS2)))  
 CBLD  =BLD*(1+(AMP1*COS((TIME+6)*6.283/24-PS1)+AMP2*COS((TIME+6)*6.283/12-PS2)))  
 
;PREDICTIONS AND RESIDUAL ERROR 
IF(CMT.EQ.5) THEN 
 IPRE  = CBLS*(1+ALSY*(INHx+A(7)))  ;Individual predicted systolic blood pressure (BP)    
 IRES  = DV - IPRE                  ;Individual residuals  
 W     = ADD_SYS                    ;Additive residual error systolic BP 
 Y     = IPRE+ERR(1)*W               
ELSE 
 IPRE  = CBLD*(1+ALDI*(INHx+A(7)))  ;Individual predicted diastolic BP    
 IRES  = DV - IPRE                  ;Individual residuals 
 W     = ADD_DIA                    ;Additive residual error diastolic BP 
 Y     = IPRE+ERR(1)*W 
ENDIF 
 DEL            = 0                  
 IF(W.EQ.0) DEL = 1                 ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)      ;Individual weighted residuals 
 
$ESTIMATION SIG=3 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT MSFO=msfo.msf 
$COVARIANCE PRINT=E 
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$PROBLEM Sunitinib - VEGFA model 
 
;----------------------------------------- 
;  UNITS                                  | 
;  TIME - HOURS                           | 
;  DOSE - UG                              | 
;  CL - L/HOUR                            | 
;  VOLUMES - L                            | 
;  VEGFA - PG/ML                          | 
;------------------------------------------ 
 
$INPUT ID TIME AMT DV EVID CMT PART AGE BW HGT SEX  
       KAx MTTx Nx RPSx FM=DROP CLx V1x Qx V2x CLMx VM1x ;Individual parameters from the 
previous PK step 
          ;TIME relative to 6 AM on Day 0 - this is necessary in order to include  
          ;the baseline measurements of day 0  
          ;DV = VEGFA concentrations    
 
$DATA Data_input_file_VEGF-A.csv 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL  
NCOMP=5 
COMP=(DEPOTD,DEFDOSE)  ;Dosing compartment 
COMP=(CENTRAL)         ;Sunitinib central compartment 
COMP=(PERIPH)          ;Sunitinib peripheral compartment 
COMP=(MET)             ;SU12662 central compartment 
COMP=(TRANS)           ;VEGFA transduction compartment  
 
$THETA 
(0,100)        ; THBLVA       - Baseline VEGFA 
(0,0.75)       ; THPART       - Fractional difference of BLVA in PART1 
(4 FIX)        ; THKD         - Dissociation constant 
(0,0.8)        ; THALVA       - Intrinsic activity (alpha) 
(0,3)          ; THGAM        - Exponent of the power function 
(0,10)         ; THTAU        - Signal transduction time 
(0,0.2)        ; CV_VA        - Proportional residual error 
 
$OMEGA 0.05    ; ETABLVA      - Interindividual variability in BLVA 
$OMEGA 0.5     ; ETAALPHA     - IIV of ALPHA 
$OMEGA 0.4     ; ETATAU       - IIV of TAU 
 
$SIGMA 1 FIX 
 
$PK 
 
;Increase maximum number of integrations of the differential equations 
"FIRST 
" COMMON /PRCOMG/ IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" IMAX=99000000 
 
;DRUG SPECIFIC 
 KD   = THKD          
 
;SYSTEM SPECIFIC   
IF(PART.EQ.2) THE 
 BLPART = THBLVA*THPART**0       ; PART2 
ELSE 
 BLPART = THBLVA*THPART**1       ; PART1 
ENDIF 
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 BLVA  = BLPART*EXP(ETABLVA) 
  
 ALVA  = THALPHA*EXP(ETAALPHA)  
 TAU   = THTAU*EXP(ETATAU)  
 GAM   = THGAM 
 
;PK PART   
 FABS  =  1                   ;Fraction absorbed          
 FM    =  0.21                ;Fraction metabolized 
 RPS   =  RPSx                ;Ratio FPRE/FSYS 
 
 SQ   =  SQRT(1+2*RPS+RPS**2-4*RPS*FM) 
 FPRE =  0.5+0.5*RPS-0.5*SQ   ;Fraction metabolized presystemically 
 FSYS =  FPRE/RPS             ;Fraction metabolized systemically 
 
 KA  = KAx                    ;Description see PK model 
 CL  = CLx 
 V1  = V1x 
 V2  = V2x 
 Q   = Qx 
 CLM = CLMx 
 VM1 = VM1x 
 MTT = MTTx 
 N   = Nx 
 KTR=(NN+1)/MTT               ;Transit rate constant 
  
 S2=V1 
 S3=V2  
 S4=VM1 
 
;SETTING UP THE DOSE  
IF(NEWIND.NE.2) THEN  
 TDOS=26               ;For every new individual the time of the first dose is set to 
 ON=0                  ;to 26h after 6 AM on day 0 
 DOSE=0                ;Reset dose 
ENDIF                 
 
;TIME AFTER DOSE 
IF(AMT.GT.0) THEN      ;If a dosing event is found in the data file 
 TDOS=TIME             ;time of dosing and the dose are set accordingly 
 ON=1                  ;Switch on the transit compartments when a dose is given 
 DOSE=AMT*FABS       
ENDIF 
 TAD=TIME-TDOS        ;Time after dose 
 
;DELETE NONMEMS DOSE RECORD 
 F1=0                 ;This necessary for the transit model to work 
  
;STERLING APPROXIMATION OF (LOG) FACULTY N (see Savic et al. 2007) 
 L=LOG(2.5066)+(N+0.5)*LOG(N)-N 
 
;INITIALIZATION OF TRANSDUCTION COMPARTMENT 
 A_0(5)=0 
 
$DES 
 X=0.00001  ;To avoid LOG(0) when DOSE=0 
 
;TRANSIT COMPARTMENTS OF ABSORPTION (see Savic et al. 2007) 
IF(T.GE.TDOS)THEN  
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*(T-TDOS)+X)-KTR*(T-TDOS)-L) 
         -(1-FPRE)*KA*A(1)-(FPRE)*KA*A(1) 
ELSE 
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*T +X)-KTR*T-L)-(1-FPRE)*KA*A(1)-
(FPRE)*KA*A(1) 
ENDIF 
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;DISPOSITION 
 DADT(2)= (1-FPRE)*KA*A(1)-Q/V1*A(2)+Q/V2*A(3)-CL/V1*A(2)      ;Sunitinib central 
compartment 
 DADT(3)=                 +Q/V1*A(2)-Q/V2*A(3)                 ;Sunitinib peripheral 
compartment 
 DADT(4)=     FPRE*KA*A(1)-CLM/VM1*A(4)       +CL/V1*A(2)*FSYS ;SU12662 central 
compartment 
 
;TYROSINE KINASE INHIBITION  
 AC= A(4)/VM1*(1-0.90)+A(2)/V1*(1-0.95)      ;Unbound active concentration (outside of 
$DES) 
 IF(AC.LE.0) AC=0                            ; 95% PB sunitinib, 90% PB SU12662 
   
 INH   = FC/(KD+FC)                          ;Fractional tyrosine kinase inhibition 
 DADT(5)=(INH**GAM-A(5))/TAU                 ;Signal Transduction of INH  
   
$ERROR 
 IPRED  = BLVA*(1+ALVA*A(5))    ;Individual predicted VEGFA concentrations 
 IRES   = DV - IPRED            ;Individual residuals 
 W      = CV_VA*IPRED           ;Proportional residual error 
 Y      = IPRED+ERR(1)*W 
   
 DEL            = 0 
 IF(W.EQ.0) DEL = 1             ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)  ;Individual weighted residuals 
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT MSFO=msfo.msf 
$COVARIANCE PRINT=E 
placeholder 
Code 9-7 NONMEM control stream for the sunitinib sVEGFR-2 model 
$PROBLEM Sunitinib - VEGFR2 model 
 
;----------------------------------------- 
;  UNITS                                  | 
;  TIME - HOURS                           | 
;  DOSE - UG                              | 
;  CL - L/HOUR                            | 
;  VOLUMES - L                            | 
;  VEGFR2 - PG/ML                         | 
;------------------------------------------ 
 
$INPUT ID TIME AMT DV EVID CMT PART AGE BW HGT SEX  
       KAx MTTx Nx RPSx FM=DROP CLx V1x Qx V2x CLMx VM1x ;Individual parameters from the 
previous PK step 
          ;TIME relative to 6 AM on Day 0 - this is necessary in order to include  
          ;the baseline measurements of day 0  
          ;DV = VEGFR2 concentrations    
 
$DATA Data_input_file_sVEGFR-2.csv 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL  
NCOMP=5 
COMP=(DEPOTD,DEFDOSE)  ;Dosing compartment 
COMP=(CENTRAL)         ;Sunitinib central compartment 
COMP=(PERIPH)          ;Sunitinib peripheral compartment 
COMP=(MET)             ;SU12662 central compartment 
COMP=(VEGFR2)          ;VEGFR2 compartment 
 
$THETA 
(0,9000)       ; THBLVR       - Baseline VEGFR2 
(4 FIX)        ; THKD         - Dissociation constant 
(0,1)          ; THALVR       - Intrinsic activity 
(0,0.002)      ; THKOUT       - Rate of loss of VEGFR2 response 
(0,0.05)       ; CV_VR2       - Proportional residual error 
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$OMEGA 0.0105  ; ETABLVR2     - Interindividual variability in BLVR2 
$OMEGA 0.6     ; ETAALPHA     - IIV of ALPHA 
$OMEGA 0.01    ; ETAKOUT      - IIV of KOUT 
 
$SIGMA 1 FIX 
 
$PK 
 
;Increase maximum number of integrations of the differential equations 
"FIRST 
" COMMON /PRCOMG/ IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
" IMAX=99000000 
 
;DRUG SPECIFIC 
 KD   = THKD          
 
;SYSTEM SPECIFIC                     
 BLVR   = THBLVR2*EXP(ETABLVR2) 
 ALVR   = THALPHA*EXP(ETAALPHA)  
 KOUT   = THKOUT*EXP(ETAKOUT) 
 
;PK PART   
 FABS  =  1                   ;Fraction absorbed          
 FM    =  0.21                ;Fraction metabolized 
 RPS   =  RPSx                ;Ratio FPRE/FSYS 
 
 SQ   =  SQRT(1+2*RPS+RPS**2-4*RPS*FM) 
 FPRE =  0.5+0.5*RPS-0.5*SQ   ;Fraction metabolized presystemically 
 FSYS =  FPRE/RPS             ;Fraction metabolized systemically 
 
 KA  = KAx                    ;Description see PK model 
 CL  = CLx 
 V1  = V1x 
 V2  = V2x 
 Q   = Qx 
 CLM = CLMx 
 VM1 = VM1x 
 MTT = MTTx 
 N   = Nx 
 KTR=(NN+1)/MTT               ;Transit rate constant 
  
 S2=V1 
 S3=V2  
 S4=VM1 
 
;SETTING UP THE DOSE  
IF(NEWIND.NE.2) THEN  
 TDOS=26               ;For every new individual the time of the first dose is set to 
 ON=0                  ;to 26h after 6 AM on day 0 
 DOSE=0                ;Reset dose 
ENDIF                 
 
;TIME AFTER DOSE 
IF(AMT.GT.0) THEN      ;If a dosing event is found in the data file 
 TDOS=TIME             ;time of dosing and the dose are set accordingly 
 ON=1                  ;Switch on the transit compartments when a dose is given 
 
DOSE=AMT*FABS       
ENDIF 
 TAD=TIME-TDOS        ;Time after dose 
 
;DELETE NONMEMS DOSE RECORD 
 F1=0                 ;This necessary for the transit model to work 
  
;STERLING APPROXIMATION OF (LOG) FACULTY N (see Savic et al. 2007) 
 L=LOG(2.5066)+(N+0.5)*LOG(N)-N 
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;INITIALIZATION OF THE VEGFR2 COMPARTMENT 
 A_0(5)=BLVR 
 
KIN=BLVR*KOUT ;Rate of production of the VEGFR2 response    
 
$DES 
 X=0.00001  ;To avoid LOG(0) when DOSE=0 
 
;TRANSIT COMPARTMENTS OF ABSORPTION (see Savic et al. 2007) 
IF(T.GE.TDOS)THEN  
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*(T-TDOS)+X)-KTR*(T-TDOS)-L)-(1-
FPRE)*KA*A(1)-(FPRE)*KA*A(1) 
ELSE 
 DADT(1)=ON*EXP(LOG(DOSE+X)+LOG(KTR+X)+N*LOG(KTR*T +X)-KTR*T-L)-(1-FPRE)*KA*A(1)-
(FPRE)*KA*A(1) 
ENDIF 
 
;DISPOSITION 
 DADT(2)= (1-FPRE)*KA*A(1)-Q/V1*A(2)+Q/V2*A(3)-CL/V1*A(2)      ;Sunitinib central 
compartment 
 DADT(3)=                 +Q/V1*A(2)-Q/V2*A(3)                 ;Sunitinib peripheral 
compartment 
 DADT(4)=     FPRE*KA*A(1)-CLM/VM1*A(4)       +CL/V1*A(2)*FSYS ;SU12662 central 
compartment 
 
;TYROSINE KINASE INHIBITION  
 AC= A(4)/VM1*(1-0.90)+A(2)/V1*(1-0.95)      ;Unbound active concentration (outside of 
$DES) 
 IF(AC.LE.0) AC=0                            ; 95% PB sunitinib, 90% PB SU12662 
   
 INH    = FC/(KD+FC)                         ;Fractional tyrosine kinase inhibition 
 DADT(5)= KIN*(1/(1+ALVR*INH))-KOUT*A(5)    ;Indirect response model 
 
$ERROR 
 IPRED  = A(5)                  ;Individual predicted VEGFR2 concentrations 
 IRES   = DV - IPRED            ;Individual residuals 
 W      = CV_VR2*IPRED          ;Proportional residual error 
 Y      = IPRED+ERR(1)*W 
   
 DEL            = 0 
 IF(W.EQ.0) DEL = 1             ;To prevent division by 0 
 IWRE           = IRES/(W+DEL)  ;Individual weighted residuals 
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT MSFO=msfo.msf 
$COVARIANCE PRINT=E 
placeholder 
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######################################################################################## 
#                                                                                      # 
#      Clinical trial simulation of blood-pressure-based dose individualization        # 
#                                                                                      # 
######################################################################################## 
 
#Loading additional packages 
require(splus2R) 
require(hapsim) 
require(survival) 
 
#Fixed effects parameters 
#--------------------------------------------------------------------------------------- 
thCL_F_sunitinib<-32.4 
thCL_fa_SU12662 <-14.6 
fm              <-0.21 
fub_sunitinib   <-0.05 
fub_SU12662     <-0.1 
thBL_dia        <-67.6 
thAlpha_dia     <-0.145 
Kd              <-4 
 
#Concatenate parameters that will be subject to Monte Carlo simulation 
theta <- c(thCL_F_sunitinib,thCL_fa_SU12662,thBL_dia,thAlpha_dia) 
npar  <- length(theta) #number of fixed effect parameters 
 
#Variance-covariance matrix for the random effects: 
#--------------------------------------------------------------------------------------- 
omCL_F_sunitinib <- 0.073 
omCL_fa_SU12662  <- 0.167 
covCL            <- 0.0776 
omBL_dia         <- 0.0075 
omalpha_dia      <- 0.411 
 
#Combine in 4x4 matrix               
omega <- matrix(c(omCL_F_sunitinib,covCL,          0,       0, 
                  covCL,           omCL_fa_SU12662,0,       0, 
                  0,               0,              omBL_dia,0, 
                  0,               0,              0,       omalpha_dia) 
                  ,nrow=4,ncol=4,byrow=TRUE) 
  
#Residual error of diastolic blood pressure 
#--------------------------------------------------------------------------------------- 
sigma <- 6.6                  
                                                     
# Treatment schedule 
#--------------------------------------------------------------------------------------- 
dose    <- 50     # Initial dose (mg)    
tau     <- 24     # Dosing interval (h) 
dayson  <- 28     # Days on treatment per cycle 
cymax   <- 20     # Maximum number of cycles to be simulated (study duration) 
cylength<- 42     # Cycle length in days                  
cydays  <- cylength*(c(1:cymax)-1)+dayson  # Days of patient status  
                                           # assessment (day 28 in every cycle)    
nrep   <- 500     # Number of trial replicates 
npat   <- 150     # Number of patients 
ngroup <- 2       # Number of treatment groups 
           
BP_target <- 1.16 # Blood pressure target increase (relative to baseline) 
 
# Initialize arrays where (intermediate) results are stored 
#--------------------------------------------------------------------------------------- 
MCarray     <- rep(NA,(npat*npar*nrep))  # Here Monte Carlo simulated individual  
dim(MCarray)<- c(npat,npar,nrep)    # paramters will be stored 
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# Final results arrays 
FinTAB     <- rep(NA,(14*nrep)) 
dim(FinTAB)<- c(14,nrep)  
sumTAB     <- rep(NA,(length(cydays)*(nrep+4)*2)) 
dim(sumTAB)<- c(length(cydays),(nrep+4),2) 
 
# Intermediate results arrays 
IntTAB     <- rep(NA,(npat*8*nrep)) 
dim(IntTAB)<- c(npat,8,nrep) 
dBPBL      <- data.frame(matrix(data=NA,nrow=npat,ncol=nrep))     
KM         <- as.list(1:nrep)    
COX        <- as.list(1:nrep)    
              
for (repli in 1:nrep){  # Replicate loop begins here 
    ## Monte Carlo simulation ## 
    #----------------------------------------------------------------------------------- 
    #For every trial replicate a new set of patients is simulated 
          
    # Random sampling from the variance-covariance matrix 
    etas   <- rmvnorm(npat, mean=rep(0,ncol(omega)), cov=omega)   
    # Intermediate matrix of individual parameters  
    par.ind <- matrix(rep(theta,npat),nrow=npat,byrow=T)       
     
    for (n in 1:npat){ 
            par.ind[n,1]<-par.ind[n,1]*exp(etas[n,1]) # CL_F_sunitinib 
            par.ind[n,2]<-par.ind[n,2]*exp(etas[n,2]) # CL_fa_SU12662 
            par.ind[n,3]<-par.ind[n,3]*exp(etas[n,3]) # BL_diastolic 
            par.ind[n,4]<-par.ind[n,4]*exp(etas[n,4]) # Alpha_dia 
    }      
    MCarray[,,repli]<-par.ind  # Store in the Monte Carlo array 
    #-----------------------------------------------------------------------------------  
 
    gr.size1<-npat/ngroup    # Size of group1 (standard dose group, SDG) 
    gr.size2<-npat-gr.size1  # Size of group2 (individualized dose group, IDG) 
    start<-1                 # Start patient-counter counter for group1 
    end<-gr.size1            # Last patient of group1 
 
    for (gr in 1:ngroup){    # First "treat" group1 then group2 
      if (gr==2){  
      start<-gr.size1+1 
      end<-npat 
      } 
      for (pat in start:end){ # Treat every individual sequentially 
         ### Initialize patient specific variables                                           
          doseI          <- dose # Individual dose  
          F_EVENTS       <- 0    # Counts if patient experienced fatigue      
          STAT           <- 0    # Status: 0 = alive , 1 = dead 
          AHT            <- 0    # Antihypertensive therapy; 0 = NO , 1 = YES 
          etime          <- 0    # Elapsed time 
          prev.time      <- 0    # Previous time 
          cyc            <- 1    # Cycle number 
           
          ## Individual parameters for the current  
           # patient in the current replicate 
          iCL_F_sunitinib   <- MCarray[pat,1,repli] 
          iCL_fa_SU12662    <- MCarray[pat,2,repli] 
          iBL_dia           <- MCarray[pat,3,repli] 
          iAlpha_dia        <- MCarray[pat,4,repli]    
          # baseline blood pressure (with random error) 
          dBPBL[pat,repli]  <- iBL_dia+rnorm(1,0,sigma) 
                                  
         #------------------------------------------------------------------------------ 
            while (STAT==0 && cyc<=cymax){  
              # Continue treatment as long as patient  
              # is alive and maximum number of  
              # cycles has not been reached   
              IntTAB[pat,7,repli] <- doseI # Save current dose 
              IntTAB[pat,8,repli] <- AHT   # Save antihypertensive treatment status 
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                ## Calculate AUCs and concentrations 
                #----------------------------------------------------------------------- 
                 AUC_sunitinib <-    doseI/iCL_F_sunitinib 
                 AUC_SU12662   <- fm*doseI/iCL_fa_SU12662 
                 AUCsum        <- AUC_sunitinib+AUC_SU12662 
                 AUCdaily      <- AUC_sunitinib*28/42     # Average daily AUC  
                                                          #  as used by Houk et al. 2009 
                  
                 sunitinib_Css <- 1000*AUC_sunitinib/tau  # Steady-state (SS)  
                                                          #  concentration of  
                                                          #  sunitinib (ng/mL) 
                 SU12662_Css   <- 1000*AUC_SU12662/tau    #  SS concentration of SU12662 
                 ACss          <- (SU12662_Css*fub_SU12662      # Sum of unbound  
                                  +sunitinib_Css*fub_sunitinib) #  concentrations at SS  
                                                                #(=active concentration) 
                                                                         
                  
                ## Calculate diastolic blood pressure (dBP) at SS (with residual error) 
                #----------------------------------------------------------------------- 
                 INH           <- ACss/(Kd+ACss)        # at steady-state INH=ISIG=TSIG  
                 dBP           <- iBL_dia*(1+iAlpha_dia*(INH+INH))+rnorm(1,0,sigma)           
                 dBPrel        <- dBP/dBPBL[pat,repli]  # dBP relative to pretreatment  
                                                        #  value              
                # Start antihypertensive treatment if dBP >= 100 mmHg  
                # (hypertension according to CTCv4.0 grade 3 ) 
                if (dBP>=100) AHT<-1         
                            
                ## Calculate survival 
                #----------------------------------------------------------------------- 
                # Parameters of the Weibull survival function from Houk et al. 2009 
                  bl <-  110     # baseline 
                  sl <-  485     # slope 
                  gam <- 1.78    # gamma 
 
                  phi   <- (bl+sl*AUCdaily)         
                  ctime <- cylength*(cyc-1)+dayson # current time in days 
                  etime <- ctime-prev.time      # elapsed time since previous assessment 
                   
                  # Survival function 
                  St <- exp(-(log(2)*(ctime/phi)**gam))  
                  # Probability density function 
                  PDF<- (log(2)*(gam/ctime)*(ctime/phi)**(gam)* 
                        (exp(-(log(2)*(ctime/phi)**gam)))) 
                  # Hazard rate  
                  Ht <- PDF/St 
                  # Probability of death since last assessment (in the interval etime) 
                  Pd <- Ht*etime     
                  # Draw random sample from a binomial distribution with probability pE  
                  STAT  <- rbinom(1,1,Pd) # 0 = alive, 1 = dead                                           
                  ## Dose individualization 
                  #--------------------------------------------------------------------- 
                  # Assess if patient has fatigue 
                  #--------------------------------------------------------------------- 
                  FATIGUE <- 0   # Reset fatigue indicator in every cycle                                  
                  # Calculate probability of grade 3/4 Fatigue  
                  # according to FDA Pharmacometrics Review of sunitinib 
                  pF    <- exp(0.5144*AUCsum-3.2164)/ 
                        (1+exp(0.5144*AUCsum-3.2164))   # Total probability in 17 cycles  
                  pFcyc <- 1-(1-pF)**(1/17)             # Probability per cycle 
                  # Random sample from a binomial distribution with probability pF                         
                  FATIGUE<-rbinom(1,1,pFcyc)     # 0 = no fatigue, 1 = fatigue event  
                    if (FATIGUE==1 && doseI>25){ # If patient has fatigue and current                      
                     doseI<-doseI-12.5           #  dose is >25 mg then reduce dose  
                     F_EVENTS<-1                 # Save if patient experienced fatigue 
                     }       
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                  #--------------------------------------------------------------------- 
                  # Blood-pressure-based dose individualization 
                  #--------------------------------------------------------------------- 
                  if (gr==2) { # if current patient belongs to IDG 
                    if (FATIGUE==0 && doseI<87.5 && AHT==0){  
                      # only increase dose if patient has currently no fatigue  
                      # and is not on antihypertensive treatment 
                      # and the upper dose limit of 87.5 mg has not been reached 
 
                      if (dBPrel<BP_target) { # If dBP increase is below the target 
                          doseI<-doseI+12.5   # then increase dose by 12.5 mg 
                      }   
                    } 
                  }  
  
               IntTAB[pat,1,repli]<-pat      # current ID 
               IntTAB[pat,2,repli]<-gr       # current group 
               IntTAB[pat,3,repli]<-ctime    # Save current time  
               IntTAB[pat,4,repli]<-STAT     # status 
               IntTAB[pat,5,repli]<-F_EVENTS # number of fatigue events  
               IntTAB[pat,6,repli]<-cyc      # save current cycle number 
               prev.time<-ctime              # set previous time to current time                           
               cyc<-cyc+1                    # count up the cycle number 
            }# End of cycle loop 
         }# End of patient loop 
     }# End of group loop 
 
       
    ### Analysis of trial results 
    #----------------------------------------------------------------------------------- 
      # Apply cox-proportional model for the comparison between the two groups 
      COX[[repli]] <- coxph(Surv(IntTAB[,3,repli],IntTAB[,4,repli])~IntTAB[,2,repli])  
          
      # Number of patients with severe fatigue events     
      FES  <- sum(IntTAB[IntTAB[,2,repli]==1,5,repli]) # in the SDG 
      FEI  <- sum(IntTAB[IntTAB[,2,repli]==2,5,repli]) # in the IDG 
      FESp <- 100*FES/(gr.size1)                       # as percentage 
      FEIp <- 100*FEI/(gr.size2)                         
      pFE  <- prop.test(c(FES,FEI),c((gr.size1),(gr.size2))) #P-value for the difference  
                                                       # in fatigue incidence       
   
      # Number of patients receiving AHT 
      AHTs  <-sum(IntTAB[IntTAB[,2,repli]==1,8,repli]) # in the SDG 
      AHTi  <-sum(IntTAB[IntTAB[,2,repli]==2,8,repli]) # in the IDG 
      AHTsp <- 100*AHTs/(gr.size1)                     # as a percentage 
      AHTip <- 100*AHTi/(gr.size2)    
        
      # Median time to death                   
      TTDS <- median(IntTAB[IntTAB[,2,repli]==1,3,repli]) # in the SDG 
      TTDI <- median(IntTAB[IntTAB[,2,repli]==2,3,repli]) # in the IDG       
      p    <- summary(COX[[repli]])[[9]][3]               # P-value (log-rank test) 
      HR   <- summary(COX[[repli]])[[7]][1]               # Hazard ratio IDG/SDG  
       
      FinTAB[1,repli] <- repli 
      FinTAB[2,repli] <- TTDS 
      FinTAB[3,repli] <- TTDI 
      FinTAB[4,repli] <- TTDI-TTDS 
      FinTAB[5,repli] <- p 
      FinTAB[6,repli] <- FESp 
      FinTAB[7,repli] <- FEIp 
      FinTAB[8,repli] <- FEIp-FESp 
      FinTAB[9,repli] <- pFE[[3]] 
      FinTAB[10,repli]<- HR 
      FinTAB[11,repli]<- LdoseS 
      FinTAB[12,repli]<- LdoseI 
      FinTAB[13,repli]<- AHTsp 
      FinTAB[14,repli]<- AHTip 
}# End of replicate loop 
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### FINAL RESULTS 
----------------------------------------------------------------------------------------
- 
# Overall survival (i.e., median time to death) (95% CI):  
quantile(FinTAB[2,],  c(0.5,0.025,0.975), na.rm=T) # in the SDG 
quantile(FinTAB[3,],  c(0.5,0.025,0.975), na.rm=T) # in the IDG 
# Hazard ratio (95% CI) 
quantile(FinTAB[10,], c(0.5,0.025,0.975), na.rm=T)  
# log-rank p-value (95% CI) 
quantile(FinTAB[5,],  c(0.5,0.025,0.975), na.rm=T)  
# Incidence(%) of severe fatigue (95% CI) 
quantile(FinTAB[6,],  c(0.5,0.025,0.975), na.rm=T) # in SDG  
quantile(FinTAB[7,],  c(0.5,0.025,0.975), na.rm=T) # in the IDG 
#Percentage of patients requiring AHT 
quantile(FinTAB[13,], c(0.5,0.025,0.975), na.rm=T) # in SDG 
quantile(FinTAB[14,], c(0.5,0.025,0.975), na.rm=T) # in IDG 
placeholder 
placeholder 
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